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Diacylglycerol Lipase α (DAGLα) and β (DAGLβ) hydrolyse diacylglycerol 
(DAG) to produce 2-arachidonoylglycerol (2-AG), the main endogenous 
ligand for the cannabinoid receptors 1 (CB1) and 2 (CB2). Anatomical and 
pharmacological studies, complimented by knockout models, of these 
enzymes have implicated them in CB1/2 mediated processes such as axonal 
growth and guidance during development and neurogenesis and synaptic 
signalling in the adult. Despite considerable knowledge about the functions of 
these enzymes, little is known about their regulation.  
To start to address this, we used bioinformatics tools to generate a model of 
the catalytic domain of the DAGLs which revealed a regulatory loop (putative 
lid) shielding the catalytic site of these enzymes, similar to other lipases like 
hormone sensitive lipase (HSL). A phospho-map of the DAGLs generated by 
collating phosphoproteomic data revealed several phosphorylation sites that 
were well placed to regulate an 'open' and 'closed' confirmation of the lid, 
thereby regulating substrate access to the active site. We developed a 
cellular assay monitoring DAGL dependent CB1 activation as well as 
surrogate substrate assays to directly monitor the catalytic activity of the 
DAGLs. Assay results revealed that the kinases PKA and PKC enhanced 
DAGL dependent CB1 signalling. However these kinases did not affect 
DAGL activity against the surrogate substrates; this might be explained by 
the surrogate substrates having access to the active site irrespective of the 
position of the regulatory loop. The catalytic domains of the DAGLs were 
purified using a baculovirus expression system and in the case of DAGLβ we 
were able to demonstrate using in vitro phosphorylation and 
phosphoproteomic studies that PKA and PKC can directly phosphorylate the 
regulatory loop of this enzyme. A phospho-specific antibody against one of 
these sites (S570) was generated and validated and conditions were 
identified that could up and down regulate phosphorylation at this site in cells.  
In summary, the first structure/function model for the DAGLs is reported here 
together with considerable evidence for direct phosphorylation of the catalytic 
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Chapter 1 : Introduction 
1.1 From cannabis to the endocannabinoid (eCB) system 
‘Cannabis’ has been used for recreational and medicinal purposes for 
centuries dating back to as early as 2700 BC (Russo et al., 2008). However, 
it wasn't until the 1960s that Gaoni and Mechoulam successfully isolated and 
synthesized the major ‘psychoactive’ ingredient of cannabis, Δ9–
tetrahydrocannabinol (THC), one of the major milestones in cannabis 
research (Mechoulam and Gaoni, 1965). Besides its psychotropic affects, 
THC is associated with a range of pharmacological effects including 
analgesia and anti-inflammation. It took several years of research aided by 
the development of radio-labelled THC probes to determine that the actions 
of THC were receptor driven, culminating in the cloning and identification of 
the cannabinoid receptor 1 (CB1) from a rat brain cDNA library (Matsuda et 
al., 1990). Shortly after, Munro et al. reported the cloning of the cannabinoid 
receptor 2 (CB2) from a leukemic cell line (Munro et al., 1993). The 
cannabinoid receptors are G-protein coupled receptors (GPCRs) and have 
been shown to regulate a range of cellular processes by their downstream 
signalling pathways. Inhibition/activation of adenylate cyclase (resulting in an 
increase/decrease in cyclic AMP and protein kinase A (PKA) signalling), 
activation of phosphatidylinositide 3-kinase/protein kinase B  (PI3-
kinase/AKT) signalling and regulation of calcium and potassium ion channels 
are some of the main responses elicited by the cannabinoid receptors linking 
them to a diverse range of cellular processes (Bosier et al., 2010). The CB1 
and CB2 receptors share 44% overall identity, CB1 is predominantly 
expressed in the nervous system whereas CB2 is predominantly expressed 
in the immune system (Sugiura et al., 2006).  
Identification of CB1 and CB2 as molecular targets for THC initiated the hunt 
for their endogenous ligands (eCBs). Cannabimimetic probes were crucial in 
the discovery of the cannabinoid receptors. These probes (often 
radiolabelled), like CP 55,940 were modelled on THC and then manipulated 
to achieve greater potency (Herkenham et al., 1990; Xie et al., 1996). They 
were identified as cannabimimetic based on their ability to bind to 
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cannabinoid receptors and to trigger cannabinoid like behavioural symptoms 
(hypoactivity, hypothermia, catalepsy and analgesia) and physiological 
responses (increase/decrease in cellular cAMP and calcium levels) (Martin et 
al., 1991; Fride and Mechoulam, 1993; Howlett, 1995). Cannabimimetic 
probes also proved valuable in the discovery of the two most well studied 
eCBs - N-arachidonoylethanolamine, also called anandamide (AEA) (Devane 
et al., 1992), and 2-arachidonylglycerol (2-AG) (Mechoulam et al., 1995; 
Sugiura et al., 1995) (Figure 1.1).  
Devane et al. tested the ability of fractionated organic solvent extracts from 
porcine brains to displace a radiolabelled cannabinoid probe (HU-243) from 
rat synaptosomal membranes which enabled them to isolate and identify the 
first putative eCB AEA. AEA also demonstrated cannabimimetic properties in 
a mouse isolated vas deferens twitch assay (Devane et al., 1992). 
Mechoulam et al. isolated 2-AG from canine guts and demonstrated binding 
of 2-AG to the membranes of cells overexpressing CB1 and CB2 receptors. 
They also demonstrated the ability of 2-AG to cause THC like responses in 
vivo in mice (Mechoulam et al., 1995) and in the same year Sugiura et al. 
reported the ability of 2-AG to displace the radioactive cannabinoid probe CP 
55,940 from cannabionid receptors in rat brain synaptosomes (Sugiura et al., 
1995). 
Subsequently a number of other candidate eCBs like virodhamine (Porter et 
al., 2002) and noladin ether (Hanus et al., 2001) have been discovered 
based on their structural relationship with AEA and 2-AG and their ability to 
bind and activate the cannabinoid receptors, however their physiological 
relevance as eCBs has yet to be determined and some of them are present 
at very low levels (Figure 1.1). Similarly, other putative cannabinoid receptors 
have been identified based on their ability to bind CB1/2 ligands (Baker et al., 
2006; Ryberg et al., 2007). For example GPR55 is a GPCR activated by l-α-
lysophosphatidylinositol (LPI) and although GPR55 can indeed interact with 
certain CB1/2 drugs, any physiological relevance for this has yet to be 













Figure 1.1. Structure of the eCBs 
Structures of the two most well studied endocannabionids – Anandamide 
(AEA) and 2-Arachidonoylglycerol (2-AG) and two putative endocannabionids 
Virodhamine and Noladin are presented above. Anandamide and Noladin 
exhibit greater affinity towards CB1 when compared to CB2. 2-AG exhibits 
similar affinity towards both cannabinoid receptors. Virodhamine on the other 
hand exhibits greater affinity towards CB2 versus the CB1 receptor (Adapted 





The umbrella term - the eCB system is generally used to collectively describe 
the two most well studied eCBs (AEA and 2-AG), their target receptors (CB1 
and CB2), as well as the enzymes involved in their synthesis and 
degradation which will be discussed in the next section.  
1.2 Synthesis and degradation of the eCBs AEA and 2-AG 
Following the discovery that AEA and 2-AG can bind and activate the 
cannabinoid receptors, several groups focussed on identifying pathways 
involved in their synthesis and degradation in order to establish physiological 
roles for these molecules. As this thesis is focussed on the major 2-AG 
synthesising enzymes DAGLα and DAGLβ, this section will briefly discuss 
AEA synthesis and degradation before a more detailed report on 2-AG 
metabolism.  
1.2.1 AEA synthesis and degradation 
AEA belongs to a class of lipids called N-acyl ethanolamines (NAE). Multiple 
synthetic pathways have been described for AEA as discussed below (Figure 
1.2). Di Marzo et al. used [3H]ethanolamine labeled cultured neurons to 
demonstrate ionomycin stimulated AEA synthesis. They also identified the 
presence of an AEA precursor N-arachidonyl phosphatidylethanolamine in 
neurons which could be hydrolyzed to AEA using rat homogenates, 
presumably due to an endogenous phosphodiesterase (Di Marzo et al., 
1994). This calcium stimulated AEA synthesis is believed to involve 2 steps, 
first calcium activates a transacylase (yet to be identified) which catalyses the 
formation of N-acyl phosphatidylethanolamine (NAPE) using 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC), followed by 
the hydrolysis of NAPE to AEA by a phosphodiesterase (Figure 1.2A).  
Okamoto et al. cloned the phosphodiesterase - NAPE-specific phospholipase 
D (NAPE-PLD) which could indeed convert NAPE to AEA. This enzyme is 
expressed in various organs in mice, including the brain (Okamoto et al., 
2004), and very soon established itself as the likely synthetic enzyme for 







Figure 1.2. Putative pathways involved in AEA synthesis and the 
primary pathway involved in AEA degradation 
A. An unidentified N-acyl transacylase (NAT) is believed to catalyse 
the formation of N-acyl phosphatidylethanolamine (NAPE) using 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC). NAPE 
can then be hydrolysed to anandamide (AEA) by a NAPE-specific 
phospholipase D (NAPE-PLD). 
B. The serine hydrolase α/β-hydrolase 4 (ABH4) can deacylate both 
NAPE to lyso-NAPE and then lyso-NAPE to glycero-NAPE. 
Glycerophosphodiesterase 1 (GDE1) can then convert glycero-NAPE 
to AEA. Rat tissues also contain lysoPLD activity that can convert 
lyso-NAPE to AEA. 
C. A third pathway involved in the lipopolysaccharide (LPS) 
stimulated synthesis of AEA in macrophages involves an unidentified 
phospholipase C (PLC) converting NAPE to phospho-AEA and then 
phosphatases including protein tyrosine phosphatase 22  (PTPN22) 
that convert phospho-AEA to AEA. 
D. Fatty acid amide hydrolase (FAAH) hydrolyses AEA to arachidonic 
acid (AA) and ethanolamine. 










Surprisingly however, no differences in AEA levels were observed in the 
brains of NAPE-PLD wild type and knockout (KO) mice (Leung et al., 2006).  
Brain homogenates did however have significantly lower activity in assays 
converting NAPE to AEA. These assays contained high concentrations of 
calcium, surprisingly the calcium independent 'NAPE-PLD' activity observed 
in knockout brains were almost equivalent to wild type controls revealing an 
alternative pathway for AEA synthesis.  
The NAPE-PLD KO data suggested that multiple pathways may exist for AEA 
synthesis, with the potential to compensate for each other. Subsequently, at 
least two other pathways involved in the synthesis of AEA have been 
reported (Figure 1.2B and 1.2C). Simon et al. reported that a significant 
amount of NAPE-PLD independent AEA synthesis could be blocked by a 
serine hydrolase inhibitor methoxy arachidonyl fluorophosphonate (MAFP) 
and also demonstrated using mouse brain tissues in vitro that this AEA 
synthesis occurred via the conversion of lyso-NAPE to AEA. Furthermore 
EDTA blocked the conversion of lyso-NAPE to AEA and resulted in the 
accumulation of the intermediate glycero-NAPE (Simon and Cravatt, 2006). 
Subsequently, this was also demonstrated ex vivo (Simon and Cravatt, 
2008). This led to the cloning and identification of the serine hydrolase α/β-
hydrolase 4 (ABH4) which can deacylate both NAPE to lyso-NAPE and then 
lyso-NAPE to glycero-NAPE (Simon and Cravatt, 2006). The EDTA sensitive 
conversion of glycero-NAPE to AEA was attributed to a metal dependent 
phosphodiesterase - the integral membrane enzyme 
glycerophosphodiesterase 1 (GDE1) (Simon and Cravatt, 2008) (Figure 
1.2B). Both ABH4 and GDE1 were found to be expressed in various tissues 
including the brain, however, neither GDE1 KO mice nor GDE1-NAPE-PLD 
double KO mice showed a significant decrease in AEA levels in the brain 
compared to wild type controls (Simon and Cravatt, 2010). Additionally, rat 
brain tissues have been shown to contain lysoPLD activity than can generate 
AEA from lyso-NAPE (Sun et al., 2004). 
A third pathway involved in the LPS stimulated synthesis of AEA in 
macrophages has also been described involving an unidentified 
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phospholipase C (PLC) and phosphatases including protein tyrosine 
phosphatase 22  (PTPN22) (Liu et al., 2006) (Figure 1.2C).  
The AEA synthesis pathways have generally been identified by the presence 
of putative AEA precursor/intermediate molecules in tissues coupled with the 
identification of some of the endogenous enzymes capable of producing AEA 
from these precursors in vitro.  Knock-out studies so far have failed to identify 
a 'bulk' pathway for AEA synthesis suggesting that different pathways can 
work in a co-operative and compensatory manner to maintain AEA levels in 
tissues. Development of pharmacological tools specifically targeting the 
various enzymes as well as cloning the as of yet unidentified enzymes 
involved in AEA synthesis will help shed further light on pathways 
contributing to tissue/cell specific AEA levels.  This would also help in 
understanding the contribution of these pathways towards the regulation of 
basal levels and increased ‘on demand’ (e.g. calcium or LPS stimulated) 
production of AEA.   
On the other hand the primary enzyme involved in AEA degradation has 
been well characterized (Figure 1.2D). Cravatt et al. isolated and then cloned 
fatty acid amide hydrolase (FAAH) from rat liver membranes and then 
demonstrated its ability to hydrolyze AEA in vitro. FAAH was found to be 
expressed in a range of tissues and was especially abundant in the liver and 
brain (Cravatt et al., 1996). Most notably FAAH KO mice displayed a 15-fold 
increase in brain AEA levels (Cravatt et al., 2001).  
Despite the fact that AEA has shown cannabimimetic activities in vitro and in 
vivo, certain questions with regards to its role as an 'eCB' still remain 
unanswered. AEA has been shown to act only as a partial CB1 and CB2 
agonist but shown to be a full/partial agonist (tissue-dependent) for other 
receptors like vanilloid receptors  (Burkey et al., 1997; Sugiura et al., 1999; 
Zygmunt et al., 1999; Sugiura et al., 2000b; Ross, 2003). The development of 
pharmacological tools to disrupt AEA synthesis in vivo coupled with a better 




In contrast to AEA, 2-AG is a full agonist of both the CB1 and CB2 receptors 
and also the most abundant eCB in the brain leading to the argument that 2-
AG is indeed the 'true' eCB (Table 1.1) (Sugiura et al., 1999). Several factors 
have enabled a detailed inspection of the role of 2-AG as an eCB. A better 
understanding of 2-AG synthesis and degradation/metabolic pathway in the 
brain has been pivotal to this and is discussed in the next section.  
1.2.2 2-AG synthesis and degradation 
2-AG as the name suggests consists of a glycerol molecule with an 
arachidonoyl group present at the sn-2 position. Prior to the discovery of 2-
AG as an eCB, this molecule was primarily studied as a substrate for 
arachidonic acid (AA) synthesis (Chau and Tai, 1981; Prescott and Majerus, 
1983). This section will first discuss early reports into 2-AG synthesis in the 
context of AA synthesis followed by more recent reports focusing on 2-AG 
synthesis as an eCB (Sugiura et al., 2006).  
1.2.2.1 2-AG as an intermediate for AA synthesis 
During the 1970s and 1980s, 2-AG was primarily studied as an intermediate 
in the synthesis of AA where AA subsequently served as an inflammatory 
mediator through a range of pathways. This AA synthesis pathway involves 
PLC activity that can release DAG (more specifically 1-stearoyl-2-
arachidonoyl-sn-glycerol) from phospholipids, followed by sn-1 specific DAGL 
activity to form the monoacylglycerol (MAG) 2-AG and subsequently the 
release of AA from 2-AG by a MAG lipase activity (MAGL) (Figure 1.3). 
In one of the earlier studies, Rittenhouse-Simons observed the rapid but 
transient accumulation of a DAG in thrombin activated platelets (Rittenhouse-
Simmons, 1979). The study used [3H]AA labelled platelets to show that 
phosphatidylinositol (PI) was the likely precursor of DAG and demonstrated 
in vitro that platelets indeed possessed endogenous PLC activity that could 
hydrolyse PI to DAG. A separate study went on to demonstrate thrombin 
(and the calcium ionophore A23187) treatment of human platelets resulted in 
rapid depletion of PI, with a corresponding rise in free inositol, providing 




Table 1.1. 2-AG is present at several fold higher levels than AEA in the 
brain 
Brain region AEA (pmol/g) 2-AG (nmol/g) 
Fold diff 
(2-AG/AEA) 
Medulla 44.9 ± 5.9 10.5 ± 0.2 234 
Cortex 13.6 ± 2.8 4.3 ± 2.4 316 
Limbic forebrain 28.1 ± 19.8 10 ± 5.1 356 
Brainstem 87.0 ± 45.1 14.0 ± 7.1 161 
Striatum 51.5 ± 24.4 10.7 ± 0.3 208 
Hippocampus 45.8 ± 2.6 12.6 ± 1.8 275 
Diencephalon 10.2 ± 2.3 2.0 ± 0.1 196 
Cerebellum 14.8 ± 7.0 3.5 ± 2.4 237 
Mesencephalon 30.2 ± 17.7 4.0 ± 2.6 133 
 
Lipids were extracted from rat (10-12 weeks old) brains using chloroform-
methanol. Deuterium-8 labelled 2-AG and AEA standards were added to the 
extracts. 2-AG and AEA were then purified using silica gel column 
chromatography and normal-phase high pressure liquid chromatography 
(NP-HPLC) and measured using gas chromatography-electron impact mass 











Figure 1.3. Pathways involved in 2-AG synthesis and the 
primary pathway involved in 2-AG degradation 
Several pathways have been described for 2-AG synthesis. 
Sequential actions of phospholipase C (PLC) and then diacylglycerol 
lipase (DAGL) catalyse the conversion of phospholipids to 
diacylglycerol (DAG) and then to 2-AG. DAG hydrolysis to 2-AG by 
DAGLα and DAGLβ has been identified as the major pathway for 2-
AG synthesis in the nervous system and liver. Other putative 
pathways involved in 2-AG synthesis have also been described. 2-
arachidonoyl lysophosphatidic acid (2-arachidonoyl LPA) is present 
in rat brains and can be converted to 2-AG using brain homogenates 
(presumably via a phosphatase). Phospholipase A1 (PLA1) activity 
that can convert phospholipids (PI) to lysophospholipids (LPI) and 
membrane lyso-PLC (LPI-PLC) activity capable of converting the 
lysophospholipid to 2-AG have been described. The major 2-AG 
degradation pathway involves the hydrolysis of 2-AG to arachidonic 
acid (AA) and glycerol by monoacylglycerol lipase (MAGL). (Adapted 















Bell et al. identified the accumulated DAG as 1-stearoyl-2-arachidonoyl-sn-
glycerol and demonstrated that platelet membrane fractions possessed 
lipase(s) activity capable of releasing the arachidonoyl group in vitro (Bell et 
al., 1979). As they observed an increase in AA (did not observe 2-AG) 
following thrombin stimulation in platelets they hypothesised that a DAGL 
directly released AA from the sn-2 position of the DAG. Chau et al. used 
DAG radiolabelled at either the sn-1 or sn-2 position to demonstrate that 
DAGL activity in platelet microsomes preferentially hydrolysed 1-stearoyl-2-
arachidonoyl-sn-glycerol at the sn-1 position, generating  2-AG, with an 
optimum pH of 3.5. They also demonstrated the presence of MAGL activity in 
the microsomes that released AA from 2-AG, with a more alkaline optimum 
pH (Chau and Tai, 1981). In a separate study, Okazaki et al. demonstrated 
that microsomal fractions from human decidua vera tissue contained both 
DAGL and MAGL activity. The DAGL cleaved at the sn-1 position, with a 
preference for an arachidonoyl group in the sn-2 position (compared to 
oleoyl). The MAGL preferentially cleaved 2-AG (compared to 2-oleoyl-sn-
glycerol), and both lipase activities showed differential cellular fractionation 
profiles (Okazaki et al., 1981). These were indeed important studies in 
demonstrating the stereo-specificity of the endogenous DAGL activity (for the 
sn-1 position) and the presence of a separate MAGL activity that was 
capable of releasing AA from 2-AG.  
Prescott and Majerus went on to report the transient accumulation of not only 
the DAG, but 2-AG as well, in thrombin stimulated platelets indicating that the 
DAGL-MAGL activity was physiologically relevant (Prescott and Majerus, 
1983). Similar to previous studies, they also demonstrated in vitro that the 
DAGL activity preferentially cleaved DAG at the sn-1 position with an 
arachidonate group present at the sn-2 position. Importantly, they were able 
to separate the endogenous platelet MAGL activity from the DAGL activity 
using ion exchange chromatography. Platelet DAGL activity was also shown 
to be inhibited by RHC-80267 in vitro, and this pivotal study has led to the 
widespread use of this small molecule as a relatively selective DAGL inhibitor 
(Sutherland and Amin, 1982). 
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Further studies went on to confirm the presence of the distinct DAGL and 
MAGL activity in other cells and tissues. Heparin sepharose affinity 
chromatography was successfully used to separate MAGL and DAGL 
activities from bovine brain (Farooqui et al., 1984). Human neutrophil extracts 
were shown to possess DAGL and MAGL activity by using synthetic 
substrates, these activities were stimulated by the calcium ionophore A23187 
(Balsinde et al., 1991). Radio-labelling studies of Swiss 3T3 cells, a fibroblast 
cell line, were used to demonstrate an increase of 2-AG production and 
release following platelet-derived growth factor (PDGF) treatment 
(Hasegawa-Sasaki, 1985).  
The peptide bradykinin which is known to increase intracellular calcium levels 
was found to transiently increase DAG (2-fold) and MAG (3-fold) levels which 
preceded a 3-fold increase in AA levels in [3H]AA labelled rat dorsal root 
ganglion (DRG) neurons implicating a DAGL and MAGL in calcium 
stimulated AA release. Increases in inositol phosphates (1, 2 and 3) were 
also observed indicating PLC as a likely source of the DAG. The AA increase 
was significantly reduced by calcium channel blockers and chelators but not 
by a PLA2 inhibitor (at concentrations up to 20µM). Similarly, the calcium 
ionophore A23187 caused an increase in DAG (7-fold), 2-AG (1.7-fold) and 
AA (27-fold) in DRG neurons (Gammon et al., 1989). In a subsequent study, 
the same group used [3H]AA and [14C]stearic acid  labelled DRG neurons to 
demonstrate that bradykinin preferentially increased the level of the DAG 1-
stearoyl-2-arachidonoyl-sn-diacylglycerol which is then hydrolysed to 2-AG 
and subsequently AA. Additionally, bradykinin stimulated AA formation was 
inhibited by the DAGL inhibitor RHC-80267 (Allen et al., 1992).  
Indeed, several lines of evidence strongly indicated the presence of a DAGL 
that was capable of hydrolysing DAG to 2-AG with 2-AG acting as an 
intermediate in AA synthesis. It wasn't until 2-AG was identified as an eCB in 
1995 (Mechoulam et al., 1995; Sugiura et al., 1995) that it was considered as 
a signalling molecule in its own right, which raised further interest towards 
understanding its metabolic pathways in the nervous system.  
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1.2.2.2 2-AG synthesis in the nervous synthesis (as an eCB) 
In the late 1990s numerous studies reporting the presence and abundance of 
2-AG in the nervous system were published. Stella et al. reported that 2-AG 
levels in rat brains were 170 times higher than AEA (Stella et al., 1997). 
Kondo et al. also reported that 2-AG levels in rat brains were higher when 
compared to other tissues including the liver, spleen, lung, and kidney 
(Kondo et al., 1998). Bisogno et al., measured 2-AG levels in 9 different brain 
regions (including the hippocampus and cerebellum) and found it to be ~150 
to 300-fold more abundant than AEA (Bisogno et al., 1999b) (Table 1.1). 
Other groups too detected 2-AG in the nervous system including rat retinal 
tissue (Straiker et al., 1999), spinal cord, and the DRG (Huang et al., 1999).  
These reports establishing 2-AG as the most abundant eCB were 
accompanied by efforts to identify pathways involved in its synthesis. Two 
studies published in 1997 were the first reports describing 2-AG synthesis as 
an eCB. Stella et al. found that electrically stimulating hippocampal slices 
resulted in a 4-fold increase (calcium-dependent) in 2-AG suggesting that 
neural activity could stimulate 2-AG synthesis. They also observed a calcium 
dependent increase in 2-AG levels in [14C]AA labelled cultured neurons, this 
was blocked by a PI specific PLC inhibitor as well as the DAGL inhibitor 
RHC-80267 implicating a PLC-DAGL pathway in the production of 2-AG in 
the hippocampus (Stella et al., 1997). Bisogno et al. pre-labelled a mouse 
neuroblastoma cell line (a neuronal cell model) with [3H]AA to demonstrate 
ionomycin stimulated 2-AG synthesis. They also observed potential DAGL 
and MAGL activity in homogenates using synthetic substrates. Importantly, 
these cells express the CB1 receptor and ~20% of the (ionomycin stimulated) 
2-AG was found in the media, possibly so that it could fulfil its role as an eCB 
(Bisogno et al., 1997). The ionomycin stimulated 2-AG levels was blocked by 
the DAGL inhibitor RHC-80267 (which also caused an increase in DAG 
levels) but not by 4 different PLC inhibitors. Furthermore, they observed a 
corresponding decrease in phosphatidic acid (PA) levels with increases in 2-
AG levels following ionomycin stimulation. The ionomycin stimulated 2-AG 
levels was also blocked by two PA-phosphohydrolase inhibitors and 




These results collectively implicated a PA-DAG pathway in 2-AG synthesis in 
neuroblastoma cells. A similar pathway involved in 2-AG synthesis has also 
been described in a microglial cell line (Carrier et al., 2004).  
2-AG synthesis in a range of cells/tissues in response to numerous stimuli 
has since been reported. Endothelin 1 (endothelin A receptor and calcium 
dependent) and ionomycin stimulated 2-AG production (5-fold) in primary 
mouse astrocyte cultures (Walter and Stella, 2003). ATP enhanced 2-AG 
levels via P2X7 receptors in a calcium, PI-PLC, and DAGL dependent 
manner in astrocytes (Walter et al., 2004). Additionally, MAGL inhibitors 
enhanced the ATP stimulated 2-AG levels, once again implicating the PLC-
DAGL-MAGL pathway in 2-AG metabolism in astrocytes and microglia 
(Walter et al., 2004; Witting et al., 2004). The link between P2X7 activation 
and 2-AG synthesis is not surprising as both are involved in the production of 
key inflammatory molecules like TNF-α (Lister et al., 2007; Hsu et al., 2012). 
Kondo et al. reported evidence for calcium independent 2-AG synthesis 
pathway(s) in the brain. They found that 2-AG production in rat brain 
homogenates was greatly enhanced after 5 min treatment with CaCl2 (~6-
fold) but a 2-fold increase in 2-AG levels was also observed in the presence 
of a calcium chelator, implying the presence of calcium independent 
pathways for 2-AG synthesis (Kondo et al., 1998). Ethanol (~1.7-fold), 
ionomycin (~2-fold) and glutamate (~1.6-fold) have also been found to 
increase 2-AG levels in primary cultures of cerebellar granular neurons 
(CGNs) (Basavarajappa et al., 2000).  
Neurotransmitters too can enhance 2-AG levels. Sugiura et al. reported ~5-
fold increase in brain 2-AG levels of rats that were first treated intra-
peritoneally with picrotoxinin. Picrotoxinin can cause sustained stimulation of 
excitatory neurons by interfering with transmission of the inhibitory 
neurotransmitter - γ-Aminobutyric acid (GABA) (Sugiura et al., 2000a). In 
primary cortical neuron cultures, the neurotransmitter glutamate and NMDA 
enhanced 2-AG levels (~3-fold) in a calcium dependent manner, this effect 
was blocked by the NMDA receptor antagonist (MK801) (Stella and Piomelli, 
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2001). Interestingly, an earlier study had reported that glutamate or NMDA 
elevated DAGL activity in primary mouse neuronal cultures, this was inhibited 
by the NMDA receptor antagonists dextrorphan and MK-801 (Farooqui et al., 
1993). 
Most of the studies mentioned above and in the previous section implicated 
DAGL activity in 2-AG synthesis in the nervous system as well as in other cell 
types including neutrophils and platelets. Several groups attempted to purify 
and characterise the enzyme(s) responsible for the DAGL activity. As 
mentioned earlier, Farooqui et al. were able to separate MAGL and DAGL 
activity found in a solubilised microsomal fraction from bovine brain. They 
found that the DAGL activity bound to heparin sepharose, whereas the 
MAGL activity did not bind (Farooqui et al., 1984). They went on to 
demonstrate that the DAGL activity was enriched in plasma membrane and 
microsomal fractions, could be solubilised by Triton X-100 and inhibited by 
the DAGL inhibitor RHC-80267. Interestingly, the plasma membrane and 
microsomal activities showed some differences. Microsomal DAGL activity 
was stimulated by Triton X-100 and CaCl2 whereas plasma membrane DAGL 
activity was unaffected by CaCl2, and inhibited by Triton X-100. Whether 
these activities represented two distinct enzymes was unclear due to the 
crude nature of the fractions (Farooqui et al., 1986).  The same group 
managed to subsequently purify DAGL from bovine brain microsomes and 
plasma membrane using a multiple column chromatographic procedure 
(Farooqui et al., 1989). The enzymes had apparent molecular weights of 
27kDa (microsomal) and 52kDa (plasma membrane) as determined by SDS-
PAGE. An antibody raised against the microsomal enzyme cross-reacted 
with the plasma membrane enzyme indicating they could be related isoforms, 
isoenzymes or that the 27kDa protein was a degradation product of the 
52kDa protein (Farooqui et al., 1989).  In a follow up study, the microsomal 
enzyme displayed a preference for 1-2-sn-DAG over 1-3-sn-DAG and 
stearate over palmitate at the sn-1 position. It was also directly activated by 
PKA but not MgCl2 or CaCl2 (Rosenberger et al., 2007). Efforts to purify 
DAGL extended beyond the brain. Lee et al. partially purified DAGL from 
bovine aorta and found it to be potently inhibited by a selective lipase 
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inhibitor tetrahydrolipstatin (THL) (Lee et al., 1995). Moriyama et al. also 
managed to purify DAGL from human platelets with an apparent molecular 
weight of 33kDa and its activity was inhibited by RHC-80267 (Moriyama et 
al., 1999). 
However, despite considerable headway in the partial characterisation of the 
biochemical/enzymatic properties of one or more DAGL activities in the 
1980s and 1990s, the molecular identity of these enzymes was not resolved. 
It was not until almost a decade after the discovery of 2-AG as a putative 
eCB, that the enzymes largely responsible for its synthesis were cloned.  
1.2.2.3 Discovery of the elusive Diacylglycerol Lipases 
Our group was interested in the role cell adhesion molecules (CAMs) like 
NCAM, N-cadherin, and L1 play in regulating axonal growth and guidance 
during development and found that several of these molecules regulated 
growth cone motility by signalling through the fibroblast growth factor 
receptor (FGFR) resulting in calcium influx through N and L-type calcium 
channels that was necessary and sufficient to drive the axonal growth 
response. Pivotal experiments included the use of dominant negative FGFR 
expression studies to show that NCAM, N-cadherin and L1 promoted neurite 
outgrowth in PC12 cells as well as in cerebral neurons via a FGFR-PLCγ 
pathway (Saffell et al., 1997). A considerable body of evidence from several 
groups supported this “CAM/FGFR hypothesis” and extended it to a 
pathogenic role in the migration of some cancer cells (Nieman et al., 1999; 
Cavallaro et al., 2001; Suyama et al., 2002); however it remained unclear as 
to how activation of PLCγ was coupled to calcium influx into growth cones. 
Important insights, including the observation that a DAGL inhibitor (RHC-
80267) could block at a step downstream from the activated FGFR, but 
upstream from calcium influx, led to the hypothesis that direct cross-talk 
between the FGFR and cannabinoid receptors might mediate the response 
(Williams et al., 1994b; Williams et al., 1994a). In support, the CB1 receptor 
was shown to be expressed in growth cones of cerebellar neurons and the 
CB1 receptor antagonists AM251 and AM281 (but not a CB2 receptor 
antagonist) were found to inhibit FGF2 and N-cadherin stimulated neurite 
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outgrowth in primary cerebellar neuron cultures. Similarly, CB1 agonists 
stimulated neurite outgrowth, a response that was also blocked by N and L-
type calcium channel antagonists (Williams et al., 2003). In addition to this, 
FGF, NCAM, N-cadherin and L1 stimulated neurite outgrowth was inhibited 
by the DAGL inhibitor RHC-80267 (Williams et al., 1994b; Williams et al., 
1994a), and FGF, but not WIN55,2122-2 (CB1 agonist) stimulated neurite 
outgrowth was blocked by another DAGL inhibitor THL (Bisogno et al., 2003). 
These results collectively revealed that FGFR stimulated neurite outgrowth 
signalled through the eCB system via a PLCγ-DAGL-CB1 pathway (Williams 
et al., 2003).  
In order to identify the elusive DAGL, our group used the sequence of a 
fungal enzyme with both MAGL/DAGL activity to probe mammalian genome 
sequences which identified two distantly related enzymes that were 
subsequently shown to be specific DAGLs and named - diacylglycerol lipase 
α (DAGLα) and β (DAGLβ) (Bisogno et al., 2003). COS-7 cells 
overexpressing these enzymes showed 3-fold greater activity against 1-
stearoyl-2-arachidonoy-sn-glycerol when compared to untransfected cells. 
This activity was inhibited by the DAGL inhibitors RHC-80267 and THL thus 
verifying the catalytic activities of these enzymes. When tested against a 
range of radio-labelled DAGs as substrates, these enzymes showed 
selectivity for the sn-1 position. Besides demonstrating DAGL catalytic 
activity in vitro,  expression of these enzymes resulted in increased total 2-
AG levels (cells + media) in the transfected cells (Bisogno et al., 2003). 
Similarly, overexpressing DAGLα in Neuoro-2A cells resulted in an increase 
in 2-AG and stearic acid and a decrease in 1-stearoyl-2-arachidonoyl-sn-
glycerol, whereas knocking down  DAGLα  caused a decrease in 2-AG and 
stearic acid and an increase in 1-stearoyl-2-arachidonoyl-sn-glycerol levels 
(Jung et al., 2007). These results indeed demonstrated that DAGLα and 
DAGLβ were capable of hydrolysing DAG to 2-AG in vitro and in cells. 
Moreover, immunohistochemistry showed the enzymes to be expressed in 
the right place at the right time to mediate the well established function for an 
eCB synthesising enzyme in retrograde synaptic transmission and the 
emerging role in axonal growth and guidance. More specifically, DAGLα was 
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shown to be present in developing axonal tracts, but to become restricted to 
dendrites in the adult brain (Bisogno et al., 2003). These results will be 
discussed in more detail later. 
RT-PCR and gene expression profiling showed that DAGLα expression was 
particularly high in the central nervous system and pancreas (Bisogno et al., 
2003) which correlates well with this enzymes role in synaptic signalling in 
the brain (Gao et al., 2010) and the involvement of DAGL activity in 
pancreatic amylase secretion (Hou et al., 1997). DAGLβ was also expressed 
in the nervous system, but expression levels were particularly high in 
macrophages and microglia which correlates well with its recently established 
role in inflammation (Bisogno et al., 2003; Gao et al., 2010; Hsu et al., 2012). 
In situ hybridisation studies in the adult mouse brain revealed that DAGLα 
expression was highest in the hippocampus (in pyramidal cells but not in 
non-pyramidal cells), cerebellar cortex (Purkinje cells but not in granule cells) 
and dentate granule cells. Moderate expression was also observed in the 
cerebral cortex, olfactory bulb and thalamus (Figure 1.4A). DAGLβ 
expression levels were high in the cerebral cortex, cerebellar cortex 
(especially granular layer), olfactory bulb and dentate gyrus and low in the 
thalamus and hippocampal pyramidal cells (Figure 1.4B) (Yoshida et al., 
2006). Additionally, numerous immunohistochemistry studies using different 
antibodies further characterised the expression of the DAGLs in the brain 
(Bisogno et al., 2003; Yoshida et al., 2006; Berghuis et al., 2007; Mulder et 
al., 2008).  
These studies collectively demonstrated that the DAGLs were expressed in 
the brain, were catalytically capable of hydrolysing DAG to 2-AG and 
contributed towards cellular 2-AG levels in cells. In the last decade (since the 
DAGLs were cloned), a flurry of pharmacological and anatomical studies 
have revealed the importance of the DAGLs in eCB signalling. A range of 
DAGL dependent CB1/2 processes like axonal growth and guidance, 
synaptic signalling and adult neurogenesis have been identified and 




Figure 1.4. DAGLα and β in situ hybridization studies in the adult 
mouse 
In situ hybridisation studies in the adult mouse brain revealed that both 
DAGLα and DAGLβ are expressed in the adult mouse brain. DAGLα 
expression was highest in the hippocampus (Hi) (in pyramidal but not in non-
pyramidal cells), cerebellar (Cb) cortex (Purkinje cells but not in granule cells) 
and dentate granule cells. Moderate expression was also observed in the 
cerebral cortex (Cx), olfactory bulb (OB) and thalamus (Th) (A). DAGLβ 
expression levels were high in the cerebral cortex (Cx), cerebellar (Cb) cortex 
(especially granular layer), olfactory bulb (OB) and dentate gyrus and low in 
the thalamus (Th) and hippocampal (Hi) pyramidal cells. (Adapted from 
(Yoshida et al., 2006). (Cb, cerebellum; CP, Caudate–putamen; Cx, cerebral 
cortex; Hi, hippocampus; Mb, midbrain; MO, medulla oblongata; OB, 
olfactory bulb; Th, thalamus). Scale bar 1mm. 
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Besides the DAGL pathway, other pathways involved in 2-AG synthesis have 
also been described (Figure 1.3). Nakane et al. detected 2-arachidonoyl 
lysophosphatidic acid (2-arachidonoyl LPA) in rat brains and also 
demonstrated that brain homogenates could convert 2-arachidonoyl LPA to 
2-AG (presumably via a phosphatase) (Nakane et al., 2002). Ueda et al. 
showed that rat brain extracts contained an EDTA insensitive PI-PLA1 
activity (converting PI to LPI) and a membrane LPI-PLC activity (converting 
LPI to 2-AG) using synthetic substrates (Ueda et al., 1993; Tsutsumi et al., 
1994). These multiple (potential) pathways involved in 2-AG synthesis could 
introduce significant redundancy in 2-AG synthesis, as was observed for AEA 
where knockout studies failed to reduce AEA levels.  
However, in 2010, two independent studies detailing knockout studies of the 
DAGLs in mice were important breakthroughs in establishing the DAGLs as 
major contributors to 2-AG levels in various tissues as well as establishing 
them as key mediators of eCB signalling (Gao et al., 2010; Tanimura et al., 
2010). A remarkable 80% reduction of 2-AG levels was observed in the 
brains and spinal cord of adult DAGLα KO mice establishing this enzyme as 
the major 2-AG synthesising enzyme in the nervous system. A 50% reduction 
in 2-AG levels was observed in the brains of adult DAGLβ KO mice with no 
significant reduction in the spinal cord detected. On the other hand a 90% 
reduction in 2-AG levels was observed in the liver of the DAGLβ KO mice, 
compared to a 60% reduction in the DAGLα KO mice (Figure 1.5). 
The differences in the reduction of 2-AG levels observed in various tissues 
obtained from the DAGLα and DAGLβ knockout studies suggest that the 
individual contribution of the DAGL isoforms towards 2-AG levels is different 
depending on the tissue. Furthermore these enzymes appear to maintain 
tissue 2-AG levels in a cooperative and compensatory manner. A much 
unexpected observation made in the DAGL KO animals was the parallel 
reductions in AA and 2-AG in some tissues, most notably in the brains of 
DAGLα KO mice and the liver of DAGLβ KO mice (Figure 1.5), this will be 




Figure 1.5. Reduction of 2-AG (and AA) levels in DAGL KO mice 
Reduction of 2-AG levels in the brain, spinal cord, liver, and adipose tissue of 
the DAGL KO mice was measured relative to wild type tissue. An 80% 
reduction of 2-AG levels was observed in the brains and spinal cord of adult 
DAGLα KO mice. A 50% reduction in 2-AG levels was observed in the brains 
of adult DAGLβ KO mice with no significant reduction in the spinal cord 
detected. A 90% reduction in 2-AG levels was observed in the liver of the 
DAGLβ KO mice, compared to a 60% reduction in the DAGLα KO mice. In 
adipose tissue, a 50% reduction in 2-AG levels was observed in the DAGLα 
KO mice, no significant reduction was detected in the DAGLβ KO mice. 
Reduction in AA levels in the KO tissues compared to wild type tissues is 







The DAGL knockout studies therefore identified the DAGLs as the major 2-
AG synthesising enzymes, especially in the brain and liver. Similarly, a 
MAGL was found to be the key 2-AG hydrolysing enzyme in the brain. Dinh 
et al. cloned MAGL from a rat brain cDNA library and found it to be widely 
expressed in the brain. HeLa cell extracts overexpressing MAGL contained 
increased 2-AG (but not AEA) hydrolase activity and MAGL overexpression 
in rat primary cortical neurons resulted in reduced accumulation of 2-AG 
following NMDA+carbachol stimulation (Dinh et al., 2002). In addition to this, 
inhibiting or genetically deleting MAGL increases 2-AG levels by 5 to 30-fold 
(Long et al., 2009; Schlosburg et al., 2010; Piro et al., 2012). Although other 
enzymes like FAAH, alpha/beta hydrolase domain 6 (ABHD6) and ABHD12 
can indeed hydrolyse 2-AG, ~85% of the 2-AG hydrolysing activity in the 
brain has been attributed to MAGL (Blankman et al., 2007).  
Pharmacological studies have since shown that this enzyme can limit 2-AG 
and CB1 mediated synaptic signalling (Makara et al., 2005; Szabo et al., 
2006; Hashimotodani et al., 2007c; Pan et al., 2009; Straiker et al., 2009) 
making it a key regulator of DAGL signalling. 
1.3 Physiological roles of the DAGLs 
In the last decade, since the DAGLs were cloned, numerous studies have 
revealed their importance in eCB signalling. The DAGL inhibitors THL and 
RHC-80267, often but not always used alone, have been important tools in 
attributing various functions to the DAGLs. Hoover et al. evaluated the 
selectivity of these inhibitors by competitive activity based protein profiling 
(ABPP) (Hoover et al., 2008). 
As part of this study they evaluated the ability of THL and RHC-80267 to 
prevent binding of a generic serine hydrolase active site probe 
(fluorophosphonate) to its targets (which include the DAGLs) in a complex 
proteome (brain). They discovered that both inhibitors bound to other serine 
hydrolases. Crucially however, the overlap of their 'non-specific' targets was 
very small (2) (Hoover et al., 2008). Therefore, observations made using both 
these inhibitors, especially in conjunction with other tools (CB1/2 
agonists/antagonists) can be taken as convincing evidence for a DAGL 
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dependent CB1/2 process. These pharmacological studies have been 
supported by elegant anatomical studies of the eCB system enabling a 
detailed inspection into the localisation of the DAGLs (especially DAGLα) 
relative to the cannabinoid receptors and MAGL. However, it was the 
knockout studies that ultimately provided the most critical evidence to truly 
establish the DAGLs as key mediators of eCB signalling. The physiological 
roles of the DAGLs are discussed below. 
1.3.1 Axonal growth, guidance, fasciculation and target selection  
The detrimental effect pre-natal exposure of cannabis can have on 
neurodevelopment of the offspring is well documented (reviewed in 
(Keimpema et al., 2011). In this context, CB1 receptor expression has been 
detected in the human foetal brain (Wang et al., 2003), suggesting a role of 
eCB signalling in neurodevelopment. It was therefore not surprising to find 
that DAGL dependent eCB signalling plays important roles during 
development, namely in axonal growth and guidance and this is discussed 
below.  
The CB1 receptor is expressed in the first born neurons of both the central 
and peripheral nervous system (Begbie et al., 2004). During development, 
both the CB1 receptor and DAGLα/β are found to be expressed in axons and 
growth cones of developing neurons, in close proximity to each other 
(Berghuis et al., 2007; Mulder et al., 2008; Wu et al., 2010) therefore implying 
an autocrine role for them in axonal development. 
Pharmacological and/or genetic disruption of the CB1 receptor has indeed 
been shown to impair various axonal processes in vivo and in vitro. CB1 KO 
mice display abnormal axonal fasciculation and path-finding (Mulder et al., 
2008; Wu et al., 2010). For example, CB1 receptor deletion specifically in 
cortical GABAergic neurons results in impaired target selection in vivo 
(Berghuis et al., 2007). Genetic and pharmacological disruption of the CB1 
receptor causes abnormal axonal growth and fasciculation in pyramidal 
neurons of mice during late stage development and at birth (Mulder et al., 
2008). Similar detrimental effects of CB1 receptor deletion have been 
reported in corticothalamic and thalamocortical projections (Wu et al., 2010). 
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Additionally, Watson et al. used pharmacological studies in chick embryos, 
along with knock-down studies in zebra fish embryos, to demonstrate the 
requirement of the CB1 receptor for axonal growth and fasciculation. For 
example, treating chick embryos with the CB1 antagonist AM251 perturbed 
directionality of axonal growth in various CNS ganglia (Watson et al., 2008). 
Further studies have implicated DAGLα/β in these processes. 
Pharmacological studies in vitro have shown that DAGL mediated CB1 
receptor signalling can regulate neurite outgrowth. CB1 agonists can 
stimulate neurite outgrowth in cerebellar neuron cultures as a model, an 
effect that was not only inhibited by CB1 antagonists, but also by the DAGL 
inhibitor THL as well as N/L type calcium channel antagonists (Bisogno et al., 
2003; Williams et al., 2003). Similarly, FGFR stimulated neurite outgrowth in 
these cultures are blocked by CB1 antagonists, the DAGL inhibitor RHC-
80267 as well as a PLCγ inhibitor  (Williams et al., 1994b; Williams et al., 
1994a; Saffell et al., 1997; Williams et al., 2003). These results collectively 
revealed that FGFR stimulated neurite outgrowth signalled through the eCB 
system via a - PLCγ-DAGL-CB1 receptor pathway. In addition to this, retinoic 
acid (RA) treatment of Neuro-2A cells causes an increase in DAGLα and 
DAGLβ expression (and 2-AG) levels and also stimulates neurite outgrowth. 
Blocking 2-AG degradation, treating these cells with a stable 2-AG analogue, 
or overexpressing the DAGLs stimulated neurite outgrowth in these cells. 
Similarly, knocking down the DAGLs (individually or both) inhibited the RA 
stimulated neurite outgrowth (Jung et al., 2011). Interestingly, a CB1 
antagonist blocked neurite outgrowth in these cells when overexpressing 
DAGLα but not DAGLβ. These findings have helped to explain a much earlier 
observation that was made before 2-AG was established as a cannabinoid 
receptor ligand. In these earlier studies, the DAGL inhibitor RHC-80267 
inhibited FGFR mediated axonal growth in rat retinal ganglion cell cultures 
(from E13.5) and perturbed the directionality of axonal growth towards the 
optic fissure in retinal whole-mounts  (Brittis et al., 1996). RHC-80267 also 
inhibited FGFR mediated neurite outgrowth in Xenopus retinal neuron 
cultures and inhibited axonal growth rate of retinal ganglion cells in vivo, 
shortened retinotectal projections were also observed (Lom et al., 1998). 
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These pharmacological studies have been further supported by anatomical 
studies demonstrating that the DAGLs are well placed to regulate CB1 
signalling in axons during development. For example, immunohistochemistry 
studies in chick embryos have detected expression of the DAGLs in the 
vicinity of the CB1 receptors in developing axons (Watson et al., 2008). In 
mice, during development, the DAGLs are found to be expressed in axonal 
tracts (Bisogno et al., 2003). More specific reports have demonstrated that 
DAGLα is expressed in the axon shafts and growth cones of pyramidal 
neurons in close proximity to CB1 receptors (Mulder et al., 2008), therefore 
enabling autocrine 2-AG signalling to regulate CB1 signalling. On the other 
hand paracrine 2-AG signalling between thalamocortical (DAGLβ) and 
corticothalamic (CB1) axons (in close proximity) has been also been 
implicated in axonal development (Wu et al., 2010). 
The pharmacological, genetic, and anatomical studies detailed above 
demonstrate the importance of DAGL dependent eCB signalling in axonal 
development. As mentioned briefly above, immunohistochemistry studies 
reveal a shift in the expression patterns of DAGLα/β from the axons during 
development to the dendrites in the adult brain that may correlate with a shift 
in function towards synaptic signalling as discussed in the next section 
(Bisogno et al., 2003). 
1.3.2 Synaptic signalling 
The restricted expression of the DAGLs to dendritic spines and the CB1 
receptor to pre-synaptic terminals in the adult brain clearly points to a role for 
eCB signalling in the regulation of synaptic function (Oudin et al., 2011a). In 
this context, early reports suggested that cannabinoids could regulate 
neurotransmitter release, revealing a potential physiological role for the eCBs 
(Gill et al., 1970; Roth, 1978).  
During the 1990’s retrograde signalling at synapses became a well accepted 
phenomenon. This referred to the release of ‘a messenger’ from the 
depolarized post-synaptic site which then acts on the pre-synaptic terminal to 
suppress further neurotransmitter release (e.g. the inhibitory GABA and the 
excitatory glutamate), thus providing an elegant mechanism to regulate 
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synaptic strength and plasticity (Alger, 2012). The generation of CB1 
antibodies in the late 1990's began to shed light on the localisation of this 
receptor in the adult brain. The CB1 receptor was found to be located to the 
soma of 5 day old hippocampal neurons but shifted to neurites in 4 week old 
cultures (Twitchell et al., 1997) . In adult rat brains, CB1 was localised to the 
pre-synaptic terminals of cerebellar granular and basket neurons which form 
synaptic contacts on dendritic spines on the Purkinje cells (Egertova et al., 
1998). Similarly, CB1 was found to be localised in pre-synaptic terminals of 
hippocampal CCK positive basket neurons (Katona et al., 1999). 
Subsequently other immunohistochemistry studies supported by knockout 
studies have indeed confirmed that CB1 receptors are predominantly 
expressed in pre-synaptic terminals throughout the adult brain and spinal 
cord, including that of the hippocampus and cerebellum (Katona et al., 2006; 
Kawamura et al., 2006). The CB1 receptor was therefore well placed to 
modulate transmitter release, possibly in response a retrograde messenger.  
Besides its localisation, pharmacological studies have demonstrated that 
CB1 activation can inhibit neurotransmitter release (e.g. GABA, Glutamate, 
acetylcholine) in cultured neurons as well as from slices from various parts of 
the brain including the hippocampus, cerebellum and the cerebral cortex 
(reviewed in (Schlicker and Kathmann, 2001). For example, Cadogan et al. 
demonstrated that AEA and the CB1 agonist CP 55940 could inhibit 
dopamine release in electrically stimulated rat striatal slices, this was mostly 
reversed by the CB1 antagonist SR 141716 (Cadogan et al., 1997). The CB1 
agonist WIN 55,212-2 also  inhibited electrically evoked GABA and 
acetylcholine release from human hippocampal slices, this was once again 
reversed by SR 141716A (Katona et al., 2000).   
Further pharmacological studies coupled with electrophysiology 
demonstrated the role of the CB1 receptor as not only a modulator of 
neurotransmitter release but also of synaptic transmission itself. Evoked 
excitatory postsynaptic current (eEPSC) and spontaneous inhibitory 
postsynaptic currents (sIPSCs) in Purkinje cells of cerebellar slices were 
inhibited by the CB1 agonist WIN 55212-2, an effect blocked by the CB1 
antagonist SR 141716 (Takahashi and Linden, 2000). 
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If an endogenous messenger could mediate pre-synaptic CB1 dependent 
inhibition of EPSCs or IPSCs then depolarization-induced suppression of 
inhibition/excitation (DSI/E) should not only be blocked by CB1 antagonists, 
but also occluded by CB1 agonists i.e. the effect of the retrograde messenger 
will not be observed as the CB1 receptors are pharmacologically activated 
prior to the depolarisation step. In 2001, several papers used this approach 
to implicate eCBs as the retrograde messenger that affect CB1 mediated 
suppression of neurotransmitter release. In Purkinje cells of cerebellar slices, 
the CB1 antagonist AM251 blocked DSI whereas the CB1 agonist WIN 
55212-2 occluded DSI (Kreitzer and Regehr, 2001b). This strongly indicated 
that DSI was mediated by the action of an endogenous CB1 agonist that 
acted on CB1 receptors (in response to depolarisation of the post synaptic 
cell). Similarly, AM251 blocked and WIN 55212-2 occluded DSE in Purkinje 
cells (Kreitzer and Regehr, 2001a). This phenomenon was not restricted to 
the cerebellum, in pyramidal neurons of hippocampal slices, the CB1 
antagonists AM251 and SR141716 blocked DSI, and this was once again 
occluded by WIN 55212-2 (Wilson and Nicoll, 2001). DSE and DSI were 
shown to be mediated via calcium influx in the depolarised post-synaptic cell 
(Kreitzer and Regehr, 2001a; Brenowitz and Regehr, 2003; Rancz and 
Hausser, 2006).  
In 2001, two additional studies reported a different mechanism (independent 
of depolarisation) of eCB release from the post-synaptic cell as a retrograde 
messenger involving the activation of post-synaptic receptors (receptor 
driven eCB release - RER). Activation of type 1 metabotropic glutamate 
receptors (mGluR) in Purkinje cells was found to inhibit neurotransmitter 
release from excitatory climbing fibers in a CB1 dependent manner. This 
mechanism did not rely on a calcium influx in the post synaptic cell (Maejima 
et al., 2001). Additionally, in hippocampal slices, activation of type 1 mGluRs 
was found to enhance DSI and this was blocked by CB1 and mGluRs 
antagonists. Furthermore, both DSI and type 1 mGluRs dependent inhibition 
of IPSCs were absent in CB1 KO mice (Varma et al., 2001).  
Therefore, CB1 receptors were well placed (pre-synaptically) to act as a 
target for a retrograde messenger and their modulation could indeed regulate 
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neurotransmitter release and synaptic transmission. Being the most 
abundant eCB in the brain, 2-AG is an obvious candidate to act as the 
retrograde messenger. Following the cloning of DAGLs in 2003, 
immunohistochemical studies in various parts of the brain have found DAGLα 
to be located post-synaptically in the adult brain and excluded from the pre-
synapse. Bisogno et al. reported that the DAGLs were absent from axons in 
the adult mouse brain but present in dendrites (Bisogno et al., 2003). Using 
electron microscopy Yoshida et al. carried out extensive DAGLα localisation 
studies in the adult mouse brain and found them predominantly localised to 
post-synaptic dendritic spines in both cerebellar and hippocampal neurons 
(Yoshida et al., 2006). Similarly DAGLα was located to the dendrites in 
medium spiny neurons of the striatum while CB1 was predominantly located 
at axon terminals (Uchigashima et al., 2007). Katona et al. also used electron 
microscopy to demonstrate that at hippocampal glutamatergic synapses, 
DAGLα was localised at the plasma membrane of dendritic spines, in 
compliment to the CB1 receptor which was localised at pre-synaptic axonal 
terminals (Katona et al., 2006). DAGLα is therefore perfectly placed to 
respond to post-synaptic depolarisation and synthesise 2-AG as a retrograde 
messenger. 
Pharmacological studies using DAGL inhibitors provided further evidence to 
support the role of DAGLα/β in retrograde synaptic signalling. A recently 
developed and relatively specific DAGL inhibitor OMDM-188 (Ortar et al., 
2008) can block various forms of retrograde signalling including DSI in 
hippocampal slices and cultures as well as in striatal and cerebellar slices. 
OMDM-188 also blocked DSE in cerebellar slices and IPSC suppression 
induced by mGluR1/5 agonist DHPG in hippocampal neuron cultures 
(Hashimotodani et al., 2013). Similarly, THL can block DSI and DSE in 
mouse cerebellar slices, DSI in the rat cerebellum and DSI in rat 
hippocampal neuron cultures (Szabo et al., 2006; Hashimotodani et al., 
2008). 
However, conflicting evidence using the DAGL inhibitors have been reported 
(reviewed in (Min et al., 2010a). For example, one study reported that none 
of the three DAGL inhibitors - OMDM-188, RHC-80267 or THL inhibited DSI 
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in hippocampal slices (Min et al., 2010b). Differences in the methods of drug 
application coupled with the lipophilic nature of these inhibitors may explain 
the conflicting results obtained using the DAGL inhibitors. The knockout 
models of the DAGLs were therefore crucial tools for critically testing the role 
of the DAGLs in retrograde signalling, and for determining if DAGLα and or 
DAGLβ were required for this. 
Two independent studies indeed reported the loss of eCB mediated 
retrograde signalling at synapses (hippocampus, cerebellum, and striatum) in 
DAGLα KO mice. This coupled with the significant reduction in 2-AG levels in 
the brains of the DAGLα KO animals demonstrated that DAGLα mediated 
production of 2-AG was the key pathway involved in retrograde signalling at 
synapses in the brain (Tanimura et al., 2010 and Gao et al., 2010). These 
studies also demonstrated that DAGLα and not DAGLβ was the key mediator 
of this function as no defects in retrograde signalling were observed in the 
DAGLβ KO mice.  
Several aspects of DAGL dependent 2-AG release at synapses are still 
poorly understood. Mechanisms behind 2-AG release and its retrograde 
transport at the synapse are yet to be addressed. The increase in 2-AG 
production within the post-synaptic cell is mediated via a calcium influx 
and/or via the activation of post synaptic receptors (e.g. mGluR5) by 
neurotransmitters (reviewed in (Hashimotodani et al., 2007a). Type1 mGluRs 
can activate PLCβ thereby increasing DAG levels (Figure 1.6) 
(Hashimotodani et al., 2007b). The calcium influx may also cause an 
increase in 2-AG levels via PLCβ dependent and independent pathways 
(Hashimotodani et al., 2007a) (Figure 1.6). Increasing substrate (DAG) levels 
via PLCβ would indeed increase DAGL activity and 2-AG levels. However, 
other mechanisms affecting the DAGLs (localisation, activation) may also 
occur in response to the calcium influx or receptor activation. A recent report 
found increased DAGL activity in DHPG (mGluR5 agonist) treated 





Figure 1.6. General molecular mechanism behind 2-AG retrograde 
signalling 
Depolarisation of the post-synaptic cell causes an influx of calcium via 
voltage-gated calcium channels (VGCC). The influx in calcium stimulates 
DAGLα dependent 2-AG production and release via PLCβ dependent and 
independent (unknown) pathways. Similarly, activation of postsynaptic group 
I metabotropic glutamate receptors (I mGluRs) activates PLCβ resulting in 
increased DAGLα dependent 2-AG production and release which is referred 
to as receptor driven eCB release (RER). Calcium influx and RER can work 
co-operatively to enhance retrograde signalling via PLCβ and is referred to 
as calcium assisted RER (Ca-RER). The released 2-AG targets presynaptic 
CB1 where its β/γ subunits probably couple to VGCC to suppress 
neurotransmitter release.(Adapted from (Castillo et al., 2012). 
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Another study has demonstrated a role for calcium/calmodulin-dependent 
protein kinase IIa (CamKIIa) in the regulation of DAGL activity. In this study, 
enhanced DSE was observed in striatal slices from mice expressing mutated 
CamKIIa, which has reduced activity (Shonesy et al., 2013). These effects 
were also seen using a CamKIIa inhibitory peptide. Furthermore, striatal 
DAGLα and 2-AG levels were enhanced in the CamKIIa mice versus wild 
type mice. They also demonstrated that phosphorylation of DAGLα (but not 
DAGLβ) by CamKIIa inhibits its activity in vitro. The calcium influx in the post-
synaptic cells could therefore activate CamKIIa which in turn could inhibit the 
activity of DAGLα thereby modulating/fine tuning retrograde signalling.  
Further studies focussing on the DAGLα at the synapses may indeed reveal 
other mechanisms for its regulation.   
1.3.3 Neurogenesis 
Neurogenesis in the adult mammalian brain occurs in two niches - the 
subventricular zone (SVZ) of the lateral ventricle and the subgranular zone 
(SGZ) in the dentate gyrus (DG) of the hippocampus, via proliferation and 
differentiation of neural progenitor/stem cells (NP/NSC). The newly 
generated neurons in the SVZ migrate via the rostral migratory stream (RMS) 
to the olfactory bulb (OB) where they integrate. In the adult hippocampus, the 
NSCs form dentate granules cells that then integrate into the local circuitry 
(reviewed in (Ming and Song, 2011).  
Expression profiles of the DAGLs and CB1/2 receptors support a role for 
DAGL dependent cannabinoid signalling in adult neurogenesis. The CB1 
receptor is expressed in the rat dentate gyrus (Morales and Backman, 2002) 
and SVZ (Xapelli et al., 2013). High expression of DAGLα and DAGLβ are 
also seen in the SVZ (Goncalves et al., 2008) and in the DG (Yoshida et al., 
2006). Several studies have confirmed the expression of CB1 receptors in 
NP/NSCs in vivo (Jin et al., 2004; Jiang et al., 2005; Aguado et al., 2006) and 
in cultures (Aguado et al., 2005; Aguado et al., 2006; Molina-Holgado et al., 
2007; Rubio-Araiz et al., 2008; Xapelli et al., 2013). Similarly CB2 receptors 
are expressed in NP/NSCs in vivo and in cultures (Palazuelos et al., 2006; 
Molina-Holgado et al., 2007; Rubio-Araiz et al., 2008). In further support of 
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the expression profiles, CB1 and CB2 agonists have been found to promote 
proliferation/neurogenesis in NP/NSC cultures, and this effect has generally 
been reversed by antagonists and absent in CB1 and CB2 KO mice (Aguado 
et al., 2005; Palazuelos et al., 2006; Molina-Holgado et al., 2007; Rubio-Araiz 
et al., 2008).  
CB1 and CB2 antagonism can also block basal proliferation in these cultures 
indicating a role for eCBs in NP/NSC proliferation (Molina-Holgado et al., 
2007). Expression of DAGLα in NP/NSC cultures has been detected (Molina-
Holgado et al., 2007) and 2-AG levels in NP/NSC cultures have been 
reported to be 100 times higher than AEA (Aguado et al., 2005) indicating 
that the DAGLs are likely candidates to mediate the neurogenic effects of the 
cannabinoid receptors. Further evidence supporting the role of DAGLα/β and 
the cannabinoid receptors in adult neurogenesis has been provided by in vivo 
studies in animal models. 
In the hippocampus, a 50% reduction in adult neurogenesis has been 
observed in the DG of adult CB1 KO mice. (Jin et al., 2004). Additionally, a 
CB2 agonist caused increased proliferation in the DG, this effect was not 
seen in CB2 KO mice which also showed decreased proliferation compared 
to wild type controls (Palazuelos et al., 2006). Similarly, a significant 
reduction in proliferation (~20-30%) was observed in the hippocampus of 
adult DAGLα and DAGLβ KO mice compared to wild type controls, implying a 
role for both these enzymes in hippocampal neurogenesis (Gao et al., 2010). 
The results above indicate that DAGLα and DAGLβ as well as CB1 and CB2 
play a role in neurogenesis in the adult hippocampus.  
Similar studies implicating the DAGLs and CB1/2 signalling in neurogenesis 
in the adult SVZ have also been presented. A 50% decrease in neurogenesis 
in the SVZ of adult CB1 KO mice has been reported (Jin et al., 2004). 
However, CB1 antagonist treatment did not affect neurogenesis in the SVZ in 
adult mice (Goncalves et al., 2008). The reduction of neurogenesis in the 
CB1 KO may therefore be a developmental defect. On the other hand, CB2 
agonists caused an increase and CB2 antagonists caused a decrease in 
neurogenesis in the SVZ of adult mice. Proliferating cells in the SVZ of the 
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adult mice (including neuroblasts) express high levels of DAGLα and a 
reduction in SVZ neurogenesis was observed in adult mice treated with 
DAGL inhibitors (Goncalves et al., 2008). In adult DAGLα KO mice, a 50% 
reduction in proliferation coupled with a 50% reduction in neuroblasts was 
observed in the SVZ when compared to wild type controls, demonstrating 
reduced neurogenesis in the KO animals (Gao et al., 2010). No significant 
reduction in proliferation was observed in the SVZ of DAGLβ KO mice. The 
results above implicate the involvement of a DAGLα-CB2 pathway in 
neurogenesis in the adult SVZ.  
The DAGLs and cannabinoid receptors have also been implicated in the 
differentiation of oligodendrocyte progenitor cells (Gomez et al., 2010; 
Gomez et al., 2011) and in the migration of neuroblasts from the SVZ to the 
OB (Oudin et al., 2011b).  
Collectively these results demonstrate a role for the DAGLs and the 
cannabinoid receptors in adult neurogenesis in both the hippocampus and 
SVZ.   
1.3.4 Eicosanoid signalling - a non-cannabinoid role for the DAGLs 
One of the most unpredicted outcomes of the genetic deletion of the DAGLs 
in mice was the impact this had on AA levels where parallel reductions 
between 2-AG and AA levels were observed (Figure 1.5). PLA2 was 
generally believed to be the primary enzyme involved in AA synthesis, it was 
therefore very surprising when no reduction in AA levels in the brain were 
observed in cPLA2 KO mice. (Rosenberger et al., 2003). The ~80% 
reduction of AA (and 2-AG) levels in the brains of DAGLα KO mice provided 
strong evidence that the DAGL-MAGL pathway was the principle source of 
AA in the brain (Gao et al., 2010). This indicated a role beyond eCB 
signalling for the DAGL-MAGL signalling axis where the DAGLs may also 
generate 2-AG as a substrate for MAGL rather than as an eCB. As part of 
this model - the hydrolysis of 2-AG by MAGL would have the direct function 
of generating AA per se as opposed to terminating the action of 2-AG at eCB 
receptors. This pathway would serve to maintain the steady state levels of 
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AA and also serve as a responsive pathway to generate signalling pools of 
AA in inflammatory states.  
In further support of this model, MAGL inhibition in vivo, resulted in an 
increase in 2-AG levels coupled with a complimentary decrease in AA levels 
in mouse brain, spinal cord, liver, spleen, and lung (Nomura et al., 2008a; 
Nomura et al., 2008b). In the brain, treatment with the MAGL inhibitor JZL184 
brought about relatively large increases (8 to 20-fold) in 2-AG levels (Long et 
al., 2009). These increases seem particularly high to support a notion that 2-
AG hydrolysis by MAGL is predominantly carried out to terminate eCB 
signalling. Similarly, MAGL KO mice brains contain 5 to 10-fold greater 2-AG 
levels than wild type mice, which is coupled with not only a 5-fold decrease in 
AA but also with a decrease in levels of eicosanoids like prostaglandin E2 
(PGE2), PGD2 and thromboxane B2 (TXB2) (Schlosburg et al., 2010; Piro et 
al., 2012). AA derived eicosanoids are involved in various physiological and 
pathological processes including inflammation (reviewed in (Harizi et al., 
2008) and include prostaglandins, leukotrienes and lipoxins.  
In a separate study, inhibiting MAGL or knocking it out increased brain levels 
of 2-AG by about 5-fold and reduced AA and PGE2 (basal and LPS 
stimulated) levels 3 to 5-fold. MAGL inhibition also reduced LPS stimulated 
inflammatory cytokine levels (IL1α, IL1β, IL6 and TNFα) by ~4 to 8-fold (in a 
CB1/2 independent manner) as well as LPS-induced microglial activation 
(Nomura et al., 2011). Furthermore MAGL inhibition in cPLA2 KO mice 
revealed that cPLA2 made a much smaller contribution towards LPS 
stimulated PG synthesis compared to MAGL. Firstly, in the brain, cPLA2 KO 
mice did not show any reduction in basal AA levels compared to a 5 to 10-
fold reduction in MAGL KO mice or following MAGL inhibition. Secondly, only 
a 20% reduction in LPS stimulated AA levels was observed in the cPLA2 KO 
mice when compared to a 3 to 5-fold reduction in MAGL KO mice or following 
MAGL inhibition. In addition to this, studies in other tissues comparing MAGL 
and cPLA2 KO mice revealed that MAGL was mainly responsible for 
regulating basal and LPS stimulated levels of AA, PGE2 and PGD2 in the 
liver and lung whereas cPLA2 played a more prominent role in the gut and 
spleen. (Nomura et al., 2011).  
57 
 
The knockout studies of the DAGLs demonstrating reduced 2-AG and AA 
levels coupled with MAGL KO studies which show an increase in 2-AG levels 
and a decrease in AA levels demonstrate the importance of the DAGL-MAGL 
axis in maintaining AA levels in vivo. The corresponding reduction of 
eicosanoids linked to decreases in AA and increases in 2-AG levels following 
pharmacological or genetic disruption of MAGL further confirms that the AA 
generated by 2-AG hydrolysis is not simply a by-product. This is further 
supported by a recent report where a reduction in 2-AG (~3 to 5-fold), AA (~2 
to 3-fold) and the eicosanoids PGE2 and PGD2 (~2 to 5-fold) was observed 
in macrophages derived from DAGLβ KO mice or following the selective 
inhibition (in vivo) of DAGLβ in wild type macrophages (Hsu et al., 2012). 
Similarly, a reduction in the LPS stimulated levels of various eicosanoids and 
cytokines was also reported in primary macrophage cultures from DAGLβ KO 
mice or from wild type macrophages treated with selective DAGLβ inhibitors 
(Hsu et al., 2012). The DAGLs may therefore be interesting drug targets for 
inflammation.  
1.4 A pathological and therapeutic perspective on the DAGLs 
The role of the DAGLs as key eCB signalling mediators as well as potential 
inflammatory mediators has implicated them in various diseases linked to the 
nervous system.   
Dorsolateral periaqueductal gray (dlPAG) is a region in the brain involved in 
nociceptive signalling. mGLuR5 and DAGLα (post-synaptically) and CB1 
(pre-synaptically) are expressed in this region. mGLuR5 antagonism in this 
brain region reduces stress antinociception. On the other hand activation of 
mGLuR5 in this brain region enhances stress antinociception, an effect 
blocked by a mGLuR5 antagonist as well as a CB1 antagonist. DAGL 
inhibition and DAGLα knock-down, specifically targeted in this region also 
suppressed stress antinociception. Collectively these results implicate a role 
for DAGL mediated synaptic signalling (receptor driven eCB release and 
retrograde signalling) towards stress antinociception (Gregg et al., 2012).   
Fragile X syndrome (causes autism, mental retardation) is caused by the 
failure to express Fragile X mental retardation protein (FMRP). FMRP plays 
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an important role in the transport of various mRNA to the synapses (Sidorov 
et al., 2013). A recent report has demonstrated a role for FMRP in the 
transport and precise localisation of DAGLα mRNA at the synapse (Jung et 
al., 2012). In addition to this, genetic deletion of FMRP disrupted mGluR5 
signalling at the synapses, an effect that was overcome by blocking 2-AG 
hydrolysis. Furthermore blocking 2-AG hydrolysis in FMRP KO mice restored 
behavioural deficits caused by the deletion of the gene. Pharmacological 
tools to activate DAGLα may therefore hold therapeutic potential towards 
treating certain aspects of Fragile X syndrome.  
The role of the DAGL-MAGL pathway in AA and thereby eicosanoids 
production in the brain has also implicated them in neurodegenerative 
diseases. For example, elevated brain levels of AA and eicosanoids like 
PGE2, PGD2 and TXB2 are observed in an Alzheimer's disease mouse 
model (PS1/APP+) (Piro et al., 2012). Genetic deletion of MAGL in this model 
increased 2-AG levels and reduced AA and eicosanoid levels by 
approximately 5 to 10-fold. MAGL ablation was also found to reduce 
microglia and astrocyte activation, inflammatory cytokine levels as well as 
amyloid plaques (4-fold). Similarly, the MAGL inhibitor JZL184 was found to 
increase 2-AG levels and reduce AA, eicosanoid and inflammatory cytokine 
levels (independent of CB1/2 receptors) in vivo, in this model (Piro et al., 
2012). In a separate study, in a model for Parkinson's disease, MAGL 
deletion or inhibition prevented MPTP (the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) induced increases in AA, PGE2 and PGD2 as well 
as neuronal loss in the brain, in a CB1/2 independent manner (Nomura et al., 
2011). The studies above have focussed on the disruption of MAGL activity 
to prevent neuroinflammation. Similar studies on the DAGLs to evaluate their 
therapeutic potential in neuroinflammation models would be interesting, 
especially considering the dramatic reduction of AA levels in DAGL KO mice 
(Gao et al., 2010). Additionally, the role of the DAGLs in neurogenesis may 
hold therapeutic potential in counteracting the effects of neuronal loss in 
neurodegenerative diseases and brain injury. 
The pathological roles of the DAGLs extend beyond the brain. Considering, 
the large reduction of 2-AG and AA levels observed in the liver of DAGLβ KO 
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mice (Figure 1.5), it is not surprising that eCB signalling has been implicated 
in liver disease. Increased CB1 expression, DAGLβ expression and 2-AG 
levels were observed in the liver of mice following ethanol feeding and has 
been linked to alcohol induced hepatic steatosis (Jeong et al., 2008). In 
addition to this, a reduction in ethanol induced hepatic steatosis and 
inflammation was observed in CB1 KO (global or hepatocyte specific) mice or 
in wild type mice treated with a CB1 antagonist. This was found to be 
mediated by hepatocyte CB1 receptors (Jeong et al., 2008; Trebicka et al., 
2011). The increases in DAGLβ (but not DAGLα or MAGL) expression and 2-
AG (but not AEA) levels in the liver following ethanol feeding were localised 
to hepatic stellate cells (Jeong et al., 2008). Collectively these results 
implicate paracrine 2-AG signalling in the pathogenesis of hepatic alcohol 
induced steatosis (Bataller and Gao, 2012). Similar results have also 
implicated CB1 in the pathogenesis of high fat diet induced hepatic steatosis 
(Osei-Hyiaman et al., 2008). Examining the effects of alcohol and high fat 
diet on hepatic steatosis using the DAGLβ KO mice will help assess the 
therapeutic potential of DAGLβ in treating these conditions.  
Additionally, MAGL deletion or inhibition enhanced 2-AG levels, reduced AA 
and eicosanoid levels, reduced hepatic neutrophil infiltration and reduced 
levels of inflammatory, liver damage and cell death markers in vivo following 
hepatic ischemia/reperfusion-induced tissue injury (Cao et al., 2013). This 
MAGL inhibition mediated reduction in liver disease biomarkers was 
complimented by a CB1 antagonist or CB1 ablation but partially reversed by 
CB2 antagonism or ablation. This suggests that the hepatoprotective affects 
of the MAGL inhibitor are partially mediated by cannabinoid signalling via the 
CB2 but not CB1 receptor and partially by inhibition of eicosanoid production. 
In this context, CB2 activation has been linked with a down regulation of 
inflammation and associated injuries in a number of diseases (Pacher and 
Mechoulam, 2011). On the other hand, as mentioned above, CB1 activation 
is linked with the pathogenesis of alcohol and high fat diet induced liver 
disease (Jeong et al., 2008; Osei-Hyiaman et al., 2008). Further studies 
exploring the link between DAGLα/β, CB1/2 and the production of 
inflammatory mediators in different cell types will help establish the relative 
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contribution of cannabinoid and non cannabinoid 2-AG signalling in 
inflammatory responses, which in turn will help devise therapeutic strategies 
to target MAGL, DAGLα/β and CB1/2 in order to treat inflammatory diseases.  
The cannabinoid receptors have been long standing targets for drug 
discovery (reviewed in (Pertwee, 2012; Skaper and Di Marzo, 2012; Pacher 
and Kunos, 2013). Three CB1/2 agonists are currently used in clinic. Marinol 
contains THC, the active ingredient of cannabis and is used as an appetite 
stimulant and to suppress chemotherapy side effects like nausea. Cesamet 
contains a synthetic THC analogue and is also used to suppress 
chemotherapy side effects like nausea. Sativex is a 50/50 mix of THC and 
the other major cannabis constituent cannabidiol (less psychoactive). Sativex 
is used to treat neuropathic pain and spasticity related to multiple sclerosis 
(Pacher and Kunos, 2013). Despite these successes, there have also been 
several failures too, most notably in the case of the small molecule CB1 
antagonist Rimonabant. Rimonabant was approved for the treatment of 
obesity; however, it later had to be withdrawn due to unwanted side-effects 
which included depression and suicidal thoughts (Moreira and Crippa, 2009).  
As key regulators of eCB signalling, the DAGLs provide alternative targets to 
modulate CB1/2 receptor activity. DAGLα and DAGLβ demonstrate different 
tissue specific contributions towards 2-AG (and AA) levels and hence 
targeting them individually could prove to be therapeutically attractive and 
achievable. DAGLα is responsible for most of the 2-AG in the brain whereas 
DAGLβ is responsible for most of the 2-AG in the liver. Theoretically, one 
could exploit the impermeability of the blood brain barrier to prevent DAGLβ 
inhibitors causing unwanted neurological side effects. A DAGLβ selective 
inhibitor (50 times more potent against DAGLβ than DAGLα) has recently 
been developed (Hsu et al., 2012), this provides encouraging signs that 
differences in these enzymes can be exploited by medicinal chemistry.  
Understanding how the DAGLs are regulated, which may include both 
overlapping and distinct mechanism for these enzymes will help further our 
understanding of these enzymes and eCB signalling and support longer term 
studies to evaluate their therapeutic potential as drug targets.  
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1.5 Aims and objectives 
At the start of this project, two studies characterising DAGL KO mice were 
published, driving home the important physiological roles these enzymes 
played in processes like neurogenesis and synaptic signalling (Gao et al., 
2010; Tanimura et al., 2010). Indeed, a combination of pharmacological, 
anatomical and knockout studies have recognized the DAGLs as major 
regulators of eCB signalling, however, very little is known about how these 
enzymes are regulated.  
Several studies have reported increases in DAGL dependent 2-AG signalling 
in response to a range of stimuli, including calcium and FGF (Williams et al., 
2003; Aguado et al., 2005; Sugiura et al., 2006). These increases in 2-AG 
signalling and hence DAGL activity can partially, on occasions be explained 
by increased substrate availability due to the associated increase in activity 
of PLCβ/γ. Enhanced 2-AG release from a pre-formed pool could also play a 
role in enhancing 2-AG signalling, however several reports have measured 
increased 2-AG levels in response to various stimuli, strongly suggesting that 
activation mechanisms of the major 2-AG synthesising enzymes - DAGLα 
and β do exist.  
Phosphorylation is one of the most common mechanisms involved in the 
modulation of enzymatic activity, including that of several lipases like the 
hormone sensitive lipase (HSL). Therefore, in order to further our 
understanding of how the DAGLs are regulated, we decided to investigate 
the potential role of phosphorylation in the regulation of DAGL activity. 
The specific aims of the thesis were:- 
(1) To use bioinformatics and related tools to develop a working model for 
DAGL   regulation 
(2) To develop a cellular assay to measure DAGL-dependent eCB 




(3) To evaluate the use of surrogate substrates to directly measure DAGL 
activity in membranes and intact cells 
(4) To purify the catalytic domain of DAGLs in an active state to determine 
phosphorylation sites (phospho-sites) in direct kinase assays 





















Chapter 2 : Materials and Methods 
2.1 General solutions, constructs, primers, antibodies and drugs  




50mM Tris pH 8.0, 150mM NaCl, 10mM MgCl2, 2mM CaCl2, 5% glycerol, 
1% Triton X-100, 1mM Na3VO4, 10mM NaF, 1mM PMSF and 1x 'Complete 
protease inhibitors' (Roche). 
 
Mowiol mounting solution 
17% (w/v) Mowiol 4-88 (Calbiochem), 33% (v/v) glycerine in PBS. 
 
4% paraformaldehyde  
4% (w/v) paraformaldehyde in PBS, pH 7.4.  
 
Phosphate buffered saline (PBS)  
1 PBS tablet (Oxoid) in 100ml water to give KCl (0.20g/l); KH2PO4 (0.20g/l); 
NaCl (8g/l); Na2HPO4 (1.15g/l). 
 
PBST 





5x SDS protein loading buffer 




25mM Tris, 200mM glycine, 0.1% SDS. 
 
Transfer buffer 
25mM Tris, 200mM glycine, 20% methanol. 
 
Trypsin-EDTA 










30% acrylamide/Bis (National 
Diagnostics) 
3.3ml 2.5ml 1.67ml 
1M Tris, pH 8.8 3.7ml 3.7ml - 
1M Tris, pH 6.8 - - 1.25ml 
10% SDS 100µl 100µl 100µl 
H2O 2.38ml 3.63ml 6.91ml 
TEMED 6.6µl 6.6µl 20µl 
10% ammonium persulphate 66µl 66µl 50µl 
 
 
SDS-polyacrylamide gels - Phos-tag 
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Reagent 7.5% gel 5% stacking gel 
30% acrylamide/Bis (National 
Diagnostics) 
2.33ml 1.67ml 
1.5M Tris, pH 8.8 1.75ml - 
1M Tris, pH 6.8 - 1.25ml 
10% SDS 70µl 100µl 
H2O 2.52ml 6.91ml 
TEMED 20µl 20µl 
10% ammonium persulphate 100µl 50µl 
5mM Phos-tag 98µl - 
10mM MnCl2 98µl - 
 
 
DNA vectors and constructs 





Made by Dr 
Fiona Howell 





pENTR Dr Louise Saul 
Used to generate GST-






Mutation corrected by 
SDM (K545T) then 
used as a template for 
other constructs, 
 pDONOR207 Invitrogen 
Used as a shuttle 
vector for gateway 
cloning 
 pCDNA-DEST47 Invitrogen 







Used to generate 
DAGLα/β-V5 constructs 
which were in turn used 
to generate cell lines 
V5α11 and V5β4 
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 pDEST20 Invitrogen 
Used to generate GST-




All primers were ordered from either Sigma or Invitrogen. 
Primers to correct K545 mutation to T545 in the human DAGLβ pBluescriptR 

































Cell line Source Culture media 
Tango (CB1) U2OS Osteosarcoma 
McCoy's 5A modified 
10% FCS 
COS-7 Monkey kidney DMEM 10% FCS 
Sf9 S. frugipera (insect cells) Sf900 II SFM 
 
Primary antibodies 
Antibody Company Species Application Dilution 
β-actin Abcam Rabbit Western 1/500 
DAGLα Dr.M. Watanabe Rabbit Western 1/1000 




Eurogentec Rabbit Western 1/500 
GFP Invitrogen Rabbit Western 1/1000 
GFP Invitrogen Rabbit ICC 1/1000 
GRASP65 Abcam Rabbit ICC 1/5000 
GST Millipore Rabbit Western 1/1000 
V5 Invitrogen Mouse Western 1/1000 
V5 Invitrogen Mouse ICC 1/1000 
Hoechst 
3342  (blue) 
 
Invitrogen  ICC 1/10,000 
 
* rabbit antibody raised and purified against DAGLβ epitope SSDSPLDSPTKYPLT 
68 
 




Antibody Company Species Application Dilution 
AlexaFluor 
488 
Invitrogen mouse ICC 1/2000 
AlexaFluor 
488 
Invitrogen rabbit ICC 1/2000 
AlexaFluor 
594 
Invitrogen rabbit ICC 1/2000 
HRP-
conjugated 
Vector Lab. mouse Western 1/3000 
HRP-
conjugated 
Vector Lab. rabbit Western 1/3000 
IR-Dye 680 Licor mouse Western 1/5000 



















2.2 Bioinformatics (homology modelling/phosphorylation related 
predictions) 
Primary sequence alignments were performed using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). Secondary structure predictions 
were performed using NetSurfP 
(http://genome.cbs.dtu.dk/services/NetSurfP/). DAGL phospho-maps were 
compiled by collating data from PhosphositePlus 
(http://www.phosphosite.org). Prediction of phosphorylation sites (phospho-
sites) were performed using DISPHOS (http://www.dabi.temple.edu/disphos/) 
and NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/). Prediction of 
kinases potentially responsible for phosphorylating the DAGLs was carried 
out using a phospho-motif finder (http://www.hprd.org/PhosphoMotif_finder). 
2.3 Molecular biology 
Human DAGLα-V5 (pCDNA6.2/V5-DEST) 
The full length human DAGLα gene was first amplified from the DAGLα-V5-
6His(C) construct mentioned in the table above. The gene was amplified by 
PCR with flanking attB1 and attB2 sites at the 5’ and 3’ ends respectively and 
with no stop codon, using the primers mentioned above. PCR was carried out 
using Pfu ultra polymerase (Stratagene). The reaction mix (50µl) contained 
5µl 10X Pfu reaction buffer, 0.4µl 100mM deoxyribonucleotide triphosphate 
mix, 1µl template (200ng/µl), 1µl each of forward and reverse primer (100µM 
stock), 1µl Pfu ultra polymerase, 2µl DMSO and 38.6µl water. PCR was 
performed as follows: denaturing at 95ºC for 2 minutes followed by 30 cycles 
each consisting of 95ºC for 30sec, 65ºC for 30sec and 72ºC for 3 minutes 30 
sec, then a final extension time of 72°C for 10 minutes. The PCR products 
were analysed by agarose (1%) gel electrophoresis using TAE buffer and 
1µg/ml ethidium bromide.  
The PCR product detected at the expected size was gel extracted (Qiagen 
kit) and then cloned into the gateway shuttle vector pDONOR207 using the 
BP clonase II kit (Invitrogen) as follows - 150ng PCR product, 150ng 
pDONOR207 and 2µl BP clonase II mix in a total reaction volume of 10µl 
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were incubated at 25°C for 1 hour and then treated with 1µl Proteinase K for 
10 minutes at 37°C. 5µl of the reaction was then transformed into Top10 
chemically competent E. coli cells (Invitrogen) and plated on LB gentamicin 
(12.5µg/ml) agar plates. The plates were incubated overnight at 37°C. At 
least 2 of the colonies obtained were then grown in 5ml LB gentamicin 
cultures and the plasmid DNA was extracted (Qiagen miniprep kit).  
Sequence of the construct (DAGLα pENTR) was then confirmed by DNA 
sequencing (Beckman Coulter genomics) and used as part of a gateway LR 
clonase II (Invitrogen) reaction to shuttle the gene into the pCDNA6.2/V5-
DEST vector as follows. 150ng of the DAGLα pENTR construct, 150ng of 
pCDNA6.2/V5-DEST and 2µl LR clonase II mix in a total reaction volume of 
10µl were incubated at 25°C for 1 hour and then treated with 1µl Proteinase 
K for 10 minutes at 37°C. 5µl of the reaction was then transformed into 
Top10 chemically competent E. coli cells and plated on LB ampicillin 
(100µg/ml). The plates were incubated overnight at 37°C. At least 2 colonies 
obtained were then grown in 5ml cultures and the plasmid DNA was 
extracted (Qiagen Miniprep kit). Sequence of the construct (human DAGLα-
V5) was then confirmed by DNA sequencing (Beckman Coulter genomics). 
Correction of the K545 mutation to T545 in the human DAGLβ pBluescriptR 
(Image clone 4830264) construct 
A K545 mutation detected in the DAGLβ image clone was corrected to T545 
by site directed mutagenesis using the QuikChange II XL kit (Agilent) using 
the primers mentioned above. PCR (50µl) was carried out using the following 
settings - 95°C 1min, 18 cycles each consisting of 95°C for 50sec, 60°C for 
50sec, 68°C for 10min, and then a final step of 68°C for 10min. The PCR 
reaction was then treated with 1µl Dpn1 for 1 hour at 37°C and after which 
5µl of the reaction was transformed into Top10 chemically competent E. coli 
cells and plated on LB ampicillin (100µg/ml). The plates were incubated 
overnight at 37°C. At least 2 colonies obtained were then grown in 5ml 
cultures and the plasmid DNA was extracted (Qiagen Miniprep kit). The 
corrected sequence was then confirmed by DNA sequencing (Beckman 
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Coulter genomics). This enabled the expression of DAGLα with a C-terminus 
V5 tag using mammalian expression systems. 
Human DAGLβ-V5 (pCDNA6.2/V5-DEST) 
The full length human DAGLβ gene was first amplified from the DAGLβ 
pBluescriptR (corrected) construct mentioned above. The gene was amplified 
by PCR with flanking attB1 and attB2 sites at the 5’ and 3’ ends respectively 
and with no stop codon as described for the human DAGLα-V5 construct. 
DAGLβ pENTR and subsequently DAGLβ-V5 were generated as described 
for DAGLα-V5. This enabled the expression of DAGLβ with a C-terminus V5 
tag using mammalian expression systems. 
Human DAGLβ-GFP (pCDNA-DEST47) 
The DAGLβ pENTR construct generated above was used to shuttle DAGLβ 
into pCDNA-DEST47 using the LR clonase II kit (Invitrogen) as described for 
the DAGLα-V5 construct. This enabled the expression of DAGLβ with a C-
terminus GFP tag using mammalian expression systems. 
GST-6His-Tev-DAGLα 229-687 (pDEST20) 
6His-Tev-DAGLα 229-687 (catalytic domain) pENTR construct was used to 
shuttle 6His-Tev-DAGLα 229-687 into pDEST20 using the LR clonase II kit 
(Invitrogen) as described for the DAGLα-V5 construct. This enabled 
expression of the DAGLα catalytic domain (CD) with an N-terminus GST-
6His-Tev tag using the baculovirus expression system. 
GST-DAGLβ 228-672 (pDEST20) 
DAGLβ 228-672 (catalytic domain) was first amplified from the DAGLβ 
pBluescriptR (corrected) construct using the primers mentioned above. The 
gene was amplified by PCR with flanking attB1 and attB2 sites at the 5’ and 
3’ ends respectively (with a stop codon) as described for the human DAGLα-
V5 construct. DAGLβ 228-672 pENTR was generated as described for 
DAGLα. Subsequently the DAGLβ 228-672 gene was shuttled into pDEST20 
using the LR clonase II kit (Invitrogen), as described for the DAGLα-V5 
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construct. This enabled expression of the DAGLβ catalytic domain with an N-
terminus GST tag using the baculovirus expression system.   
2.4 Cell culture 
The Tango-CB1 (referred to as Tango cells) cells were cultured at 37°C and 
5% CO2 in McCoy's 5A modified media with the following supplements - 10% 
FCS (unless otherwise stated), 0.1mM non essential amino acids, 25mM 
HEPES (pH 7.3), 1mM sodium pyruvate, 100U/ml penicillin, 100µg/ml 
streptomycin, 200µg/ml zeocin, 50µg/ml hygromycin and 100µg/ml geneticin 
(Invitrogen). The V5α11 and V5β4 cell lines described below were cultured in 
the same media as the Tango cells, supplemented with the antibiotic 
blasticidin. The COS-7 cells were grown in Dulbecco's Modified Eagle Media 
(DMEM) containing 10% FCS. 
2.5 Tango assay 
All the reagents for the Tango-CB1 (Tango) assay were obtained from 
Invitrogen. 20,000 Tango cells/well were seeded in a 96-well black clear 
bottom plate (Costar) in a total volume of 120 µl Freestyle assay media or 
McCoy's 5A media supplemented with 1% FCS as indicated. The cells were 
cultured overnight and then treated with the drugs as indicated. Generally, 
the treatments were diluted from higher concentrations to 5x stocks in the 
indicated media and 30µl was added to the appropriate wells. The plate was 
then incubated for the indicated times at 37°C before 30µl of 6x substrate mix 
(Invitrogen) was added to the wells. Following this, the plate was incubated in 
the dark at room temperature for 2 hours. CB1 activation was then measured 
and quantified as a ratio of the fluorescence signal in the blue channel 
(excitation 409nm, emission 460nm) and the FRET signal in the green 
channel (excitation 409nm, emission 530nm) using the FlexStation 
(Molecular Devices). The FRET signal is generated by the intact substrate 
whereas the fluorescence signal corresponds to the cleaved substrate 
(cleaved by β-lactamase). In some cases the data is presented as a 





Transfections of the Tango or COS-7 cells with the DAGLα/β constructs were 
carried out in 6 well dishes (~90% confluent) using the Lipofectamine 2000 
transfection reagent (Invitrogen). Prior to the transfections, where 
appropriate, the media was replaced with antibiotic free media. For the 
transfections, 4µg plasmid DNA was incubated with 150µl Opti-MEM media 
for 5 minutes. At the same time 10µl Lipofectamine 2000 was incubated with 
150µl Opti-MEM media for 5 minutes. These were then pooled and incubated 
for 20 minutes. Following this, the transfection mix was added to the cells, 
which were then incubated for 5 hours at 37°C. The media was subsequently 
changed and the cells were cultured overnight. At this point, 24 hours post 
transfection, cells were generally trypsinised and seeded into 24 well plates 
for ICC (described below) or in 6 well plates/10cm dishes for lysis and 
Western blotting analysis. Cells were generally fixed or lysed 48 hours post 
transfection.  
2.7 Immunocytochemistry 
10,000 cells per well were seeded onto 13mm poly-lysine coated coverslips 
and cultured overnight after which they were fixed in 4% paraformaldehyde 
for 30 minutes at room temperature. The fixed cells were washed three times 
with PBS and then permeabilised with 0.2% Triton X-100/PBS for 10 
minutes. The permeabilised cells were washed three times with PBS before 
blocking with 1% BSA/PBS (block solution) for 30 minutes. The cells were 
then incubated with the primary antibodies (diluted in block solution) for 1 
hour at room temperature or overnight at 4oC. Following that, cells were 
washed with PBS before the addition of the appropriate goat anti-
mouse/rabbit AlexaFluor 488/594 secondary antibodies diluted in block 
solution. This was incubated for a further hour before a final three washes 
with PBS. In some instances cells were also stained with the nuclear stain 
Hoechst 33258 which was used at a dilution of 1:10,000 (in block solution) 
along with the secondary antibodies. After the final wash, the coverslips were 
mounted in Mowiol onto microscope slides. Images of the immunostained 
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cells were collected using the Carl Zeiss LSM 710 microscope and the Carl 
Zeiss Zen software (version 1.0.1.0). 
2.8 Generation of the stable cell lines 
Tango cells were transfected with either DAGL -V5 or DAGLβ-V5 
(pCDNA6.2/V5-DEST) DNA. 24 hours post transfection, the cells were 
trypsinised and seeded at low densities and then cells stably expressing the 
DAGLα or DAGLβ-V5 genes were selected by continuous growth in 
blasticidin. Individual colonies obtained were picked and transferred to single 
wells of a 24 well plate and cultured. Colonies (clones) were screened for 
expression by Western blotting and ICC to determine the stable expression 
of the gene and the clonal nature of the cultures. Based on this the V5α11 
and V5β4 cell lines were chosen for further experiments. 
2.9 Mammalian cell lysis and protein assay 
Cell lysis 
Cells were lysed in a standard lysis buffer (50mM Tris-HCl pH 8.0, 150mM 
NaCl, 10mM MgCl2, 1% Triton-X-100, 5% glycerol, 10mM NaF, 1mM PMSF, 
1mM Na3VO4 and 1x complete protease inhibitor cocktail (Roche Applied 
Science) as follows. Media from the cells was first aspirated and the cells 
were washed with PBS. The cells were then scraped in an appropriate 
volume of lysis buffer (6 well dish - 100-200µl/well, 10cm dish - 0.5-1ml).  
The cell suspensions were incubated at 4°C for 30 minutes using an end-
over-end rotator. After the 30 minute incubation, the cell lysates were clarified 
by centrifugation at 11,000g for 10 minutes and the supernatants were 
collected for further analysis.  
Protein assay 
Protein concentrations of the clarified lysates were determined using the 
Pierce BCA Protein assay kit (Thermo Scientific) in a 96-well flat clear bottom 
plate. The volume of BSA standards and samples (serially diluted) was 20µl. 
200µl of BCA protein detection was added to the standards and samples. 
The plate was then incubated for 20 minutes at 37°C. Following that, the 
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absorbance was measured at 562nm using a Spectramax plate reader 
(Molecular Devices). A standard curve was generated using BSA (5 to 
250µg/ml) and the concentration of the lysates was determined using an 
appropriate dilution.  
2.10 Membrane preparation, cellular fractionation and protein assay 
Membrane preparation 
Media from cells cultured in 10cm dishes was aspirated and the cells were 
washed using PBS. The cells were then scraped in 1ml (per dish) of the 
following lysis buffer - 20mM HEPES pH7.0, 2mM DTT, 0.25M sucrose, 
10mM NaF, 1mM Na3VO4 and 1x 'Complete' protease inhibitor (Roche) and 
then homogenised on ice using a Polytron (PT 1200 E) homogeniser (three 
~7sec bursts at the maximum setting with 30sec interval in between). The 
homogenates were then subjected to centrifugation at 100,000g for 30 
minutes at 4°C. The supernatants obtained were discarded and the pellets 
(membrane enriched fraction) were resuspended in 200µl of lysis buffer, with 
the sucrose excluded, using the Polytron homogeniser. This membrane 
resuspension was then aliquoted (generally 20µl) and stored at -80°C. 
Cellular fractionation 
For the cellular fractionation experiments, cells were homogenised as 
described above and then subjected to centrifugation for 30 minutes at 1,000, 
19,000 or 100,000g. The supernatants and pellets (resuspended as 
described for the membranes above) were then aliquoted (generally 20µl) 
and stored at -80°C. 
Protein assay 
Protein concentration of the membranes and fractions was determined using 
the Coomassie (Bradford) Protein Assay Kit (Thermo Scientific) in a 96-well 
flat clear bottom plate. The volume of BSA standards and samples (serially 
diluted) was 20µl. 200µl of the Coomassie assay reagent was added to the 
standards and samples. The plate was then incubated for 10 minutes at room 
temperature. The absorbance was then measured at 595nm using a 
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Spectramax plate reader (Molecular Devices). A standard curve was 
generated using BSA (5 to 250µg/ml) and the concentrations of the 
membranes/fractions were determined using an appropriate dilution. 
2.11 Phosphatase treatment of membranes 
100µg V5α11 or Tango membranes were incubated with 50 units of calf 
intestinal phosphatase (NEB) at 37ºC for 60 minutes in 1x NEBuffer and a 
total reaction volume of 500µl. 
2.12 Western blotting 
Sample preparation and SDS-PAGE 
Samples were diluted using water and 5x SDS protein loading buffer to a 
concentration of 1µg/µl and then denatured by boiling for 5 minutes. 
Typically, 20µg of the denatured samples were loaded on the gels and then 
resolved at a setting of 100 volts for ~2 hours using the SDS-running buffer, 
till the dye front exited the gel.  
Transfer 
The resolved proteins on the gel were transferred to a nitrocellulose 
membrane (GE healthcare) using the transfer buffer either for 1 hour at 100 
volts (4°C) or overnight at 20 volts (room temperature). 
Blocking, primary and secondary antibody incubations 
Membranes were typically blocked for 1 hour at room temperature in PBS 5% 
milk and then incubated overnight at 4°C with the primary antibody (diluted in 
PBST 2% milk). The membranes were then washed in PBST (4 times, 10 
minutes each) and then incubated for 1 hour at room temperature with the 
secondary antibody (diluted in PBST 2% milk). Following this, the 
membranes were washed in PBST (4 times, 10 minutes each) and then PBS 
(1 time for 10 minutes).  
Detection and quantification 
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The proteins on the membranes were either detected using Enhanced 
Chemiluminescence (ECL) or ECL Plus reagents (GE Healthcare) and X-ray 
film (GRI) or using the Odyssey imaging system (LI-COR). The membranes 
visualised using ECL were quantified using the ImageJ software whereas the 
membranes visualised using the Odyssey system were quantified using the 
Odyssey software. Typically the band of interest was normalised to a loading 
control (β-actin or tag like GST or V5) and then effects of treatments were 
quantified relative to an untreated normalised control.  
2.13 Coomassie stained SDS-PAGE 
For Coomassie staining, samples were resolved by SDS-PAGE as described 
above. The gels were then incubated with Coomassie stain (1g Coomassie 
brilliant blue R-250, 50ml acetic acid, 500ml methanol, 450ml water) for 20 
minutes at room temperature on a shaker. The stain was then discarded and 
the gels were incubated in destaining solution (10% acetic acid, 20% 
methanol) for 90 minutes. The destaining solution was changed every 30 
minutes. Following this, the gels were stored in water.  
2.14 PNPB activity assay 
Membrane assay 
Membranes were typically diluted to 4x the final assay concentration (FAC) 
using 50mM HEPES pH 7.5, 5% DMSO (assay buffer) and then 50µl/well 
was dispensed in a 96-well clear polypropylene plate (normally 3 replicate 
wells). 50µl of the drug (4x FAC) or assay buffer was added to the 
membranes which were then incubated for 5 minutes at room temperature. 
The substrate PNPB (Sigma) was diluted to 40x FAC using DMSO and then 
to 2x FAC using 50mM HEPES pH 7.5. 100µl of the diluted substrate was 
added to each well and the OD400 was measured every 12 seconds for 30 
minutes using a Spectramax plate reader (Molecular devices). Typically, the 
total assay volume was 200µl containing 12.5µg/ml membranes, 250µM 
PNPB, and 5% DMSO. The reactions rates were generally calculated over 
the first 10 minutes using 3 replicate wells.  
Live cell assay 
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Cells were seeded at a density of 40,000/well of 96-well plates in Freestyle 
media (Invitrogen) and maintained overnight. Prior to assaying, the media 
was discarded and the cells were washed with 50mM HEPES pH 7.5 (assay 
buffer). 100µl of drugs (2x FAC) or assay buffer was then added to the wells 
following which the plate was incubated for 5 minutes or for the indicated 
times. PNPB was diluted to 100x FAC in DMSO and then to 2x FAC in assay 
buffer. 100µl was then added to each well and the activity was measured as 
described for the membrane assay (6 replicate wells). Typically, the total 
assay volume was 200µl containing 500µM PNPB, and 1% DMSO. 
2.15 DiFMUO activity assay 
Membrane assay 
Membranes were typically diluted to 4x the final assay concentration (FAC) 
using 50mM MES pH 6.5, 5% DMSO (assay buffer) and then 50µl was 
dispensed in each well of a 96-well clear polypropylene plates (normally 3 
replicate wells). 50µl of the drug (4x FAC) or assay buffer was added to the 
membranes which were then incubated for 5 minutes at room temperature. 
The substrate DiFMUO (Invitrogen) was diluted to 40x FAC using DMSO and 
then to 2x FAC using 50mM MES pH 6.5. 100µl of the diluted substrate was 
added to each well and the fluorescence (excitation 360nm, emission 450nm) 
was measured every 30 seconds for 30 minutes using the FlexStation 
(Molecular devices). Typically, the total assay volume was 200µl containing 
12.5µg/ml membranes, 10µM DiFMUO, and 5% DMSO. The reactions rates 
were generally calculated over the first 10 minutes using 3 replicate wells.  
Live cell assay 
Cells were seeded at a density of 40,000/well of 96-well plates in Freestyle 
media (Invitrogen) and maintained overnight. Prior to assaying, the media 
was discarded and the cells were washed with 50mM MES pH 6.5 (assay 
buffer). 100µl of drugs (2x FAC) or assay buffer was then added to the wells 
following which the plate was incubated for 5 minutes or for the indicated 
times. DiFMUO was diluted to 100x FAC in DMSO and then to 2x FAC in 
assay buffer. 100µl was then added to each well and the activity was 
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measured as described for the membrane assay (6 replicate wells). Typically, 
the total assay volume was 200µl containing 10µM DiFMUO, and 1% DMSO. 
2.16 EnzCheK activity assay 
Membranes were typically diluted to 4x FAC using 50 mM HEPES pH 7.5, 
10% DMSO (assay buffer) and then 25µl was dispensed in each well of a 96-
well clear polypropylene plate (normally 3 replicate wells). 25µl of the drug 
(4x FAC) or assay buffer was added to the membranes which were then 
incubated for 5 minutes at room temperature. The substrate EnzCheK 
(Invitrogen) was diluted to 20x FAC using DMSO and then to 2x FAC using 
50mM HEPES pH 7.5. 50µl of the diluted substrate was added to each well 
and the fluorescence (excitation 480nm, emission 540nm) was measured 
every 48 seconds for 10 minutes using the FlexStation. Typically, the total 
assay volume was 100µl containing 12.5µg/ml membranes, 2µM EnzChek, 
and 10% DMSO. The reactions rates were generally calculated over the first 
2 minutes using 3 replicate wells.  
2.17 Baculovirus generation and expression 
SF-900 II SFM media (Invitrogen) was used to culture the Sf9 (Spodoptera 
frugiperda) insect cells unless otherwise stated. 
Baculovirus generation 
Recombinant baculoviruses (P1) were generated and amplified using Sf9 
cells and the GST-DAGL CD pENTR constructs following the Bac-to-Bac 
system (Invitrogen). Briefly - 50µl DH10Bac competent cells (Invitrogen) were 
transformed with 5µl of the plasmid DNA and selected on LB Agar plates 
containing 50μg/ml kanamycin, 7μg/ml gentamicin,10μg/ml tetracycline, X-
gal, and IPTG. White colonies obtained were restreaked to confirm the 
selection (blue/white). The selected clones were then grown in 5ml LB 
50μg/ml kanamycin, 7μg/ml gentamicin, and 10μg/ml tetracycline, overnight 
at 37°C. The bacmid DNA was extracted from the cells and used to transfect 
Sf9 cells in 6-well plates using Cellfectin and Grace's insect media 
(Invitrogen). The media was changed to SF-900 II SFM media 5 hours post 
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transfection. The media containing the P1 viruses was collected 4-5 days 
post transfection and stored in the presence of 5% FCS in the dark at 4°C.  
In order to amplify the virus, 200mls Sf9 cells at a density of 1.2 x 106 cells/ml 
in 1L Erlenmeyer flasks were infected with 500µl of P1/2 virus and incubated 
in a shaker at 27.5°C (110rpm) for 4-5 days (or until viability <80%). The P2/3 
virus (supernatant) was then collected by centrifugation (3,000g for 10 
minutes). The cell count at time of harvest was generally ~3 x 106 cells/ml 
with a viability of 60-70%, as determined by the trypan blue exclusion 
method. The viruses were stored in the dark at 4°C in the presence of 5% 
FCS. 
Expression 
For expression, 10ml P2/3 virus was added to 200ml Sf9 cells at a density of 
2 x 106 cells/ml (in 1L Erlenmeyer flask).  The cells were cultured for 48 
hours (27.5°C and 110rpm) and then harvested by centrifugation at 3000g. 
Cell count at the time of harvest was generally ~3-4 x 10e6/ml (~75% viable).  
2.18 Purification of the GST tagged DAGL catalytic domains 
Lysis 
3 x 109 cells were resuspended (0.5 x 108 cells/ml) in lysis buffer (50mM Tris, 
150mM NaCl, 2mM DTT, 1% Triton-X-100, pH 7.8) by vortexing and then 
lysed by dounce homogenisation (10 strokes). Lysates were incubated in the 
cold room on a roller for 2 hours. The lysates were then centrifuged at 
75,000g for 60 minutes and the supernatant was collected.  
GST affinity purification  
GST purifications were performed using glutathione sepharose 4B beads 
(GE healthcare). 1ml of settled beads were equilibrated in lysis buffer and 
then incubated with the lysates in the cold room on a roller for 30 minutes. 
The beads were then collected using a plastic drip column. The collected 
beads were washed with 20 column volume wash buffer (50mM Tris, 150mM 
NaCl, 2mM DTT, 0.05% Triton-X-100, pH 7.8) and then 0.5ml elution 
fractions were collected using the elution buffer (50mM Tris, 150mM NaCl, 
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2mM DTT, 0.05% Triton-X-100, 50mM glutathione, pH 7.8). The elutions 
obtained were analysed by Coomassie stained SDS-PAGE and typically 
elutions 2-5 were stored at -80°C and used for the gel filtration 
chromatography.  
Gel filtration purification of the GST affinity purified DAGL catalytic domains 
The purification buffer used for the gel filtration chromatography was 50mM 
Tris, 150mM NaCl, 2mM DTT, 0.05% Triton-X-100, pH 7.8. Gel filtrations 
purifications were performed using an Akta prime (GE healthcare) at a flow 
rate of 1ml/minute using either the HiLoad 13/300 Superdex 200 GL or the 
HiLoad 16/600 Superdex 200 pg column (GE healthcare). 
The 13/300 column was equilibrated in 1 column volume of purification buffer 
after which 0.5ml of the GST elution (~0.5mg) was loaded and 1ml fractions 
were collected. Fractions correspoding to peaks in the chromatogram (A280) 
were analysed by Coomassie stained SDS-PAGE (20µl sample). The native 
molecular weights of the proteins in the fraction were determined using a 
chromatogram of protein standards provided by the manufacturer (GE 
healthcare). The purification using the 16/600 column was performed as 
above except 2ml (~2mg) of the GST elutions were used and 1.5ml fractions 
were collected.  
2.19 In vitro phosphorylation and Phos-tag analysis 
Kinase treatment 
0.5-1µM of GST-MBP (Millipore) or GST-DAGLα/β catalytic domain (purified 
by GST affinity and gel filtration) were incubated with varying concentrations 
of either PKA (Promega) or PKC (Invitrogen) in IVP buffer (50mM Tris, 0.05% 
Triton-X-100, 2mM DTT pH 7.8, 2.4mM ATP and 240mM MgCl2) for 1 hour at 
30ºC. Temperature, incubation times, and kinase concentrations were varied 
in some experiments. Typical reaction volumes were 24µl. Following the set 
incubation times, 6µl of 5x SDS protein loading buffer was added and the 
samples were boiled for 5 minutes. The denatured samples were analysed 
by Phos-tag Western blotting analysis as described below.  
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Phos-tag Western blotting analysis 
SDS-PAGE gels containing 70µM Phos-tag (Alpha laboratories) and 140µM 
MnCl2 were prepared and used as part of Western blotting analyses as 
described above with the following variation. After the samples were resolved 
by SDS-PAGE, the gels were incubated in transfer buffer + 1mM EDTA for 
10 minutes and then in transfer buffer for 10 minutes prior to the transfer.  
2.20 Phospho-mapping 
Tryptic digestion 
Bands of interest (~5µg of GST-DAGL CD) were excised from Coomassie 
stained gels and washed with 100mM ammonium bicarbonate (ambic) for 5 
minutes. Following this, the gel pieces were dehydrated with acetonitrile, 
dried, and then rehydrated with 10mM DTT (made up in 100mM ambic) at 
56°C for 30 minutes. The DTT solution was then discarded and the gel 
pieces were once again dehydrated with acetonitrile, dried, and then 
incubated with 55mM iodoacetamide (made up in 100mM ambic) for 20 
minutes in the dark, at room temperature. The supernatant was then 
discarded and the gel pieces were washed twice with 100mM ambic after 
which they were dehydrated with acetonitrile and then dried again. Following 
this, the gel pieces were rehydrated in a minimal volume (enough to immerse 
and rehydrate) of trypsin (13ng/ml in 50mM ambic) for 20 minutes at 4°C.  
Unabsorbed trypsin was removed and the gel pieces were submerged in 
50mM ambic and incubated at 37°C for 2 hours and then overnight at room 
temperature.  
Peptide extraction 
The supernatant from the gel pieces above was collected after which the gel 
pieces were washed with a minimal volume of 50mM ambic (enough to 
immerse the gel pieces) for 5 minutes at 37°C, the supernatant was collected 
and pooled with the initial supernatant. The gel pieces were then dehydrated 
using acetonitrile for 10 minutes at 37°C and the supernatant was once again 
collected and pooled. The wash and dehydration steps were repeated. The 
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pooled supernatants containing the peptide extract were dried down and 
stored at -80oC.  
Mass spectrometry analysis 
The peptide extracts above were resuspended in 20µl 50mM ambic and 10µl 
was used for mass spectrometry analysis. Chromatographic separations 
were first performed using an EASY NanoLC system 
(ThermoFisherScientific, UK). Peptides were resolved by reversed phase 
chromatography on a 75 m C18 EASY column using a three step linear 
gradient of acetonitrile (5-40%, 40-95%, 95-5%) in 0.1% formic acid. The 
gradient was delivered to elute the peptides at a flow rate of 300 nL/min over 
60 min. The eluate was ionised by electrospray ionisation using an Orbitrap 
Velos Pro (ThermoFisher Scientific), running the Xcaliber software v.2.1.0 
SP1.1160, with the following parameters: 50 minute acquisition; Top 20 CID 
(collision induced dissociation) method; Normalised collision energy - 35v; 
Activation Q - 0.250; Activation Time - 10ms; Lock Mass - m/z 445.120024; 
MS Scan width - m/z 400-2000; MS/MS Scan width - m/z 100-2000, 30 sec 
dynamic exclusion). The MS/MS analyses were conducted using collision 
energy profiles that were chosen based on the mass-to-charge ratio (m/z) 
and the charge state of the peptide.  
The mass spectral data was processed into peak lists using Proteome 
Discoverer v1.3 (v. 1.3.0.339). The peak list was searched against the 
Uniprot database (www.uniprot.org) using Mascot software v2.2 
(www.matrixscience.com) with the following parameters: Precursor ion mass 
tolerance 10ppm; Fragment ion mass tolerance 0.8Da; Tryptic digest with up 
to three missed cleavages; Variable modifications: Acetyl (Protein N-term), 
Carbamidomethylation (C), Oxidation (M) & Phosphorylation (S, T & Y); 
Target FDR 0.01 (Strict) – 0.05 (Relaxed). Any identified phosphorylation 






Chapter 3 (Results 1): Regulation of DAGL activity - A 
bioinformatics perspective 
3.1 Introduction 
The first reports of the isolation and partial biochemical characterisation of 
DAGL activity were made almost 30 years ago (Farooqui et al., 1984, 1986). 
However, to date very little, if anything, is known about how these enzymes 
are regulated. In the last decade, since the DAGLs were cloned, several 
studies have established key physiological roles for these enzymes in 
processes like axonal growth and guidance, synaptic signalling and adult 
neurogenesis (Reisenberg et al., 2012). More recent studies have also 
focussed on their roles in diseases e.g. Fragile X syndrome and pain (Gregg 
et al., 2012; Jung et al., 2012) and on their therapeutic potential (Hsu et al., 
2012), which has raised further interest in the mechanisms regulating these 
enzymes.  
There is a considerable body of evidence describing the structure and 
function of molecules that are structurally related to the DAGLs, and a very 
large and generally untapped amount of data in public databases describing 
phospho-peptides that have been identified based on proteomic type studies. 
Likewise, there are now numerous computational tools that can predict 
phospho-sites, and indeed the kinases that might act upon them (Blom et al., 
1999; Iakoucheva et al., 2004; Amanchy et al., 2007). In this chapter I use 
structural homology and bioinformatics to build a working model that provides 
a template for determining the mechanisms that regulate DAGL activity. 
However, before that I will briefly outline some evidence that points to 
mechanisms that are likely to regulate DAGL activity. 
Several fold differences between basal and stimulated 2-AG levels have 
been reported (e.g. (Sugiura et al., 2000a; Aguado et al., 2005), raising the 
possibility that intra-molecular mechanisms to activate the DAGLs may exist. 
In the absence of a crystal structure for either DAGLα or DAGLβ, I have used 
a homology modelling approach to identify the key sites in the enzymes that 
most probably regulate function. In brief, secondary sequence alignments of 
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the mammalian DAGLs with the fungal DAGL whose crystal structure has 
been solved (Yamaguchi et al., 1991; Derewenda et al., 1994) revealed a 
large insert in the catalytic domain between the β strands 7 and 8. On 
comparison with other lipases (HSL and PL), this insert is well placed to act 
like a 'lid', preventing substrate access to the catalytic site. The activity of 
several lipases is modulated by phosphorylation; for example, in the case of 
HSL, the opening and closing of the lid is regulated by phosphorylation 
(Holm, 2003). In order to therefore explore the potential role of 
phosphorylation in the regulation of DAGL activity I searched phospho-
peptide databases and identified candidate regulatory phospho-sites within 
the DAGL sequence. 30 sites for DAGLα and 12 sites for DAGLβ were 
identified of which 9 and 12 were located within the catalytic domain. I have 
mapped these sites onto a structural model of the enzymes to identify the 
ones that are most likely to regulate substrate access to the catalytic site. 
Finally, I have used additional bioinformatics tools (DISPHOS, NetPhos2.0), 
to assess the likelihood of these sites being genuine phospho-sites as well as 
to identify candidate kinases responsible for these phosphorylation events. 
3.2 Results 
3.2.1 Primary, secondary and domain structure of the DAGLs 
DAGLα and DAGLβ both consist of a 4 transmembrane domain towards the 
N-terminus followed by an intracellular catalytic domain as represented by 
the overall domain structure of the DAGLs in Figure 3.1 (Bisogno et al., 
2003). Additionally, DAGLα contains a tail region at the C-terminus that is 
absent in DAGLβ (Figure 3.1). The predicted and apparent (by SDS-PAGE) 
molecular weight of the 1042 amino acid long DAGLα is ~120kDa and the 
672 amino acid long DAGLβ is ~70kDa (Bisogno et al., 2003). DAGLα and 
DAGLβ amino acid sequences are highly conserved between human and 
mouse: 97% identity for DAGLα and 79% for DAGLβ (Bisogno et al., 2003). 
Additionally, the amino acid sequences of the human DAGLs display an 
overall 35% homology, which is even higher in the catalytic domain (Gareth 






Figure 3.1. Domain structure of mammalian DAGLα and DAGLβ 
The DAGLs consist of an N terminal transmembrane domain, followed by a 
catalytic domain (red). DAGLα consists of a tail at the C-terminus which is 
absent in DAGLβ. Secondary structure alignments with other lipases indicate 
the presence of two inserts in the catalytic domain, a cysteine rich insert 
(yellow), and a putative lid (green). The cysteine rich insert may act as a 
palmitoylation site that could help localise the enzyme to specific membrane 
microdomains. The putative lid may regulate the activity of the enzyme by 
preventing substrate access to the catalytic site. (Adapted from (Reisenberg 









Structurally, the DAGLs belong to the alpha/beta hydrolase fold family, a 
large group of structurally related but catalytically diverse enzymes that 
include lipases, peptidases and esterases (Holmquist, 2000). They consist of 
a mostly parallel beta sheet composed of eight beta strands which are 
generally linked by alpha helices but also by loops. They all possess a 
nucleophile-acid-His catalytic triad (Ser, Asp and His in the case of the 
DAGLs) (Figure 3.2, highlighted in red). The nucleophile is located within a 
Gly-X-Nucleophile-X-Gly consensus sequence (Gly-His-Ser-Leu-Gly for the 
DAGLs, Figure 3.2, boxed), referred to as the nucleophile elbow, which plays 
an important role in presenting the nucleophile to the substrate (Nardini and 
Dijkstra, 1999). The catalytic triad and nucleophile elbow sequence are 
conserved between both human and mouse DAGLα/β as highlighted in the 
primary sequence alignment in Figure 3.2. The catalytic triad of the DAGLs 
have been experimentally verified in our lab and by others (Bisogno et al., 
2003; Pedicord et al., 2011).  
The ability of the alpha/beta hydrolase domain (ABHD) fold to accommodate 
structural insertions between the β strands contributes to the functional 
diversity observed in this family. For example, in the case of lipases, a 
commonly found insert is a lid like structure that covers and regulates 
substrate access to the catalytic site (Nardini and Dijkstra, 1999). Our group 
exploited sequence information of a fungal MAGL/DAGL from P. camembertii 
to clone the vertebrate DAGLs and the crystal structure of this minimal fold 
DAGL has been solved (Derewenda et al., 1994). In order to gain structural 
insights into the DAGLs, we generated secondary structure alignments of the 
DAGLs and the fungal lipase. This identified 2 key features - a cysteine rich 
insert (highlighted in yellow in Figure 3.1 and Figure 3.2) and a putative lid 
(highlighted in green in Figure 3.1 and Figure 3.2). These are discussed 
below.  
3.2.2 The Cysteine rich insert 
Secondary structure alignments of the DAGLs with P. camembertii revealed 









Figure 3.2. Multiple sequence alignment of the catalytic domain 
sequences of human and mouse DAGLβ and DAGLα 
Multiple sequence alignment was performed using CLUSTAL 2.1. 
The catalytic triad (Ser, Asp and His) are highlighted in red. The 
serine containing nucleophile elbow is annotated with a box. The 
cysteine rich insert and putative lid are highlighted in yellow and 





Alignment of DAGLs highlighting key structural features  
 
hDAGLβ         TDLVPSDIAAGLALLHQQQDNIR------NNQEPAQVVCHAPGSSQEADLDAELEN---- 277 
mDAGLβ         TDLVPSDIAAGFTLLHQQQDNIS------HSREPPEVVTHTPGQPQETELDAEVEN---- 277 
hDAGLα         LDIVPSDIIAGLVLLRQRQRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSQEMLR 288 
mDAGLα         LDIVPSDIIAGLVLLRQRQRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSHEMLR 288 
                *:***** **:.**:*:*           ..:   .:   *   :   ** : .:     
 
hDAGLβ         ---CHHYMQFAAAAYGWPLYIYRNPLTGLCRIGGDC----CRSRTTDYDLVGGDQLNCH- 329 
mDAGLβ         ---CHHYMPFAAAAYGWPLYIYRNPFTGLCRIGGDC----CRARDIEYDAVEGDQHNCH- 329 
hDAGLα         YKEVCYYMLFALAAYGWPMYLMRKPACGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCG 348 
mDAGLα         YKEVCYYMLFALAAYGWPMYLMRKPTCGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCG 348 
                    :** ** ******:*: *:*  ***::. .*    * :*      *  :: **   
 
hDAGLβ         -----FGSILHTTGLQYRDFIHVSFHDKVYELPFLVALDHRKESVVVAVRGTMSLQDVLT 384 
mDAGLβ         -----FASILKTTGLQYRDFIHISFHDKVYELPFIVVLDHRKESVVVAVRGTMSLQDVLT 384 
hDAGLα         CNAIAIRRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRGTLSPKDALT 408 
mDAGLα         CNAIAIRRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRGTLSPKDALT 408 
                    :   :   .:   *::: * ** *** ** *.:** *:.**:::***:* :*.** 
 
hDAGLβ         DLSAESEVLDVECEVQDRLAHKGISQAARYVYQRLINDGILSQAFSIAP-----EYRLVI 439 
mDAGLβ         DLSAESETLELGIELQDCVAHKGIAQAARYIHRRLVNDGILSQAFSVAP-----EYQLVL 439 
hDAGLα         DLTGDAERLPVEGHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIV 468 
mDAGLα         DLTGDAERLPVEGHRGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIV 468 
               **:.::* * :  .    :.***:  :*.*: ::* :: :*****.        .* *:: 
 
hDAGLβ         VGHSLGGGAAALLATMLRAAYPQVRCYAFSPPRGLWSKALQEYSQSFIVSLVLGKDVIPR 499 
mDAGLβ         VGHSLGAGAAALLAIMLRGAYPQVRAYAFSPPRGLLSKSLYEYSKDFVVSLILGMDVIPR 499 
hDAGLα         VGHSLGAGTAAILSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPR 528 
mDAGLα         VGHSLGAGTAAILSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPR 528 
               ******.*:**:*: :**  ** ::.:*:*** ** *:   ***:.*:.:::** *::** 
 
hDAGLβ         LSVTNLEDLKRRILRVVAHCNKPKYKILLHGLWYELFGGNPNNLPTELDGGDQEVLTQPL 559 
mDAGLβ         LSVTNMEDLKRRILRVIANCNKPKYKILLHGCWYGLFGGSPDNFPTELDEGTQGALTQPL 559 
hDAGLα         IGLSQLEGFRRQLLDVLQRSTKPKWRIIVG--------------------ATKCIPKSEL 568 
mDAGLα         IGLSQLEGFRRQLLDVLQRSTKPKWRIIVG--------------------ATKCIPKSEL 568 
               :.::::*.::*::* *: ...***::*::                     . :   .. * 
 
hDAGLβ         LGEQSLLTRWSPAYSFSSDSPLDSSP-KYPPLYPPGRIIHLQEEGASGRFGCCS--AAHY 616 
mDAGLβ         LGEQTLLTRYSPGY-CSSDSPLDSPT-KYPTLYPPGRIIHLEEEGGSGRFGCCS--AAQY 615 
hDAGLα         P-EEVEVTTLASTRLWTHPSDLTIALSASTPLYPPGRIIHVVHNHPAEQCCCCEQEEPTY 627 
mDAGLα         PEDQVEVTTLASTRLWTHPSDLTIALSASTPLYPPGRIIHVVHNHPAEQCCCCEQEEPTY 628 
                 ::  :*  :.    :  * *  .    ..*********: .:  : :  **.   . * 
 
hDAGLβ         SAKWSHEAEFSKILIGPKMLTDHMPDILMRALDSVVSDR----AACVSCPAQGVSSVDVA 672 
mDAGLβ         RARWAHEAEFSKILIGPKMLIDHMPDVMIRALDRVLADR----TACVSCPGQGGSSVP-- 669 
hDAGLα         FAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVD 687 
mDAGLα         FAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVD 688 













cysteine rich insert within the catalytic domain, between the first two alpha 
helices. (Figure 3.1 and Figure 3.2). It is tempting to speculate that this insert 
contains palmitoylation sites. Palmitoylation is a reversible post-translational 
modification of cysteine residues which occurs by the attachment of a 
palmitic acid via a thioester linkage (Aicart-Ramos et al., 2011) and regulates 
subcellular trafficking of proteins (Canobbio et al., 2008). This insert could 
potentially regulate DAGL activity by affecting its localisation at the 
membrane relative to its substrate and down-stream receptors (CB1/2). 
3.2.3 The DAGLs contain a putative lid like insert 
As mentioned earlier, a common structural feature among lipases is a lid like 
structure that is inserted between β strands of the canonical ABHD fold. The 
lid is responsible for the 'interfacial activation' phenomenon, commonly 
observed with these enzymes. Interfacial activation refers to the 
displacement of the lid and increased activity when the lipase comes in 
contact with a lipid phase (Nardini and Dijkstra, 1999; Holmquist, 2000). The 
lid can simply act as a physical barrier preventing substrate access e.g. 
gastric lipase (GL) (Canaan et al., 1999), but displacement of the lid can also 
lead to a structural rearrangement of the active site rendering the enzyme 
active, as in the case of pancreatic lipase (PL) (van Tilbeurgh et al., 1993). 
Presumably, the activity of the DAGLs is regulated by similar mechanisms.  
The size of the lid can vary amongst lipases. In the case of human PL, a 24 
amino acid α-helical surface loop shields the active site (Figure 3.3) (Winkler 
et al., 1990). In the case of human GL, a large cap domain (124 amino acids) 
is present between the canonical β strands 6 and 7 and is made up of 8 
helices, turns and random coils (Miled et al., 2003). In the case of hormone 
sensitive lipase (HSL), an even larger ~150 amino acid insert between the 
canonical β strands 6 and 7, often referred to as the regulatory domain or 
regulatory module, is well placed to function as the lid (Lampidonis et al., 




Figure 3.3. Fold topologies of the catalytic domain of the DAGLs 
relative to other lipases 
PL, HSL and DAGL are members of the ABHD fold family and consist of a 
core eight stranded beta sheet (dark blue) which are connected by α helices 
(red), β strands (blue, canonical in dark blue) and loops. The catalytic triad 
consisting of a Ser, Asp and His are highlighted in orange. The lid of PL is 
present after the core β strand 7. The lid region of HSL (green) is a more 
pronounced insert present between core β strand 6 and 7. In the case of the 
DAGLs, a putative lid referred to as the regulatory loop (RL) (green) is 
present between core β strands 7 and 8. An additional cysteine rich insert is 
present towards the N-terminus of the DAGL catalytic domain that may act as 
a site for palmitoylation. (Adapted from (Reisenberg et al., 2012). 
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The catalytic domains of the DAGLs contain a 50-60 amino acid insert of 
unknown structure between the β strands 7 and 8 (highlighted in green in 
Figure 3.1, Figure 3.2 and Figure 3.3). This insert is encoded by a single 
exon (Reisenberg et al., 2012), appears to be membrane proximal 
(discussed further down) and is well positioned to act as a lid, shielding the 
catalytic site (Figure 3.3). This insert is smaller than the ~150 amino acid 
regulatory domain of HSL and larger than the ~25 amino acid lid of PL, and is 
henceforth referred to as the regulatory loop (RL). One of the most striking 
features of the loop is a highly conserved short peptide sequence 
'LYPPGRIIH' (highlighted in dark blue in Figure 3.2). This polyproline 
'signature motif' is not only conserved amongst human DAGLα and β but also 
conserved between mammalian, invertebrate, and plant DAGLs (data not 
shown).  
The highly conserved nature of this sequence could implicate it as a binding 
site for an interaction partner; however this would also require the interacting 
partner to be conserved across the species. It is therefore more likely that 
this sequence is involved in an intra-molecular interaction which could 
stabilise the open/closed conformation of the enzyme. 
3.2.4 Phosphorylation of the DAGLs 
The relatively large RL in the DAGLs provides a potential regulatory 
mechanism given that lid displacement could directly determine an 'open' and 
'closed' conformation, and thereby regulate activation of the DAGLs. In this 
context, the activity of several lipases is regulated by phosphorylation at 
specific sites e.g. PLC-γ (Gresset et al., 2010), TGL4 (Kurat et al., 2009) and 
HSL (Lampidonis et al., 2011). HSL is probably the most studied lipase in 
terms of its phosphorylation. The activity of HSL is regulated by PKA in vitro 
and in cells (Lampidonis et al., 2011). PKA can phosphorylate HSL directly at 
3 different sites and can cause ~2-fold increase in activity in vitro (Holm et 
al., 1994; Anthonsen et al., 1998). In addition to this, PKA dependent 
phosphorylation of HSL in cells results in translocation of HSL to lipid 
droplets (Brasaemle et al., 2000). Interestingly, all the PKA phospho-sites in 
the HSL sequence are located in the regulatory domain and in vitro 
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phosphorylation by PKA increases the hydrophobic surface area of the 
protein, presumably due to displacement of the regulatory domain (Krintel et 
al., 2009; Lampidonis et al., 2011). This has led to a model, where in cells, in 
response to certain stimuli, phosphorylation of HSL by PKA displaces its lid 
to expose its hydrophobic core which results in increased interaction with the 
lipid droplets (Lampidonis et al., 2011).  
3.2.4.1 The DAGL phospho-map 
'PhosphositePlus' from Cell Signalling Technology (CST) is a curated web 
resource of  experimentally observed phospho-sites identified from published 
sources as well as from previously unpublished data generated at CST. This 
resource can be used to identify DAGL derived phospho-peptides and I have 
used this to generate the first comprehensive DAGLα/β phospho-maps 
(Figure 3.4). The phospho-sites highlighted in the primary sequence are 
presented in Figure 3.5. A total of 30 sites for DAGLα and 12 sites for DAGLβ 
have been identified of which 9 (2 in the RL) and 12 (8 in the RL) were 
located within the catalytic domain. The tail region of DAGLα was particularly 
heavily phosphorylated (20 sites). In the case of DAGLβ, a short stretch of 15 
amino acids located in the RL was found to be heavily phosphorylated (8 
sites). This region is poorly conserved between DAGLα and DAGLβ and no 
phospho-sites in this region of DAGLα have been identified. However, this 
could simply be because these phospho-sites have not been detected yet, 
especially considering 5 of the 15 amino acids are serine/threonines (Figure 
3.5). Overall, 7 of the sites are conserved between the DAGLs but only 1 
conserved site (S402/S378) was reported in both DAGLα and DAGLβ (Figure 
3.5). 
3.2.4.2 Note of caution towards false positives and false negatives 
With the exception of one study (Shonesy et al., 2013), all the studies 
identifying DAGL derived phospho-peptides were performed using complex 
cellular or tissue extracts, including U2OS and Jurkat T cell lines, 
synaptosomes and brain tissues (Table 3.1 and Table 3.2). When simply 
identifying proteins in a complex sample, data from multiple peptides are 










Figure 3.4. The DAGLα/β phospho-map 
Experimentally observed phospho-sites of the DAGLs are annotated 
above. The numbering is according to the human enzyme. The 
regions highlighted are - transmembrane domain (yellow), catalytic 















Figure 3.5. DAGL phospho-sites highlighted in the catalytic 
domain sequences of human and mouse DAGLβ and DAGLα 
Multiple sequence alignment was performed using CLUSTAL 2.1. 
Experimentally identified phospho-sites in the DAGL catalytic domain 
are annotated as follows - phospho-sites identified in mouse/human 
DAGLα - pink, mouse/human DAGLβ - blue, phospho-sites identified 
in both DAGLα and DAGLβ - grey. The catalytic triad (Ser, Asp and 
His) are highlighted in red. The serine containing nucleophile elbow 
is also annotated with a box. The cysteine rich insert and regulatory 
loop are highlighted in yellow and green respectively. The signature 




Alignment of DAGLs highlighting key structural features and identified phosphosites 
 
hDAGLβ         TDLVPSDIAAGLALLHQQQDNIR------NNQEPAQVVCHAPGSSQEADLDAELEN---- 277 
mDAGLβ         TDLVPSDIAAGFTLLHQQQDNIS------HSREPPEVVTHTPGQPQETELDAEVEN---- 277 
hDAGLα         LDIVPSDIIAGLVLLRQRQRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSQEMLR 288 
mDAGLα         LDIVPSDIIAGLVLLRQRQRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSHEMLR 288 
                *:***** **:.**:*:*           ..:   .:   *   :   ** : .:     
 
hDAGLβ         ---CHHYMQFAAAAYGWPLYIYRNPLTGLCRIGGDC----CRSRTTDYDLVGGDQLNCH- 329 
mDAGLβ         ---CHHYMPFAAAAYGWPLYIYRNPFTGLCRIGGDC----CRARDIEYDAVEGDQHNCH- 329 
hDAGLα         YKEVCYYMLFALAAYGWPMYLMRKPACGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCG 348 
mDAGLα         YKEVCYYMLFALAAYGWPMYLMRKPTCGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCG 348 
                    :** ** ******:*: *:*  ***::. .*    * :*      *  :: **   
 
hDAGLβ         -----FGSILHTTGLQYRDFIHVSFHDKVYELPFLVALDHRKESVVVAVRGTMSLQDVLT 384 
mDAGLβ         -----FASILKTTGLQYRDFIHISFHDKVYELPFIVVLDHRKESVVVAVRGTMSLQDVLT 384 
hDAGLα         CNAIAIRRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRGTLSPKDALT 408 
mDAGLα         CNAIAIRRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRGTLSPKDALT 408 
                    :   :   .:   *::: * ** *** ** *.:** *:.**:::***:* :*.** 
 
hDAGLβ         DLSAESEVLDVECEVQDRLAHKGISQAARYVYQRLINDGILSQAFSIAP-----EYRLVI 439 
mDAGLβ         DLSAESETLELGIELQDCVAHKGIAQAARYIHRRLVNDGILSQAFSVAP-----EYQLVL 439 
hDAGLα         DLTGDAERLPVEGHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIV 468 
mDAGLα         DLTGDAERLPVEGHRGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIV 468 
               **:.::* * :  .    :.***:  :*.*: ::* :: :*****.        .* *:: 
 
hDAGLβ         VGHSLGGGAAALLATMLRAAYPQVRCYAFSPPRGLWSKALQEYSQSFIVSLVLGKDVIPR 499 
mDAGLβ         VGHSLGAGAAALLAIMLRGAYPQVRAYAFSPPRGLLSKSLYEYSKDFVVSLILGMDVIPR 499 
hDAGLα         VGHSLGAGTAAILSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPR 528 
mDAGLα         VGHSLGAGTAAILSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPR 528 
               ******.*:**:*: :**  ** ::.:*:*** ** *:   ***:.*:.:::** *::** 
 
hDAGLβ         LSVTNLEDLKRRILRVVAHCNKPKYKILLHGLWYELFGGNPNNLPTELDGGDQEVLTQPL 559 
mDAGLβ         LSVTNMEDLKRRILRVIANCNKPKYKILLHGCWYGLFGGSPDNFPTELDEGTQGALTQPL 559 
hDAGLα         IGLSQLEGFRRQLLDVLQRSTKPKWRIIVG--------------------ATKCIPKSEL 568 
mDAGLα         IGLSQLEGFRRQLLDVLQRSTKPKWRIIVG--------------------ATKCIPKSEL 568 
               :.::::*.::*::* *: ...***::*::                     . :   .. * 
 
hDAGLβ         LGEQSLLTRWSPAYSFSSDSPLDSSP-KYPPLYPPGRIIHLQEEGASGRFGCCS--AAHY 616 
mDAGLβ         LGEQTLLTRYSPGY-CSSDSPLDSPT-KYPTLYPPGRIIHLEEEGGSGRFGCCS--AAQY 615 
hDAGLα         P-EEVEVTTLASTRLWTHPSDLTIALSASTPLYPPGRIIHVVHNHPAEQCCCCEQEEPTY 627 
mDAGLα         PEDQVEVTTLASTRLWTHPSDLTIALSASTPLYPPGRIIHVVHNHPAEQCCCCEQEEPTY 628 
                 ::  :*  :.    :  * *  .    ..*********: .:  : :  **.   . * 
 
hDAGLβ         SAKWSHEAEFSKILIGPKMLTDHMPDILMRALDSVVSDR----AACVSCPAQGVSSVDVA 672 
mDAGLβ         RARWAHEAEFSKILIGPKMLIDHMPDVMIRALDRVLADR----TACVSCPGQGGSSVP-- 669 
hDAGLα         FAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVD 687 
mDAGLα         FAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVD 688 
                * *..:  *.:::*.* ** :*:* :::..*: *: :     :* :*..    *..    
 
Phospho-sites identified in mouse/human DAGLα 
Phospho-sites identified in mouse/human DAGLβ 
Phospho-sites identified in both DAGLα and β 

















Published Cell/Tissue type Reference 
Y62 TM 0 1 
Non small cell lung 
cancer cell 
line/tumours 
(Rikova et al., 
2007) 
Y370 CD 0 1 
Non small cell lung 
cancer cell 
line/tumours 
(Rikova et al., 
2007) 
Y378* CD 0 1 
Non small cell lung 
cancer cell 
line/tumours 
(Rikova et al., 
2007) 
S396 CD 1 0 
Neuroendocrine 
tumor  
T400* CD 1 0 
Neuroendocrine 
tumor  
S402* CD 1 0 
Neuroendocrine 
tumor  
T411 CD 0 1 
HEK293T (over- 
expressed) 
(Shonesy et al., 
2013) 
S450* CD 0 1 
 
(Hsu et al., 
2011) 
T560 RL 9 0 
Jurkat T cell (8), 
K562 
(myelogenous 
leukaemia) cell line 
 
S566 RL 1 0 Jurkat T cell  
S725 Tail 0 1 
HEK293T (over- 
expressed) 
(Shonesy et al., 
2013) 




(Munton et al., 
2007; Shonesy 
et al., 2013) 
S729 Tail 0 1 
Brown fat, 
Kidney 
(Huttlin et al., 
2010) 





(Trinidad et al., 
2006; Huttlin et 
al., 2010; 
Trinidad et al., 
2012) 
S743 Tail 0 8 
HEK293T (over 
expressed) 
Brain  (3) 
Synapse (2) 
PSD 
(Trinidad et al., 
2006; Trinidad et 
al., 2008; Huttlin 
et al., 2010; 
Wisniewski et 
al., 2010; 
Goswami et al., 
2012; Trinidad et 
al., 2012; 
Shiromizu et al., 
2013; Shonesy 
et al., 2013) 
S762 Tail 1 0 Brain  
S782 Tail 0 1 
HEK293T (over 
expressed) 
(Shonesy et al., 
2013) 
S784 Tail 0 2 
Brain 
Synapse 
(Huttlin et al., 
2010; Trinidad et 
al., 2012) 





2008; Chen et 
al., 2009; Huttlin 
et al., 2010; 
Wisniewski et 
al., 2010; 
Shiromizu et al., 
2013) 
S808 Tail 0 1 
HEK293T (over 
expressed) 
(Shonesy et al., 
2013) 






Shonesy et al., 
2013) 




(Huttlin et al., 
2010; Shonesy 
et al., 2013) 
S925 Tail 0 1 Brain 
(Wisniewski et 
al., 2010) 
S952 Tail 0 2 Brain (2) 




S954 Tail 0 1 Brain 
(Wisniewski et 
al., 2010) 
S989 Tail 1 0 Brain  
T1006 Tail 1 0 Brain  




(Huttlin et al., 
2010; Shiromizu 
et al., 2013; 
Shonesy et al., 
2013) 
T1025 Tail 0 1 Brain 
(Huttlin et al., 
2010) 









Trinidad et al., 
2012; Shiromizu 
et al., 2013; 
Shonesy et al., 
2013) 
* conserved in DAGLβ 

















Published Cell/Tissue type Reference 
Y318 CD 3 0 Jurkat cells 
 




(Brill et al., 2009) 




(Brill et al., 2009) 
Y460* CD 1 0 PC12  
S570 RL 0 3 
HeLa (2) 
Jurkat T Cell, 
(Daub et al., 2008; 
Mayya et al., 2009; 
Olsen et al., 2010) 
Y573 RL 0 1 
 
(Wang et al., 2006) 
S574 RL 17 1 
breast cancer 
liver cancer (4) 
lung cancer (9) 
skin cancer (2) 
Jurkat T cell 
K562 cell 
(Mayya et al., 2009) 





S577 RL 0 3 
Brain (2) 
Jurkat T cell 
(Mayya et al., 2009; 
Tweedie-Cullen et 
al., 2009; Huttlin et 
al., 2010) 
S579* RL 0 5 
HeLa 
KG1 AML cells 
U2OS 
Brain (2) 
(Huttlin et al., 2010; 
Olsen et al., 2010; 
Raijmakers et al., 
2010; Wisniewski et 
al., 2010; Weber et 
al., 2012) 




(Dephoure et al., 
2008; Tweedie-
Cullen et al., 2009; 
Huttlin et al., 2010; 
Wisniewski et al., 
2010; Trinidad et al., 
2012) 
* Conserved in DAGLα 
* *Alignment of these sites to mouse DAGLβ is ambiguous  
 









On the other hand identifying a phospho-site from a complex sample can 
often rely on a single peptide. The peptide maybe poorly ionisable and 
present in low abundance which can result in poor quality mass spec data 
and result in false negatives. On the other hand, lowering the stringency 
criteria of phospho-peptide identification to minimise false negatives can in 
turn introduce false positives (Alcolea et al., 2009). If we were to only 
consider DAGL phospho-sites identified in at least two separate studies then 
the number of identified sites for DAGLα is reduced from 30 to 11. If the 
criteria is set to a minimum of three studies the number drops to 6 (Table 
3.1). For DAGLβ, 12 sites have been identified at least once, 7 at least twice 
and all 7 have actually been identified at least three times (Table 3.2). 
As the CST studies have not been published yet, if one was to overlook 
those then 22 DAGLα sites have been identified at least once, 10 sites at 
least twice and 5 sites at least 3 times. For DAGLβ 8 sites have been 
identified at least once, 4 at least twice and all 4 have actually been identified 
at least three times respectively. Therefore if one was to place a minimal 
requirement of 3 independent published studies to consider a phospho-site 
as genuine, then the total number of 'genuine'  phospho-sites identified for 
the DAGLs drops from 42 to 9 (5 sites for DAGLα, all in the tail and 4 sites for 
DAGLβ, all in the regulatory loop). 
3.2.5 Prediction of phospho-sites based on sequence and structure 
The substrate for the DAGLs, DAG, is generally found integrated in the 
membrane (Goni and Alonso, 1999). The DAGLs are likely to use their 
transmembrane domains coupled with mechanisms like palmitoylation to sub 
localise them at membranes, close to the substrate, and orient themselves in 
a manner that facilitates sequestration of the substrate from the membrane to 
the catalytic site. The regulatory loop (lid) is on the same face as the active 
site, and therefore likely to be membrane and substrate proximal, which 
would facilitate interfacial activation. Phospho-sites that are membrane 
proximal are more likely to regulate catalytic activity when compared to sites 
that are buried or located on the cytoplasm facing surface of these enzymes. 
A model of the catalytic domains of DAGLα and DAGLβ using structural and 
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sequence information of the P. camembertii fungal DAGL was constructed to 
determine the location of the numerous phosphorylated residues  (Figure 3.6) 
(Yamaguchi et al., 1991; Derewenda et al., 1994) . The membrane proximal 
surface was identified based on the orientation of the catalytic triad (red) that 
would need to be membrane proximal in order to hydrolyze DAG. Based on 
the location of the identified phospho-sites in the catalytic domain model, 7 
out of 9 of the DAGLα sites and 11 of the 12 DAGLβ sites were located on 
the membrane proximal surface (substrate facing). These sites are therefore 
potential candidates to regulate the opened and closed conformation of these 
enzymes (Figure 3.6, Table 3.3 and Table 3.4).  
Studies indicate that phosphorylation often occurs at sites within 
disordered/unstructured sequences, therefore disordered regions have a 
higher frequency of phospho-sites compared to ordered regions (Iakoucheva 
et al., 2004). Phosphorylation can promote structure in disordered region or 
disorder in a structured region, thus affecting inter/intramolecular changes 
(Johnson and Lewis, 2001). DISPHOS is an online resource that uses protein 
disorder information to predict phospho-sites (~80% accuracy against known 
sites) (Iakoucheva et al., 2004). The DAGL sequences were probed using 
DISPHOS to gain further information on DAGL phospho-sites. Amongst the 
identified phospho-sites all the DAGLβ residues in the regulatory loop (7/7) 
were predicted to be phosphorylated (Table 3.4), none of the corresponding 
residues in the DAGLα sequence were predicted to be phosphorylated (data 
not shown).  
None of the other identified phospho-sites in the DAGLβ catalytic domain and 
none of the identified phospho-sites in the DAGLα catalytic domain were 
predicted as phospho-sites. Most of the residues in the DAGLα tail (16/20) 
were predicted to be phospho-sites by DISPHOS (Table 3.3 and Table 3.4). 
These results provided further evidence to support the fact that some of the 











Figure 3.6. 3D model of the catalytic domains of DAGLα and 
DAGLβ 
A model of the catalytic sites of DAGLα (A) and DAGLβ (B) was 
generated using structural and sequence information of a fungal 
mono and diacylglycerol lipase from P. camembertii. The membrane 
proximal surface is adjudged based on the orientation of the catalytic 
triad (red) that need to be membrane proximal in order to hydrolyze 
DAG. Several phospho-sites identified in the catalytic domain of the 
DAGLs were found to be located on the membrane proximal surface 
of the enzyme. These sites are deemed more likely to regulate 
catalytic activity of these enzymes when compared to sites that 
maybe buried or located on the cytoplasmic facing surface and are 
represented in yellow (residues highlighted in grey are unlikely to be 
membrane proximal). The residues highlighted with black text were 
identified by mass spectrometry studies, the residues highlighted in 
with green text are conserved between DAGLα and DAGLβ but were 
identified in the other isoenzyme. (green insert - cysteine rich region, 
blue insert - regulatory loop (RL), white arrows - β strands, blue 
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ALK, Src 
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Italics - included based on homology to a site detected in DAGLβ 
Bold - identified in at least 3 published studies 
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S576 RL 3/0 Yes 
 
Yes GPCRK1 
S577 RL 0/3 Yes Yes Yes CK2 

















Italics - included based on homology to a site detected in DAGLα 
Bold - identified in at least 3 published studies 
* Alignment of these sites to mouse DAGLβ is ambiguous  






Additionally, the DAGL sequences have been interogated using a neural-
network based phosphorylation prediction tool, NetPhos 2.0, that uses 
sequence and structural data of reported phosphorylation events to predict 
phospho-sites (~70% accuracy against known sites) (Blom et al., 1999; 
Iakoucheva et al., 2004) (Table 3.3 and Table 3.4). In the catalytic domain, 4 
out of 9 (1/2 in RL) for DAGLα and 5 out of 12 (4/8 in RL) for DAGLβ were 
predicted as phospho-sites. 14 out of 20 of the identified sites in the tail 
region of DAGLα were predicted as phospho-sites. Once again, these results 
provided further evidence to support the fact that some of the phospho-sites 
within the RL of DAGLβ and tail of DAGLα are genuine. Furthermore, even if 
more stringent criteria are applied where a phospho-site is only considered 
as genuine if it has been reported at least 3 times in the literature and is 
predicted as a phospho-site by DISPHOS/Netphos2.0, 5 DAGLα phospho-
sites (all in the tail) and 4 DAGLβ phospho-sites (all in the RL) still remain.  
Finally, a phospho-motif finder algorithm has been used to identify candidate 
kinases that may phosphorylate the above sites (Table 3.3 and Table 3.4) 
(Amanchy et al., 2007). Almost all the sites (39 out of 42) lay within well 
defined consensus phosphorylation motifs reinforcing the hypothesis that 
they likely represent regulatory sites.   
3.3 Discussion and conclusions 
The ability of the ABHD fold to accommodate structural insertions contributes 
to the diversity observed in this large family of enzymes (Holmquist, 2000) 
which includes the DAGLs. A homology modelling and bioinformatics led 
approach presented here has identified two potential inserts, within the DAGL 
catalytic domains, a cysteine rich insert, and a putative lid that we refer to as 
the regulatory loop.   
The cysteine rich insert contains consensus palmitoylation sites and might 
therefore be a key regulatory motif. Palmitoylation is a reversible post-
translational modification of cysteine residues which occurs by the 
attachment of a palmitic acid via a thioester linkage (Aicart-Ramos et al., 
2011). Palmitoylation has been shown to regulate subcellular trafficking of 
proteins. For example, localisation of the small GTPase Rap2b to lipid rafts is 
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regulated by palmitoylation (Canobbio et al., 2008). Lipid rafts are membrane 
microdomains playing important roles in signal transduction and membrane 
transport. Interestingly DAG, 2-AG and DAGLα were found to be enriched in 
lipid rafts of a DRG cell line (Rimmerman et al., 2008). In order to investigate 
this further, I have searched a number of databases of palmitoylated proteins 
to determine if the DAGLs have been picked up in unbiased screens. This 
reveals three independent studies providing evidence for DAGL 
palmitoylation. Palmitoylated DAGLα has been detected in rat brain 
synaptosomes as well as in rat cortical neuron cultures (Kang et al., 2008). 
On the other hand palmitoylated DAGLβ has been identified in Jurkat cells 
(human T lymphocyte cell line) (Martin and Cravatt, 2009) and in a human 
prostate cancer cell line DU145 (Yang et al., 2010). Interestingly, the CB1 
receptor can also be palmitoylated and there is increasing evidence towards 
its localisation to lipid rafts (Bari et al., 2005; Sarnataro et al., 2005; Oddi et 
al., 2012). Palmitoylation of the cysteine rich insert could therefore play a role 
in localising the DAGLs to lipid rafts in order to place them in close proximity 
to their substrate DAG and downstream cannabinoid receptor targets.  
As mentioned earlier, a common structural feature among lipases is a lid like 
structure that is inserted between β strands of the canonical ABHD fold. The 
lid is responsible for the 'interfacial activation' phenomenon, commonly 
observed with these enzymes. Interfacial activation refers to the 
displacement of the lid and increased activity when the lipase comes in 
contact with a lipid phase (Nardini and Dijkstra, 1999; Holmquist, 2000).  
In the case of human pancreatic lipase (PL), a 24 amino acid α-helical 
surface loop shields the active site (Winkler et al., 1990). The opening of the 
lid is facilitated by an interacting partner, Procolipase. Procolipase binds to a 
C-terminal domain of PL and can also bind lipids, thus facilitating PL-lipid 
interactions in a 'difficult' bile-salt rich environment (van Tilbeurgh et al., 
1992). The opened PL lid also interacts with Procolipase, stabilising the 
opened-confirmation. The opening of the lid not only allows substrate access 
to the active site, but also causes conformational changes within the active 
site that renders it active (van Tilbeurgh et al., 1993).  
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In the case of human gastric lipase (GL), a large cap domain (124 amino 
acids) is present between the canonical β sheets 6 and 7 and is made up of 
8 helices, turns and random coils (Miled et al., 2003). The cap domain can 
structurally prevent substrate access. Crystal structure of 'opened' GL 
revealed that displacement of a smaller lid composed of 3 helices (30 amino 
acids), within the cap domain is sufficient to reveal the catalytic site (Roussel 
et al., 2002). The remaining part of the cap domain (minus the lid) forms a 
hydrophobic region around the catalytic site and probably plays a role 
towards enhancing affinity for the substrate (Roussel et al., 1999; Roussel et 
al., 2002). The 'opened' crystal structure revealed that the displaced lid 
interacts with the N-terminus of the enzyme and that no major structural 
rearrangements within the catalytic site occurred when compared to the 
closed structure, suggesting that unlike PL, even when shielded by the lid, 
the catalytic site of GL is in the active confirmation. 
Based on secondary structure predictions and alignments with other lipases 
we identified a 50-60 amino acid 'regulatory loop' (RL) in the DAGLs which is 
well placed to act as the lid and therefore regulate DAGL activity. A highly 
conserved polyproline 'signature motif' was identified in the RL of the DAGLs 
which is not only conserved amongst human DAGLα and β but also 
conserved between mammalian, invertebrate, and plant DAGLs. The highly 
conserved nature of this sequence could implicate it as a binding site for an 
interaction partner (e.g. PL-Procolipase); however this would also require the 
interacting partner to be conserved across the species. It is therefore more 
likely that this sequence is involved in an intra-molecular interaction which 
could stabilise the open/closed conformation of the enzyme (e.g. GL). 
In addition to the signature motif we also identified several phospho-sites 
within the RL that may regulate the activity of the DAGLs. Phosphorylation is 
a reversible post-translational modification involving the transfer of a 
phosphate group from ATP to the hydroxyl groups of serine, threonine, and 
tyrosine residues. This can introduce conformational changes within a 
proteins structure, thus affecting a range of cellular processes. For instance, 
phosphorylation at specific sites can cause intra-molecular changes within an 
enzyme resulting in a change in activity (increase or decrease). 
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Phosphorylation can also block or promote protein-protein interactions which 
may affect their activity, localization, and stability (degradation) (Johnson and 
Lewis, 2001; Salazar and Hofer, 2009).  
Activity of several lipases is regulated by phosphorylation e.g. TGL4, PLCγ, 
HSL (Kurat et al., 2009; Gresset et al., 2010; Lampidonis et al., 2011). As 
mentioned in the introduction, PLC-γ lies upstream of DAGL, generating 
DAG, in the FGFR pathway involved in axonal growth and guidance. Many 
tyrosine kinases directly phosphorylate PLC-γ isozymes to enhance their 
lipase activity (Gresset et al., 2010). The activities of most PLCs are inhibited 
by a disordered linker (X/Y linker) that inserts into the catalytic domain to 
prevent substrate access. Phosphorylation of the linker region of PLC-γ 
results in a large conformational change that releases this inhibition (Gresset 
et al., 2010).  
HSL is probably the most studied lipase in terms of its phosphorylation. The 
activity of HSL is regulated by PKA in vitro and in cells via multiple 
mechanisms (Lampidonis et al., 2011). In adipocytes, activation of β-
adrenergic receptors leads to a (sequential) increase in cAMP levels, PKA 
activity, HSL phosphorylation and lipolysis (Stralfors and Honnor, 1989; 
Anthonsen et al., 1998; Holm, 2003). On the other hand, insulin causes a 
reduction in cAMP levels, PKA activity, HSL phosphorylation, and lipolysis 
(Stralfors and Honnor, 1989; Eriksson et al., 1995). PKA can phosphorylate 
HSL directly at 3 different sites and phosphorylation by PKA in vitro can 
cause ~2-fold increase in HSL activity against lipid substrates (Holm et al., 
1994; Anthonsen et al., 1998). In addition to this, PKA dependent 
phosphorylation of HSL in cells results in translocation of HSL to lipid 
droplets (Brasaemle et al., 2000). Interestingly, all the PKA phospho-sites in 
the HSL sequence are located within its regulatory domain (lid). In vitro 
phosphorylation by PKA not only increases the catalytic activity of HSL but 
also increases the hydrophobic surface area of the protein, presumably due 
to the displacement of the regulatory domain (Krintel et al., 2009; Lampidonis 
et al., 2011). This has led to a model, where in cells, in response to certain 
stimuli, phosphorylation of HSL at multiple sites by PKA results in the 
localisation of HSL to lipid droplets as well as displacement of the lid resulting 
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in increased lipolysis (Lampidonis et al., 2011). Additionally, phosphorylation 
of a lipid droplet binding protein, Perilipin A by PKA, has been shown to play 
an important role in regulating the HSL-lipid drop interaction (Sztalryd et al., 
2003; Wang et al., 2009).  
The phospho-map of the DAGLs in Figure 3.4 is a schematic of the 
experimentally identified DAGL phospho-sites. A total of 42 DAGL phospho-
sites have been reported. Most of these sites have been identified by mass 
spectrometry analysis of  complex samples (tissue/cell extracts), this can 
often result in false positives/negatives for phospho-sites in low abundance 
(Alcolea et al., 2009). However, several of these sites have been identified in 
two or more independent (published studies), and these sites are also 
predicted to be candidate phospho-sites based on prediction tools 
(DISPHOS, NetPhos2.0). These prediction tools have a 70-80% success rate 
in predicting experimentally verified phospho-sites (Iakoucheva et al., 2004). 
The DAGLs therefore appear to be phosphorylated at multiple sites which in 
turn are likely to regulate the DAGLs, possibly via multiple mechanisms (inter 
and intra-molecular interactions and localisation, as in the case of HSL). 
Two regions in the DAGL sequences were especially found to be 
phosphorylated. In the case of DAGLβ, a short stretch of 15 amino acids 
located in the RL has 7 reported phospho-sites, 4 of which have been 
identified in at least three published studies. These sites (S570, S577, S579, 
S583/S584) were also predicted to be phosphorylated by NetPhos2.0 
(structure/sequence based predictor) and/or DISPHOS (disorder based 
predictor). We therefore consider these sites as likely candidates to regulate 
the opened/closed conformation of the enzyme. It is tempting to speculate 
that these phospho-sites will be conserved amongst the DAGLs, however 
this region is poorly conserved between DAGLα and DAGLβ, and no 
phospho-sites in this region of DAGLα have been identified. In addition to 
that no sites within this region of DAGLα were predicted phospho-sites 
(DISPHOS/NetPhos2.0). Nevertheless, this does not completely rule out the 
identification of phospho-sites in this region in the future (5 of the 15 amino 
acids are serine/threonines). Overall, there were 2 sites identified in the RL of 
DAGLα, however neither of these sites were identified in published sources 
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and neither were predicted to be phosphorylated by DISPHOS (one of the 
sites predicted by NetPhos2.0) so it remains to be seen whether these are 
genuine phospho-sites. As of yet, we did not identify likely candidate 
phospho-sites within the RL of DAGLα, it remains to be seen whether this 
insert is not phosphorylated or the phospho-sites have yet to be identified.  
Additional phospho-sites were identified within the catalytic domain of the 
DAGLs, however none of them have been reported more than once in 
published sources. Overall, 7 of the identified phospho- sites are conserved 
between the DAGLs but only 1 of these sites was identified in both DAGLα 
(S402) and DAGLβ (S378). This site is located within the catalytic domain but 
not the RL and is likely to be membrane proximal (based on the catalytic 
domain model). It is tempting to speculate that this phospho-site might 
represent a conserved regulatory mechanism amongst the DAGLs, however 
there is only one published report (DAGLβ) and one CST report (DAGLα) for 
this site and neither site was predicted as a phospho-site by DISPHOS (only 
the DAGLα site predicted by NetPhos2.0). The evidence supporting this site 
as a genuine phospho-site is therefore limiting. 
The tail of DAGLα, which is absent in DAGLβ, contained multiple phospho-
sites (20). 5 of these (S732, S743, S806, S1023, and S1030) have been 
reported in at least three published studies and were also predicted to be 
phospho-sites (DISPHOS/NetPhos 2.0) indicating these are genuine 
phospho-sites. In general, many of the DAGLα tail phospho-sites were 
identified in the brain (Huttlin et al., 2010; Wisniewski et al., 2010) and more 
specifically at synapses (Trinidad et al., 2006; Munton et al., 2007; Trinidad 
et al., 2008; Trinidad et al., 2012). As the localisation of DAGLα to the post 
synaptic dendritic spine is crucial for its role in synaptic signalling, these sites 
may play an important role in DAGLα localisation to the synaptic membrane. 
The tail is dispensable with regards to the catalytic activity of the enzyme 
indicating that it may not regulate catalytic activity (Pedicord et al., 2011). 
However, a recent study has demonstrated that phosphorylation in the tail 
region by CamKIIa inhibits DAGLα activity in vitro by ~50% (Shonesy et al., 
2013). The mechanism behind this is unknown but may occur due to 
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increased intramolecular interactions between the tail and catalytic domain 
(or RL, therefore preventing the lid from opening) following phosphorylation.  
We also used a phospho-motif finder to predict candidate kinases 
responsible for the DAGL phospho-sites. Almost all the sites (39 out of 42) 
lay within phospho-motifs, majority of which were present within multiple 
motifs (multiple candidate kinases). Amongst the phospho-sites that were 
identified in at least 3 published sources (5 in DAGLα (tail) and 5 in DAGLβ 
(RL)) kinases like PKA, PKC, ERK1, ERK2, GSK3 and CDK5 were frequently 
identified as candidate kinases (Table 3.3 and Table 3.4).  
In conclusion, the DAGLs are likely to use their transmembrane domains, 
possibly coupled with mechanisms like palmitoylation to sub localise them at 
the membranes, close to their substrate DAG. This would enable them to 
orient themselves in a manner facilitating DAG-catalytic site interaction. This 
would also orient the regulatory loop (lid) towards the membrane which would 
facilitate inter-facial activation. Furthermore, numerous DAGL phospho-sites 
have been reported, at least some of which appear to be genuine. Based on 
structural analogy with HSL and the membrane proximity of some of these 
sites, phosphorylation of the DAGLs (especially DAGLβ) appears to be a 
likely mechanism to regulate the activity of these enzymes by regulating the 








Chapter 4 (Results 2): Investigating DAGL activation using 
the Tango assay 
4.1 Introduction 
Several stimuli like ionomycin and LPS increase 2-AG levels in cells and 
tissues, but it is not always clear as to whether this is a signalling pool of 2-
AG (Bisogno et al., 1997; Stella et al., 1997; Varga et al., 1998; Di Marzo et 
al., 1999; Bisogno et al., 2003). Also, the mechanisms behind this are poorly 
understood. Besides monitoring physiological responses like DSI/DSE, 
studying DAGL activity generally relies on 2-AG quantification. This normally 
involves the treatment of cells/tissues with appropriate stimuli and/or drugs 
before extracting the lipids and quantifying 2-AG. Another approach involves 
testing DAGL activity in cellular/tissue extracts using synthetic DAG as a 
substrate and then once again by measuring the release of 2-AG (Bisogno et 
al., 2003; Jung et al., 2007). Quantification of 2-AG relies on mass 
spectrometry techniques (Balgoma et al., 2013) which requires an elaborate 
laboratory setup, specialised equipment and tends to be low throughput. 
Also, as hinted at above, it is unclear if the 2-AG measured in many studies 
is reflective of a signalling pool of the lipid, as opposed to a general metabolic 
pool. 
The CB1-Tango assay is a recombinant cell based assay that can be used to 
measure CB1 activation via a reporter gene (β-lactamase) system (van der 
Lee et al., 2009). The cells were primarily developed to directly measure the 
activity of small molecule CB1 receptor agonists or antagonists. However, we 
reasoned that if the cells express the DAGLs, they might be adapted to 
provide a convenient format to study DAGL-dependent activation of CB1 
receptors (Figure 4.1). The Tango cells are commercially available U2OS 
(human osteosarcoma cell line) cells that stably overexpress the human CB1 
receptor. The CB1 receptor is a chimeric molecule that contains a TEV 
protease site and a Gal4-VP16 transcription factor towards the C terminus. 
This cell line also stably expresses a β-arrestin-TEV protease fusion protein 





Figure 4.1. The Tango-CB1 cell-based assay monitoring CB1 activation 
as a potential tool to study DAGLα/β activity 
2-AG produced by DAGLα/β in the Tango cell activates the recombinant CB1 
receptor linked to a TEV protease site and a Gal4-VP16 transcription factor. 
CB1 activation results in the recruitment of TEV-protease tagged β-arrestin to 
the receptor. The TEV protease then cleaves the transcription factor which 
then binds to the UAS element upstream of a β-lactamase gene resulting in 
expression of this reporter gene (A). Activation of DAGLα/β activity by single 
or multiple kinases in response to stimuli would result in increased 2-AG 





Ligand induced activation of CB1 results in the recruitment of the TEV 
protease tagged β-arrestin to the receptor. The TEV protease then cleaves 
the Gal4-VP16 transcription factor resulting in expression of the β-lactamase 
(reporter) gene. β-lactamase activity is then monitored using a FRET based 
substrate conversion assay (van der Lee et al., 2009).  
In this chapter I will report on the successful adaptation of the Tango assay to 
monitor DAGL dependent CB1 activation. This enabled us to assess 
mechanisms regulating the activity of the DAGLs in a cellular context, with a 
primary focus on testing the hypothesis that DAGL activity is regulated by 
phosphorylation. 
4.2 Results 
4.2.1 The Tango assay can measure CB1 activation 
The response of Tango cells towards a CB1 agonist ACEA was initially 
established as this would serve as a positive control throughout (10nM to 
10µM). Preliminary experiments (conducted by others) identified optimal 
culture conditions that minimised non-specific background signals. In brief, 
Tango cells were plated onto 96-well plates and maintained overnight in the 
presence of 1% FCS in McCoy's 5A media. The cells were then treated for 4 
hours with ACEA after which CB1 activation was measured using the β-
lactamase FRET substrate. An ACEA dose dependent increase in CB1 
activation was readily detected. Maximal CB1 activation was measured 
following 0.1-1µM ACEA treatments (Figure 4.2A). This confirmed that the 
cells were responsive to CB1 activation. The ability of a CB1 antagonist 
AM251 (10nM to 10µM) to block the ACEA (1µM) response was then 
confirmed. AM251 successfully prevented the ACEA response, with maximal 
inhibition measured using 1-10µM AM251 (Figure 4.2B). These results 
confirmed that the ACEA response observed in the Tango assay was CB1 
specific and that the Tango assay could therefore successfully be used to 










Figure 4.2. The Tango assay can measure agonist mediated CB1 
activation 
Tango cells were seeded in 96-well plates and grown overnight in 
McCoy's 5A media 1% FCS. The cells were then treated for 4 hours 
with ACEA, AM251 or ACEA + AM251. CB1 activation was 
measured using the β-lactamase FRET substrate as a ratio of the 
fluorescence of the product (excitation 409 nm, emission 460 nm) 
and the FRET signal of the intact substrate (excitation 409 nm, 
emission 530 nm). 
(A) Dose-response curve for ACEA in the Tango assay following 4 
hour treatment of the Tango cells with the CB1 agonist ACEA (10nM 
to 10µM). Increased CB1 activation was observed with increasing 
concentrations of ACEA, maximal activation occurring between 0.1-
1µM. (mean of 4 wells ±SEM) 
(B) The CB1 antagonist AM251 blocks the ACEA response (1µM) in 
the Tango assay. Tango cells were treated for 4 hours with 1µM 
ACEA and increasing concentrations of AM251 (10nM to 10µM). 
AM251 concentration dependent inhibition of CB1 activation was 
observed, maximal inhibition was observed between (1µM to 10µM). 
This confirmed that the ACEA response detected in the Tango assay 























































4.2.2 A basal eCB tone is detected in the Tango cells using the Tango 
assay 
In order to determine if there was any basal endogenous eCB signalling in 
Tango cells cultured in the above conditions, cells were plated out and 
maintained in 1% FCS containing media as described above and then 
treated with the CB1 antagonist AM251 (5µM) for 4 hours. Results pooled 
from 6 independent experiments showed that this resulted in a relatively 
small negative response (~5% of the maximal ACEA response) indicating a 
low basal eCB tone (Figure 4.3). We next determined the effect of a dual 
MAGL and FAAH inhibitor JZL195 (100nM) in this model.  
This compound stimulated a small but highly significant activation of the CB1 
receptor; importantly this response was completely blocked by 5µM AM251 
(Figure 4.3). This suggests that the Tango cells have a low basal turnover of 
an eCB, the activity of which is limited by MAGL and/or FAHH. 
Having detected an eCB tone in the Tango cells using the Tango assay, 
Western blotting analysis was next used to check whether the Tango cells 
expressed 2-AG metabolising enzymes. Tango cell lysates were analysed by 
Western blotting using antibodies for the major 2-AG synthesising enzymes 
DAGLα and DAGLβ as well as the 2-AG hydrolysing enzymes MAGL and 
FAAH (Figure 4.4). Lysates obtained from the mouse neuronal stem cell line 
Cor1 were included as we have previously reported expression of these 
enzymes in this cell line (Goncalves et al., 2008). Firstly, DAGLα (115kDa) 
expression was detected in the Tango cells, albeit at lower levels than Cor1. 
A band potentially corresponding to DAGLβ (human) was also detected in 
the Tango lysates although the band was resolved at a lower molecular 
weight than the mouse DAGLβ detected in the Cor1 lysates, even though 
they share similar molecular weights (74kDa). However, a recombinant 
tagged (V5) version of human DAGLβ is also resolved at a lower molecular 
weight than mouse DAGLβ-V5 (Figure 4.10E) indicating that the band 
(~75kDa) detected in the Tango lysates is specific. These results indicate 
that DAGLα/β are expressed in the Tango cells and may therefore be 




Figure 4.3. A basal eCB tone is detected in the Tango cells 
Tango cells were seeded in 96-well plates and grown overnight in McCoy's 
5A media supplemented with 1% FCS. The cells were then treated for 4 
hours with various drugs as indicated and then CB1 activation was measured 
(generally in 6-8 replicate wells for each independent experiment) using the 
β-lactamase FRET substrate as a ratio of the fluorescence of the product 
(excitation 409 nm, emission 460 nm) and the FRET signal of the intact 
substrate (excitation 409 nm, emission 530 nm). Results are presented as a 
percentage of the maximal CB1 activation achieved using the CB1 agonist 
ACEA (1µM). (CB1 activation following treatment with 5µM AM251 
n=6±SEM, 100nM JZL195 n=13±SEM, and both JZL195 and AM251 
n=6±SEM are presented above). In each instance, n=the number of 
independent experiments. *** p < 0.001 (two tailed t-test) comparing AM251 






Figure 4.4. The Tango cells express 2-AG metabolising enzymes 
20µg of lysates from Tango and Cor1 cells were analysed by Western 
blotting using DAGLα, DAGLβ, MAGL, and FAAH antibodies. The specificity 
of the DAGL antibodies has been established using samples from DAGL 
knockout animals (not shown). β-actin was also detected as a loading 








We also detected expression of the 2-AG hydrolysing enzyme FAAH in the 
Cor1 cell lysates, however no FAAH (63kDa) was detected in the Tango 
lysates. Finally, a faint band at approximately the right size (~33kDa) was 
detected for MAGL in both the Tango and Cor1 lysates. Therefore MAGL is 
likely to limit the basal eCB signalling in the Tango cells, suggesting that 2-
AG is the probable eCB responsible for this. In further experiments, JZL195 
was included in all the treatments to prevent 2-AG hydrolysis.  
4.2.3 Calcium stimulated DAGLα/β activity detected using the Tango 
assay 
Treating cells with the calcium ionophore ionomycin increases 2-AG levels, in 
a DAGL dependent manner, in COS-7 cells (Bisogno et al., 2003). 
Furthermore, calcium influx in the post-synaptic cell is responsible for 
increased 2-AG signalling at the synapse (Hashimotodani et al., 2007a). We 
therefore tested the effects of ionomycin in the Tango assay. We treated the 
Tango cells grown in McCoy's media 1% FCS for 4 hours with different 
concentrations of ionomycin before measuring β-lactamase activity. 
Increasing concentrations of ionomycin (0.25 to 2µM) caused an increase in 
activity from ~10 to ~80% of the response stimulated by a maximally active 
concentration of ACEA (Figure 4.5).  
In order to test whether the ionomycin response reflected DAGL-dependent 
CB1 signalling, Tango cells were treated with ionomycin (2µM) in the 
presence or absence of the standard CB1 antagonist (AM251) or THL 
(10µM) or OMDM-188 (2µM); two independent DAGL inhibitors. AM251 and 
the DAGL inhibitors fully blocked the ionomycin response (Figure 4.6). 
Importantly, THL and OMDM-188 did not have a significant effect on the 
ACEA response (95.8 ± 3.1% and 88.2 ± 2.1% of the maximal ACEA 
response, n=5), confirming that their effects were upstream of the CB1 
receptor. Collectively these results implicate DAGLα/β activity in the 
ionomycin stimulated CB1 receptor activation. In order to confirm that the 
effects of ionomycin on DAGL activity were calcium mediated, we next tested 




Figure 4.5. Ionomycin treatment of Tango cells activates CB1 in the 
Tango assay 
Tango cells were seeded in 96-well plates and maintained overnight in 
McCoy's media supplemented with 1% FCS. The cells were then treated with 
different concentrations of ionomycin for 4 hours as indicated, in the 
presence of 100nM JZL195 to prevent 2-AG hydrolysis. CB1 activation was 
then measured using the β-lactamase-assay as previously described. 
Results are presented as a percentage of the maximal CB1 activation 
achieved using the CB1 agonist ACEA (1µM) (n=4-7 independent 




Figure 4.6. Ionomycin mediated CB1 activation in the Tango assay is 
DAGL dependent 
Tango cells were seeded in 96-well plates and maintained overnight in 
McCoy's 5A media supplemented with 1% FCS. The cells were then treated 
with ionomycin (2µM) for 4 hours in the presence or absence of either AM251 
(5µM), THL (10µM) or OMDM-188 (2µM). 100nM JZL195 was included in all 
the treatments to block 2-AG hydrolysis. CB1 activation was then measured 
using the β-lactamase-assay as previously described. Results are presented 
as a percentage inhibition of the ionomycin response (n=3-5 independent 








Tango cells were maintained overnight in a calcium and serum free media 
recommended for Tango cells (called Freestyle media) and then treated with 
2mM CaCl2 overnight. An increase in β-lactamase activity was apparent in 
the cultures treated with calcium containing media relative to control media, 
and this was a substantial response as it was ~70% of that seen with a 
maximally active concentration of ACEA (Figure 4.7). The CaCl2 response 
was fully blocked by AM251 (5µM), confirming that it was CB1 receptor 
dependent and by THL (10µM) and RHC-80267 (10µM) demonstrating that it 
was DAGL dependent (Figure 4.7). A possible mechanism by which calcium 
could stimulate DAGL activity is phosphorylation. Increased calcium 
concentrations within the cell may activate single or multiple kinases that 
could directly or indirectly activate the DAGLs. As discussed in chapter 3, 
several phospho-sites have been identified in the DAGL sequences and 
some of these sites are well placed to activate the enzymes. Two of the 
kinases predicted to phosphorylate the DAGLs at these sites are PKA and 
PKC, both these kinases can be activated by calcium (Steinberg, 2008; Dunn 
et al., 2009). Pharmacological activators (Castagna et al., 1982; de Souza et 
al., 1983) and inhibitors (Chijiwa et al., 1990; Martiny-Baron et al., 1993) are 
also commercially available for these kinases. We therefore decided to test 
whether calcium mediated DAGL activation in the Tango assay was PKA 
and/or PKC dependent.  
4.2.4 PKA and PKC mediated DAGLα/β activation in the Tango assay 
In order to assess whether PKA or PKC played a role in the calcium 
dependent DAGL activation measured in the Tango assay, Tango cells 
(maintained in the absence of calcium and serum) were treated with CaCl2 
(2mM overnight) in the presence or absence of either the PKA inhibitor H89 
(5µM) or the PKC inhibitor Go6976 (5µM). Both inhibitors largely blocked 
CaCl2 dependent CB1 activation in the Tango assay (Figure 4.7) but did not 
have a significant effect on CB1 activation by the CB1 agonist ACEA (88.9 ± 
6.6% and 110.6 ± 4.8% of the maximal ACEA response, n=3). This indicated 
that the calcium stimulated DAGL activity measured in the Tango assay was 




Figure 4.7. Calcium stimulated CB1 activation in the Tango assay is 
DAGL, PKA and PKC dependent 
Tango cells were seeded in 96-well plates and grown overnight in the 
suppliers Freestyle media (see methods). The cells were then treated with 
CaCl2 (2mM) overnight in the presence or absence of either the CB1 
antagonist AM251 (5µM), the DAGL inhibitors THL (10µM) or RHC-80267 
(10µM), the PKA inhibitor H89 (5µM) or the PKC inhibitor Go6976 (5µM). 
100nM JZL195 was included in all the treatments to block 2-AG hydrolysis. 
CB1 activation was then measured using the β-lactamase-assay. Results are 
presented as a percentage of the maximal CB1 activation achieved using the 
CB1 agonist ACEA (1µM) in the assay (n=3 independent experiments and 







We next tested the effects of PKA and PKC activators in the Tango assay. 
Tango cells were grown overnight in Freestyle media in the absence of 
added calcium or serum. The cells were then treated overnight with either the 
PKA activator forskolin (10µM) or the PKC activator PMA (25nM) in the 
presence or absence of either the CB1 antagonist AM251 (5µM) or the DAGL 
inhibitor THL (10µM). Both PKA and PKC activators stimulated a substantial 
β-lacatamase response that was ~50% of the maximal ACEA response 
(Figure 4.8). The effects of both activators were blocked by the CB1 
antagonist AM251 confirming that it reflected CB1 receptor activation (Figure 
4.8). Similarly the effects of both activators were also blocked by the DAGL 
inhibitor THL confirming that they were also DAGL dependent (Figure 4.8). 
These results demonstrate that PKA and PKC can activate DAGL-dependent 
eCB signalling in the Tango cells. Additionally, calcium stimulated DAGL 
activation in the Tango cells is dependent on PKA and PKC. 
Collectively, the pharmacological studies above support the following model. 
Ionomycin, CaCl2 and other pharmacological tools can activate PKA and 
PKC which in turn can activate DAGLα/β in the Tango cells. The activated 
DAGLs increase cellular 2-AG levels that results in an increase in CB1 
activation which is detected in the Tango assay. The results above lead us to 
the next set of questions. Firstly, which DAGL is responsible for the 
PKA/PKC stimulated activity in the Tango assay, is it DAGLα, DAGLβ or 
indeed both? And secondly, how do PKA and PKC activate the DAGLs, is it 
via a direct (phosphorylation) or indirect mechanism?  
In order to address these questions, a DAGLα/β gain of function approach 
was pursued using the Tango cells for the following reasons.  
- at the time of carrying out these experiments, no inhibitors that could 
distinguish between DAGLα and DAGLβ were available, the potential gain of 
function observed in the Tango assay by expressing DAGLα or DAGLβ 
transgenes would enable us to study each enzyme individually.  
- establishing and validating a gain of function DAGLα/β assay using the 
Tango cells would provide us with the 'proof of concept' that the Tango cells 
and assays could be used as a platform that would allow detailed 





Figure 4.8. PKA and PKC activate DAGLα/β in the Tango assay 
Tango cells were seeded in 96-well plates and grown overnight in Freestyle 
media in the absence of calcium and serum. The cells were then treated with 
the PKC activator PMA (25nM) or the PKA activator Forskolin (10µM) 
overnight in the presence or absence of either the CB1 antagonist AM251 
(5µM) or the DAGL inhibitor THL (10µM). 100nM JZL195 was included in all 
the treatments to block 2-AG hydrolysis. CB1 activation was then measured 
using the β-lactamase-assay. Results are presented as a percentage of the 
maximal CB1 activation achieved using the CB1 agonist ACEA (1µM) in the 







This would enable us to test whether any of the DAGLα/β phospho-sites 
discussed in chapter 3 are involved in the PKA and PKC stimulated DAGL 
activity measured in the Tango assay. 
4.2.5 Expression of DAGLα and DAGLβ transgenes in the Tango cells 
In order to overexpress DAGLα/β in the Tango cells, human DAGLα and 
DAGLβ constructs were cloned into the vector pCDNA6.2/V5-DEST. This 
vector enabled expression of the DAGL transgenes with a C-terminus V5 tag 
and also contains an antibiotic selection gene blasticidin that is a suitable 
selection marker to make stable cell lines using the Tango cells. The DAGLα-
V5 and DAGLβ-V5 constructs were transfected into COS-7 or Tango cells 
and expression was then tested by immunocytochemistry using fixed cells 
and Western blotting using lysates. COS-7 cells were used as a positive 
control as the DAGLs overexpressed in these cells are active, cause an 
increase in cellular 2-AG levels and localise to the membrane (Bisogno et al., 
2003). Immunohistochemical analysis using a V5 antibody revealed that 
human DAGLα-V5 localised to the surface of both COS-7 and Tango cells 
(Figure 4.9A and B). Western blotting analysis using the V5 antibody 
confirmed that DAGLα-V5 was expressed at the predicted molecular weight 
(120kDa) in both of the cell types (Figure 4.9C).  
 Immunocytochemical studies using a V5 antibody also indicated that human 
DAGLβ-v5 was expressed on the surface of both COS-7 and Tango cells. 
However, a dense immunopositive (V5) region of staining close to the 
nucleus was also seen in both cell types (Figure 4.10A and B). To confirm 
that this was not an artefact of this specific construct, COS-7 and Tango cells 
were also transfected with a mouse DAGLβ-V5 construct that has been 
previously characterised in COS-7 cells (Bisogno et al., 2003). 
Immunocytochemical studies of mouse DAGLβ-V5 in the Tango and COS-7 
cells using the V5 antibody revealed a similar expression profile to the human 
construct (Figure 4.10C and D). Expression was detected on the surface but 
was also concentrated in a region close to the nuclei. To ensure this was not 
an artefact of the V5 tag, a human DAGLβ-GFP construct was expressed in 




Figure 4.9. Human DAGLα-V5 is expressed at the predicted molecular 
weight and on the cell surface when transfected in Tango or COS-7 
cells 
Tango or COS-7 cells grown in 6-well plates were transfected with human 
DAGLα-V5 plasmid using lipofectamine 2000 and grown overnight. The 
transfected cells were then detached by trypsinization and seeded and grown 
overnight on poly-L-lysine coated coverslips or in a 10cm dish. Transfected 
cells grown on the coverslips were fixed and stained using a V5 antibody for 
immunocytochemical studies which revealed that DAGLα-V5 was expressed 
on the surface of both COS-7 (A) and Tango cells (B) (green - V5, blue - 
DAPI). The transfected cells grown in the 10cm dish were lysed and 20µg 
lysates were analysed by Western blotting using a V5 antibody which 
revealed that DAGLα-V5 is expressed at the predicted molecular weight 
(~120kDa) in Tango and COS-7 cells (C). Scale 20µm. 
A. Human DAGLα-v5 in COS-7 cells
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Figure 4.10. Human and mouse DAGLβ-V5 are expressed on the 
cell surface and in a peri-nuclear zone in both COS-7 and Tango 
cells 
Tango or COS-7 cells grown in 6-well plates were transfected with 
human or mouse DAGLβ-V5 plasmid using lipofectamine 2000 and 
grown overnight. The transfected cells were then detached by 
trypsinization and seeded and grown overnight on poly-L-lysine 
coated coverslips or in a 10cm dish. Transfected cells grown on the 
coverslips were fixed and stained using a V5 antibody. 
Immunocytochemical studies revealed that both human and mouse 
DAGLβ-V5 were expressed on the surface as well as in a peri-
nuclear zone in both COS-7 (A and C) and Tango cells (B and D) 
(green - V5, blue - DAPI). The transfected cells grown in the 10cm 
dish were lysed and 20µg lysates were analysed by Western blotting 
using a V5 antibody which revealed that both mouse and human 
DAGLβ-V5 are expressed close to their predicted molecular weight 









A. human DAGLβ-V5 in COS-7 cells B. human DAGLβ-V5 in Tango cells




Figure 4.11. Human DAGLβ-GFP is expressed on the cell surface and in 
a peri-nuclear zone in both COS-7 and Tango cells 
Tango or COS-7 cells grown in 6 well plates were transfected with human 
DAGLβ-GFP plasmid using lipofectamine 2000 and grown overnight. The 
transfected cells were then detached by trypsinization and seeded and grown 
overnight on poly-L-lysine coated coverslips or in a 10cm dish. Transfected 
cells grown on the coverslips were fixed and stained using a GFP antibody 
and used for immunocytochemical studies which revealed that human 
DAGLβ-GFP was expressed on the cell surface as well as in a peri-nuclear 
zone in both COS-7 (A) and Tango cells (B) (green - GFP, blue - DAPI). The 
transfected cells grown in the 10cm dish were lysed and 20µg lysates were 
analysed by Western blotting using a GFP antibody which revealed that 
human DAGLβ-GFP was expressed close to its predicted molecular weight 
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Western analysis using the V5 antibody confirmed that the human and 
mouse DAGLβ-V5 transgenes were expressed at a size close to their 
predicted molecular weights (~75kDa) in both Tango and COS-7 cells (Figure 
4.10E). Similarly the DAGLβ-GFP transgene was expressed at a size close 
to its predicted molecular weight (~100kDa) when detected by Western 
blotting using a GFP antibody (Figure 4.11C).  
The dense immunopositive region close to the nuclei was detected following 
the expression of human/mouse DAGLβ-V5 and human DAGLβ-GFP in both 
the Tango and COS-7 cells. This resembled immunocytochemical profiles 
observed in cells stained with Golgi markers (Houghton et al., 2012). In order 
to test whether the overexpressed DAGLβ was localised to the Golgi, COS-7 
and Tango cells were transfected with the human DAGLβ-V5 plasmid. 
Immunocytochemical studies were then carried out using V5 and GRASP65 
(a Golgi marker) antibodies. The overlap of immunopositivity using the 
antibodies confirmed that some of the DAGLβ expressed by the transgene 
(human DAGLβ-V5) co-localised with GRASP65, suggesting localisation to 
the Golgi (Figure 4.12).  
4.2.6 Establishing cell lines stably expressing DAGLα-V5 and DAGLβ-
V5 
Having confirmed expression of DAGLα-V5 and DAGLβ-V5 using the 
pCDNA6.2/V5DEST vector by immunocytochemistry and Western blotting 
based on transient transfection paradigms, we used the blasticidin selection 
marker in these constructs to generate Tango cell lines stably expressing 
DAGLα-V5 or DAGLβ-V5, as described in the methods sections. The cell 
lines named V5α11 (stably expressing DAGLα-V5) and V5β4 (stably 
expressing DAGLβ-V5) were found to be clonal (after 10 passages) by 
immunocytochemical analyses (V5 antibody) (Figure 4.13A and B). Western 
blotting using lysates obtained from the V5α11 and V5β4 cell lines and a V5 
antibody confirmed that DAGLα-V5 (~120kDa) and DAGLβ-V5 (~75kDa) in 
these cell lines were expressed at sizes close to their predicted molecular 










Figure 4.12. Human DAGLβ-V5 colocalises with the Golgi marker 
GRASP65 in both Tango and COS-7 cells 
Tango or COS-7 cells were grown on poly-L-lysine coverslips 
overnight and then transfected with human DAGLβ-V5 plasmid using 
lipofectamine 2000. Transfected cells were grown overnight and then 
fixed and stained using a V5 (green) and GRASP65 (red) antibody 
for immunocytochemical studies which revealed that human DAGLβ-
V5 colocalised with the Golgi marker in both Tango and COS-7 cells 
(A). An image of an individual Tango cell demonstrating the 































Figure 4.13. The cell lines V5α11 and V5β4 stably express 
human DAGLα-V5 and human DAGLβ-V5 respectively 
Tango cells were transfected with either human DAGLα-V5 or human 
DAGLβ-V5 plasmids using lipofectamine 2000 and then grown in the 
presence of the selection marker blasticidin. Clones were selected, 
expanded, and screened (immunocytochemistry and Western 
blotting) for the stable expression of the DAGL genes. Two clones 
V5α11 and V5β4 were found to stably express human DAGLα-V5 
and human DAGLβ-V5 respectively. Following ~10 passages V5α11 
and V5β4 cells were grown on poly-L-lysine coverslips overnight and 
then fixed and stained. Immunocytochemical analyses were then 
performed using a V5 antibody which confirmed that the cell lines 
were clonal and that the cells expressed the genes stably, even after 
10 passages (A and B) (green - V5, blue - DAPI). Parental Tango 
cells were used as a negative control. For Western blotting, V5α11 
and V5β4 cells grown for ~10 passages were lysed and then 20µg of 
lysates were analysed by Western blotting using a V5 antibody. 
DAGLα-V5 (V5α11) and DAGLβ-V5 (V5β4) were expressed at sizes 
close to their predicted molecular weights (120kDa and 75kDa) in 
these cell lines (C and D). Lysates from parental Tango cells were 











































In order to estimate the increase in levels of DAGLα in the V5α11 cell line 
relative to the parental Tango cells (endogenous DAGLα) we prepared 
membranes (to enrich DAGL) from both these cell lines. The DAGLs are 
enriched in membrane fractions as they are transmembrane proteins. 10µg 
of membranes were analysed by Western blotting using a DAGLα antibody. 
A band corresponding to endogenous DAGLα was detected in both sets of 
membranes (Figure 4.14A). A band at a slightly higher molecular weight than 
the endogenous DAGLα corresponding to DAGLα-V5 was only detected in 
the V5α11 membranes. 
Quantification of the band intensities indicated that DAGLα expression levels 
were 5-fold greater in the V5α11 cells compared to the Tango cells (Figure 
4.14B). This difference was predominantly due to DAGLα-V5 expression in 
the V5α11 cells. Similarly, membranes prepared from V5β4 and Tango cells 
were analysed by Western blotting using a DAGLβ antibody. Two bands 
close to the predicted molecular weight were detected in the Tango 
membranes (Figure 4.15A). It was unclear which of the two bands 
corresponded to endogenous DAGLβ. Similarly two bands were detected in 
the V5β4 membranes. The higher molecular weight band was more 
prominent compared to the corresponding band in the Tango membranes 
and was therefore identified as DAGLβ-V5 (Figure 4.15A). Quantification of 
the band intensities indicated that DAGLβ expression levels were either 4 or 
5-fold greater in the V5β4 membranes compared to the Tango membranes, 
depending on whether the two putative endogenous DAGLβ bands were 
quantified collectively or individually (Figure 4.15B). We have therefore 
successfully generated clonal cell lines that appear to express DAGLα-V5 





Figure 4.14. V5α11 express 5-fold more DAGLα than the parental Tango 
cells 
Membranes (10µg) prepared from V5α11 and Tango cells were analysed by 
Western blotting using a DAGLα antibody that recognises an epitope present 
on both the endogenous and transfected enzyme (A). The intensities of the 
annotated bands were quantified using ImageJ. The intensity of the DAGLα 
bands (normalised to β-actin) detected in the V5α11 membranes relative to 




Figure 4.15. V5β4 express 4 to 5-fold more DAGLβ than the parental 
Tango cells 
Membranes (10µg) prepared from V5β4 and Tango cells were analysed by 
Western blotting using a DAGLβ antibody that recognises an epitope present 
on both the endogenous and transfected enzyme (A). Two potential DAGLβ 
bands were detected at the predicted molecular weight (~73kDa). The 
intensities of the annotated bands were quantified using ImageJ. The 
intensity of the DAGLβ band(s) detected in the V5β4 membranes relative to 





The numerous reports on stimulus dependent increases in 2-AG levels and 
signalling in cells/tissues indicate that mechanisms to activate the major 2-
AG synthesising enzymes DAGLα and DAGLβ exist (Sugiura et al., 2000a; 
Bisogno et al., 2003; Walter et al., 2004; Aguado et al., 2005; Sugiura et al., 
2006). In the previous chapter we compiled a phospho-map of the DAGLs 
and proposed mechanisms by which these phospho-sites could regulate 
DAGL activity. In this chapter we adapted a cell based CB1 activation assay 
(Tango assay) (van der Lee et al., 2009) to study DAGL activation 
mechanisms. This assay provided a convenient 96-well microtitre assay to 
study DAGL-dependent CB1 signalling when compared to the traditional 
lower through-put mass spectrometry approaches (Bisogno et al., 2003; Jung 
et al., 2007; Pedicord et al., 2011; Balgoma et al., 2013). 
We first confirmed that the Tango cells and assay were sensitive to a CB1 
agonist and antagonist. We detected expression of DAGLα, DAGLβ, and the 
2-AG hydrolysing enzyme MAGL (but not FAAH) in these cells by Western 
blotting analysis. Our expression data is further supported by 'The Human 
Protein Atlas' (www.proteinatlas.org), a project focussed on antibody-based 
proteomics to profile the human proteome. As part of this project mRNA 
analysis of several cell lines have been carried out and are publicly available 
at www.proteinatlas.org. In U2OS (Tango background) cells, expression of 
DAGLα has been classified as medium abundance, DAGLβ high, MAGL 
medium, and FAAH as low which agrees with our Western results.  
Despite the presence of both DAGLs, there is little eCB tone in the Tango 
cells maintained in McCoy’s media supplemented with 1% FCS. This could 
be due to a lack of substrate being available under these growth conditions, 
due to the enzymes being in a closed state that restricts substrate access to 
the catalytic domain, or possibly due to MAGL acting as a “gatekeeper” by 
hydrolysing 2-AG and thereby directly preventing CB1 receptor activation 
despite the presence of basal DAGL activity. Such a “gatekeeper” role has 
recently been identified in neurons – here MAGL is excluded from the growth 
cones to allow localised DAGL-dependent eCB signalling in this 
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compartment, but enriched in the axon to prevent this signalling (Keimpema 
et al., 2013). Interestingly, treatment of the Tango cells with JZL195, a potent 
MAGL inhibitor, led to a small but highly significant increase in β-lactamase 
activity that was CB1 dependent as determined by the use of AM251. This 
supports the hypothesis that MAGL has a general gate keeping role that 
extends to non-neuronal cells. 
Interestingly, there was little if any evidence for an increase in eCB tone in 
the two cell lines that stably over express DAGLα and DAGLβ (data not 
shown as this was not a focus for this study). This clearly indicates that the 
lack of tone is not simply a consequence of low levels of enzyme expression, 
and again points to lack of substrate and/or the enzymes being in a closed 
state as a mechanism that can limit eCB signalling. 
Having confirmed that the Tango cells express reasonable levels of 
endogenous DAGLα/β, we sought to determine if we could stimulate DAGL-
dependent eCB signalling in the cells. Calcium stimulated 2-AG production 
has been widely reported (Bisogno et al., 2003; Aguado et al., 2005; Sugiura 
et al., 2006), presumably via DAGL dependent mechanisms. Here, two 
paradigms have been established that generate a robust DAGL-dependent 
CB1 response. The first involved treating cells maintained in McCoy’s 1% 
FCS media with the calcium ionophore ionomycin for 4 hours. The second 
involves maintaining the cells in the manufacturers recommended Freestyle 
media overnight and then treating them overnight with Freestyle media 
supplemented with 2mM CaCl2. Both resulted in very robust responses that 
did not fall far too short of the maximal response elicited by the CB1 agonist 
ACEA. We have therefore successfully adapted the Tango assay to measure 
a calcium stimulated DAGL-dependent eCB response. 
At least 3 different mechanisms, individually or collectively could be 
responsible for the calcium stimulated DAGLα/β-dependent CB1 response in 
the Tango cells. Firstly, calcium mediated mechanisms could cause an 
increase in substrate (DAG) levels resulting in increased DAGL activity. This 
could potentially be mediated by the activation of a PLC enzyme in the cells 
(Gresset et al., 2010). However, we have as yet been unable to block the 
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response with a general PLC inhibitor (Emma Williams, unpublished 
observation).  
Secondly, calcium could directly (or via calmodulin) interact with and activate 
the DAGLs as has been observed for other proteins (Rellos et al., 2010). The 
evidence for this is not clear. Calcium stimulated DAGL activity in vitro was 
observed with purified DAGL (activity) from some endogenous sources like 
bovine aorta (Lee and Severson, 1994) but not others like human platelets 
(Moriyama et al., 1999), brain plasma membrane (Farooqui et al., 1986), and 
brain microsomes (Rosenberger et al., 2007). Two separate studies using 
membranes overexpressing the DAGLs and synthetic DAG (as the substrate) 
in biochemical assays have shown an ~2-fold increase in DAGL activity in 
the presence of CaCl2 (Bisogno et al., 2003; Pedicord et al., 2011). In the first 
study, Bisogno et al. observed significant increases in activity (~20% to 
100%) at high (0.1 to 10mM) but not low (1 to 10µM) concentrations of CaCl2. 
In the second study, Pedicord et al. observed ~2-fold increase in activity 
using high (5mM) concentrations of CaCl2. Collectively, these results indicate 
that CaCl2 can stimulate DAGL activity in vitro, however, due to the high 
concentrations required, one cannot rule out an effect on substrate solubility 
rather than a direct effect on the enzymes (Lee and Severson, 1994; 
Rosenberger et al., 2007). Our own results on this question, presented in 
later chapters, do not support the hypothesis for a direct activation of DAGL 
activity by calcium. 
Another mechanism by which calcium could (indirectly) activate the DAGLs is 
by phosphorylation. Calcium stimulated kinases could potentially 
phosphorylate and activate the DAGLs. As discussed in chapter 3, several 
phospho-sites have been identified in the DAGL sequences and some of 
these sites are well placed to activate the enzymes by potentially regulating 
their open and closed conformation. Out of the 9 phospho-sites that 
appeared to be genuine (supported by at least three published studies), 4 
were predicted to be phosphorylated by PKA and PKC.  
The activity of DAGL purified from bovine brain microsomes was increased 3-
fold when treated with PKA in vitro (Rosenberger et al., 2007). Similarly, PKA 
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treated bovine rod membranes showed ~70% increase in DAGL activity in 
vitro (Perez Roque et al., 1998). Vellani et al. observed ~3-fold increase in 2-
AG levels when treating HEK293 cells with the PKC activator PMA, this was 
prevented by the PKC inhibitor RO318820 (Vellani et al., 2008). They 
observed similar effects with the PKA activator Forskolin and PKA inhibitor 
RpcAMPS. These increases in 2-AG are presumably mediated by one or 
both of the DAGLs. Increases in 2-AG levels in glucocorticoid stimulated 
hypothalamic slices was also shown to be PKA dependent (Malcher-Lopes et 
al., 2006). Collectively these studies coupled with the phospho-
map/phospho-prediction results in chapter 3 made PKA and PKC attractive 
kinases to study in relation to DAGL activation. Furthermore, both these 
kinases can be activated by calcium (Steinberg, 2008; Dunn et al., 2009). 
Pharmacological activators (Castagna et al., 1982; de Souza et al., 1983) 
and inhibitors (Chijiwa et al., 1990; Martiny-Baron et al., 1993) are also 
commercially available for these kinases. We therefore decided to test 
whether calcium mediated DAGL activation in the Tango assay was PKA 
and/or PKC dependent. Both PKA and PKC inhibitors blocked calcium 
stimulated DAGL dependent CB1 activation in the Tango assay. 
Furthermore, PKA and PKC activators stimulated DAGL dependent eCB 
signalling in this assay providing evidence that these two kinases can 
activate the DAGLs. It was unclear whether DAGLα, DAGLβ or for that 
matter both were responsible for the PKA/C stimulated activity as the Tango 
cells express both DAGLα and DAGLβ. No inhibitors at the time were 
available to distinguish between DAGLα and DAGLβ activity and so we 
therefore pursued a DAGLα/β gain of function approach using the Tango 
cells.  
We successfully expressed various DAGLα/β transgenes in the Tango cells 
and also successfully generated clonal cell lines expressing DAGLα-V5 
(V5α11) or DAGLβ-V5 (V5β4) at 4 to 5-fold higher levels than the 
corresponding endogenous genes. As mentioned above, this resulted in little 
if any increase in basal eCB tone using the V5α11 and V5β4 cells in the 
Tango assay compared to the parental cells (data not shown). This could 
indicate that the majority of the DAGL in these cell lines was in the inactive 
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'closed' conformation, but the alternative possibility is that substrate 
availability is the limiting factor. 
 Under stimulated conditions (e.g. ionomycin) there was some evidence for a 
greater CB1 response in the cells that over expressed DAGLα, however, 
despite several optimisation experiments (time course and dose responses of 
ionomycin) the window of the response remained quite small (at best 2-fold) 
and was deemed to be insufficient to pursue detailed gain of function studies. 
Current work in the lab is therefore focussing on genetically deleting the 
native DAGL genes in the Tango cells. This, in theory, should provide us with 
a more suitable platform to perform gain of function studies using the DAGLs. 
Ultimately, this would enable us to screen DAGL mutants in the Tango assay 
in order to investigate the role of the phospho-sites detailed in the DAGL 
phospho-maps. We would be particularly interested in identifying phospho-
sites responsible for PKA and PKC stimulated DAGL activity. 
An interesting observation made while evaluating expression of the DAGLβ 
transgene was that a significant amount of DAGLβ was localised to the Golgi. 
The functional significance of this is unknown. The lack of good antibodies for 
DAGLβ has hindered immunocytochemical studies of the endogenous 
enzyme and so despite the fact that Golgi localisation of DAGLβ was 
observed using 3 different constructs in 2 different cell lines, we cannot rule 
out the fact that this might be an artefact of overexpressing the enzyme. 
However, besides our observations, another study suggests that this 
warrants further investigation. SPIED is an online resource that has collated 
publicly available gene expression data from many different platforms. SPIED 
enables one to identify genes whose expression are frequently up or down-
regulated in conjunction with a gene of interest (Williams, 2012). For 
example, using this resource we determined that DAGLα expression 
correlates with the expression of synaptic proteins. DAGLα is responsible for 
retrograde signalling at synapses in the brain (Gao et al., 2010; Tanimura et 
al., 2010); therefore the fact that its expression is regulated with other 
synaptic proteins isn't surprising. When DAGLβ was queried using SPIED, its 
expression was found to be regulated along with Golgi proteins indicating the 
Golgi localisation observed in our results maybe physiologically relevant. 
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Current work to isolate the Golgi from various cell types in order to test for 
endogenous DAGLβ expression by Western blotting is ongoing in our lab, 
and our very recent development of an antibody that can be used to localise 
endogenous human DAGLβ in cells should help us resolve this question. 
In conclusion, our results show that calcium stimulated DAGL-dependent 
eCB signalling in Tango cells requires PKA and PKC activity, and that agents 
that activate these kinases can directly stimulate DAGL dependent eCB 
signalling. Based on the results presented that identifies regulated phospho-
sites in DAGLα and DAGLβ, and the above results, we postulated that direct 
phosphorylation of the DAGLs by PKA or PKC regulates their activity, and go 


















Chapter 5 (Results 3): Investigating DAGL activity using 
surrogate substrates 
As discussed in the previous chapters, phosphorylation of the DAGLs is a 
likely mechanism to regulate the activation of these enzymes. In order to 
understand the mechanism behind DAGL activation it is important to be able 
to directly monitor their catalytic activity. In vitro DAGL assays have 
traditionally involved the use of synthetic DAG as a substrate coupled with 
the measurement of 2-AG as the product (Bisogno et al., 2003; Jung et al., 
2007). Measuring 2-AG is no trivial task involving mass spectrometry 
techniques with limited throughput (Balgoma et al., 2013).  
Additional tools have been developed to monitor DAGL catalytic activity. For 
example generic probes including fluorophosphonate (FP) linked to either 
biotin or rhodamine have been developed that bind to catalytically active 
serine hydrolases including ABHDs (Liu et al., 1999; Kidd et al., 2001; 
Patricelli et al., 2001). These probes have been used to screen proteomes to 
identify novel serine hydrolases as well as to determine the specificity of 
various serine hydrolase inhibitors, as inhibitor binding competes with FP 
binding (Blankman et al., 2007; Hoover et al., 2008). Once the probe has 
bound to the target, the binding can be detected and measured using SDS-
PAGE methodologies including Western blotting and in-gel fluorescence, or 
the targets can be enriched and then detected and measured by mass 
spectrometry. However this tool has certain limitations. Firstly, not all serine 
hydrolases are well recognised by this probe, including DAGLα (Ben Cravatt, 
personal communication). Secondly, although binding of these probes rely on 
the catalytic sites of their targets being in the active conformation, it is 
unclear whether they are able to distinguish between lipases in their opened 
and closed conformations. And thirdly, the SDS-PAGE or mass spectrometry 
dependent detection methods involved with these probes means they have 
limited throughput.  
At least two recent reports have detailed the development of DAGL activity 
assays utilising surrogate substrates. Johnston et al. have developed FRET 
reporter substrates, which rely on DAGL activity to relieve internal quenching 
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in the reporters resulting in an increase in fluorescence (Johnston et al., 
2012). A commercially available fluorogenic lipase substrate (EnzChek 
Lipase substrate) is based on the same principle (Basu et al., 2011). 
Pedicord et al. on the other hand used two commercially available substrates 
to develop 96-well plate microtitre assays to measure DAGL activity using 
membranes from cells overexpressing DAGLα (Pedicord et al., 2011).  
The substrates used were either the chromogenic substrate 4-Nitrophenyl 
butyrate (PNPB) or the fluorogenic substrate 6,8-difluoro-4-methylumbelliferyl 
Octanoate (DiFMUO). These assays are cost effective, high throughput tools 
to study DAGL catalytic activity.  In this chapter I will report on the successful 
adaptation of these assays to not only measure DAGL activity in membranes 
but to also measure activity in intact living cells. In this chapter I have 
confirmed that these substrates can be used in assays to identify DAGL 
inhibitors and confirm the overexpression of DAGL in both cell membranes 
and living cells. However, despite developing a range of different assays 
(membrane/cell based using PNPB/DiFMUO to measure DAGLα/β activity) 
we were unable to detect changes in DAGL activity with calcium or PKA and 
PKC activators  suggesting that these surrogate substrates are unsuitable 
tools to study DAGL regulation. Potential explanations are discussed, and 
these include the possibility that the regulatory lid does not limit access of 
these substrates to the catalytic domain.  
5.1 Results 
5.1.1 DAGL substrates 
The structure of the native substrate DAG, three surrogate substrates 
(PNPB, DiFMUO, and EnzChek), and the products formed following 
hydrolysis by the DAGL enzymes are shown in Figure 5.1. PNPB is a 
chromogenic substrate whereas DiFMUO and EnzChek are fluorescent 
substrates. Details describing a human DAGLβ membrane assay using the 
EnzChek substrate are publicly available at Pubchem Bioassay. Human 
DAGLα membrane assays using PNPB and DiFMUO have been published 
(Pedicord et al., 2011) and both these substrates were used to develop 




Figure 5.1. Native and surrogate DAGL substrates 
The native (DAG) and surrogate (PNPB, DiFMUO, and EnzChek) substrates 
(molecular weights in brackets) of DAGL and the products generated 
following their hydrolysis by DAGL are presented above. PNPB is a 










5.1.2 Development of a DAGLα PNPB membrane assay 
PNPB is a chromogenic substrate; its hydrolysis is measured by detecting 
the product 4-nitrophenyl at OD400. In order to develop a DAGLα PNPB 
membrane assay, membranes were prepared from parental Tango and the 
DAGLα overexpressing V5α11 cells that had been in grown in McCoy's 
media supplemented with 10% FCS. Membranes were prepared by 
mechanically lysing the cells using a homogenizer and separating the 
membrane enriched fraction (pellet) from the soluble cytoplasmic proteins 
(supernatant) by centrifugation at 100,000g. The membrane enriched fraction 
was then resuspended in the membrane buffer (20mM HEPES pH 7.0, 2mM 
DTT) using a homogeniser and frozen in aliquots.  
The activity of different concentrations of membranes was tested (1 to 
50µg/ml) using 250µM PNPB as the substrate. Activity was determined by 
measuring the rate of product formation (ΔOD400/min) over 10 minutes. 
Increasing activity was observed with increasing concentrations of both sets 
of membranes. The V5α11 membranes were more active (~6-fold) than the 
parental Tango membranes at all the concentrations tested (Figure 5.2A). 
This difference in activity is likely to be due to DAGLα as the V5α11 
membranes are Tango cells overexpressing the human DAGLα-V5 
transgene (~5-fold higher levels Figure 4.14). A membrane concentration of 
12.5µg/ml was selected for further experiments as this was deemed to 
provide a good signal to background (no membranes) ratio and also provided 
a 6-fold window between the parental Tangos and V5α11 membranes. 
Additionally, the reaction progress curves for both sets of membranes at a 
concentration of 12.5µg/ml were found to be linear for up to 30 minutes 
(Figure 5.2B). Having established a suitable membrane concentration to use 
in the assay, activity of V5α11 and Tango membranes (12.5µg/ml) were 
tested with different concentrations of the PNPB substrate (125µM to 1mM) 
as described above. Increasing activity was observed with increasing 
substrate concentrations up to 500µM for both sets of membranes (Figure 
5.3). Approximately 6-fold greater activity was measured between the V5α11 









Figure 5.2. Measuring DAGLα activity using the chromogenic 
substrate PNPB in membranes prepared from V5α11 Tango cell 
line or parental Tango cells 
V5α11 and Tango cells were grown in McCoy's media supplemented 
with 10% FCS. The cells were lysed and membranes enriched as 
described in the methods section. The activity of different 
concentrations of V5α11 or Tango membranes, as indicated, were 
measured using PNPB (250µM) by measuring the OD400 every 12 
seconds for 30 minutes. The reaction rates were calculated over 10 
minutes and are presented above (mean of 3 wells ±SEM) (A). The 
OD400 values measured over 30 minutes using membranes at a 
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Figure 5.3. Substrate concentration response in the DAGLα PNPB 
membrane assay 
The activity of V5α11 or Tango membranes (12.5µg/ml) prepared from cells 
grown in McCoy's media supplemented with 10% FCS were tested with 
different concentrations of PNPB as indicated. The OD400 was measured 
every 12 seconds for 30 minutes. The reaction rates were calculated over 10 









Employing 500µM PNPB in the assay resulted in a higher background 
absorbance (in the absence of membranes) than expected (data not shown). 
This indicated that a concentration of 500µM was close to PNPB solubility 
limits which could introduce variability in the assay. Further experiments were 
therefore performed using 250µM PNPB as the substrate concentration, 
especially as this concentration provided the same signal window between 
V5α11 and parental Tango cells as 500µM. 
The human DAGLα-V5 transgene which was stably transfected into the 
Tango cells was probably responsible for the difference in activity between 
the V5α11 and Tango membranes detected at various membrane and 
substrate concentrations. To verify this, cellular fractions were prepared 
which would enable a comparison of activity measured in the PNPB assay to 
DAGLα-V5 protein expression in the various fractions. In order to prepare the 
fractions, V5α11 and Tango cells were homogenised and then subjected to 
centrifugation at different speeds (1000, 19,000 and 100,000g) after which 
the supernatants and pellets were separated. The pellets were resuspended 
in membrane buffer and activities of both the supernatants and pellets 
(12.5µg/ml) were measured using 250µM PNPB. DAGLα-V5 protein was also 
detected in these fractions by Western blotting using a V5 antibody. The 
activity in the non-fractionated (total) homogenates obtained from the V5α11 
cells was ~4-fold that of the parental Tango cells. This was surprising as we 
expected to see higher background (cytoplasmic) lipase activity in the total 
homogenates and therefore a lesser window between the activities measured 
in the two homogenates (Figure 5.4A). DAGLα-V5 activity was most enriched 
in the 19,000 and 100,000g pellets (6-fold more activity compared to the 
corresponding Tango fraction). Any difference in activity between the V5α11 
and Tango fractions corresponded to the positive detection of DAGLα-V5 in 
the Western blots (Figure 5.4B). No DAGLα-V5 was detected in the V5α11 
19,000 and 100,000g supernatants indicating that DAGLα-V5 was localised 





Figure 5.4. Cellular fractionation reveals high degree of specificity of 
PNPB as a substrate for DAGLα 
V5α11 and Tango cells grown in McCoy's media supplemented with 10% 
FCS were homogenised and then subjected to centrifugation at different 
speeds (1000, 19,000 and 100,000g). Supernatants and pellets were 
collected, the pellets were resuspended in membrane buffer (20mM HEPES, 
pH 7.0, 2mM DTT), and activities of both the supernatants and pellets 
(12.5µg/ml) were measured using 250µM PNPB as previously described and 
are presented above (mean of 3 wells ±SEM) (A). DAGLα-V5 was also 





We next tested the ability of three different DAGL inhibitors to inhibit DAGL 
activity in the PNPB membrane assay. Membranes prepared above were 
pre-incubated with different concentrations of OMDM-188, RHC-80267 or 
THL for 5 minutes before the PNPB was added. As described above, the 
OD400 was measured over 30 minutes and the reaction rates were calculated 
over 10 minutes. All three inhibitors inhibited activity in the assay, albeit with 
different efficacies (Figure 5.5). Only a slight inhibition of activity was 
observed in the Tango membranes using any of the three inhibitors (~25%) 
suggesting that the relatively low basal activity observed in the parental 
Tango membranes was 'non DAGL'. Furthermore, as THL is a very general 
lipase inhibitor (Borgstrom, 1988; Hadvary et al., 1988), any THL insensitive 
activity in this assay is probably non-enzymatic. A much larger inhibition of 
activity was observed in the V5α11 membranes following inhibitor treatment 
which lowered activities to the low basal level seen with parental Tango 
membranes (Figure 5.5). OMDM-188 was the most potent inhibitor, showing 
complete inhibition at ~25 to 50nM (Figure 5.5A). THL was also relatively 
potent, fully inhibiting the response at 100 to 200nM (Figure 5.5A). In 
contrast, RHC-80267 at a concentration of 100µM was required to achieve 
full inhibition of the response (Figure 5.5B). The inhibitor results provided 
further evidence that the 6-fold higher activity observed in the V5α11 
membranes was indeed DAGL activity. In further experiments, a 
concentration of 1µM THL was used as a control when measuring DAGLα-V5 
activity.  
In summary, membranes from cells that overexpressed DAGLα by ~5-fold 
showed a ~6 to 10-fold increase in hydrolytic activity against the PNPB 
substrate (Figure 5.6), this hydrolytic activity fractionated with DAGLα and 
was fully inhibited with three independent DAGL inhibitors. We can conclude 













Figure 5.5. V5α11 activity detected in the PNPB membrane 
assay is inhibited by three different DAGL inhibitors (OMDM-
188, THL, and RHC-80267) 
V5α11 and Tango membranes prepared from cells grown in McCoy's 
media supplemented with 10% FCS (12.5µg/ml) were incubated with 
different concentrations of the 3 inhibitors as indicated, for 5 minutes. 
Activity was then measured using 250µM PNPB as previously 
















































Figure 5.6. The PNPB membrane assay can be used to measure DAGLα-
V5 activity 
V5α11 or Tango membranes (12.5µg/ml) prepared from cells cultured in 
McCoy's media 10% FCS were incubated in the presence or absence of 1µM 
THL for 5 minutes. Activity was then measured using PNPB (250µM) as 
previously described (mean±SEM presented above. V5α11 n=10, Tango 
n=13, where n=the number of independent experiments) (A). The THL 
sensitive activity (total activity with THL insensitive background subtracted) is 







































5.1.3 Investigating DAGLα activation using the PNPB membrane assay 
Calcium can stimulate DAGL activity in cells (Bisogno et al., 2003; Aguado et 
al., 2005) and we have postulated that this may occur due to phosphorylation 
of the DAGLs by calcium activated kinases. In order to investigate this, we 
tested whether calcium and serum deprivation (starvation) can affect the 
DAGL activity measured in the above membrane assay. To this end V5α11 
cells were maintained overnight in the calcium and serum free media 
(Freestyle media) for 24 or 48 hours before membranes were prepared and 
DAGL activity determined in the presence or absence of 1µM THL. The 
membranes (12.5µg/ml) were pre-incubated with THL for 5 minutes after 
which PNPB was added (250µM). The OD400 was measured for 30 minute 
and the reaction rate was calculated over the first 10 minutes. A reduction in 
the total activity and THL sensitive activity (20% after 24 hours and 30% after 
48 hours) was observed in the membranes prepared from starved cells when 
compared to membranes from cells cultured in McCoy's 10% FCS (Figure 
5.7A and B). Expression levels of DAGLα-V5 in the starved and control 
membranes tested by Western blotting using a V5 antibody revealed a 
similar reduction in DAGLα-V5 levels, providing a likely explanation for the 
lower activity observed following starvation (Figure 5.7C and D).  
As previous reports have demonstrated that CaCl2 can stimulate DAGL 
activity in vitro (Bisogno et al., 2003; Pedicord et al., 2011) we decided to test 
this in the PNPB membrane assay. V5α11 membranes (12.5µg/ml) were pre-
incubated in the absence of calcium or with increasing concentrations of 
CaCl2 (0.25-4mM) for 5 minutes and then incubated in the presence or 
absence of 1µM THL for a further 5 minutes. The activity was then measured 
using 250µM PNPB as described above. The first important point is that 
DAGLα activity is maximally active in the absence of added calcium, so at 
least in the context of the PNPB substrate they do not require calcium for 
activity. Surprisingly and unexpectedly, a decrease in activity (60-80%) was 
observed with the increasing concentrations of CaCl2 (Figure 5.8). In this 
particular case, CaCl2 could have had a negative effect on substrate solubility 
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Figure 5.7. Reduction of DAGLα-V5 activity tested in the PNPB 
membrane assay following starvation is probably due to a reduction in 
DAGLα expression levels 
V5α11 cells were cultured in McCoy's media supplemented with 10% FCS or 
maintained in Freestyle media in the absence of calcium and serum for 24 or 
48 hours after which membranes were prepared as described earlier. The 
membranes (12.5µg/ml) were then incubated in the presence or absence of 
1µM THL for 5 minutes. Hydrolytic activity was then measured using PNPB 
(250µM) as previously described (mean±SEM, 0h n=7, 24h n=7, 48h n=2 
where n=number of independent experiments) (A). The THL sensitive activity 
(total activity with the THL insensitive background activity subtracted) are 
also presented (B). Western blotting using a V5 antibody of the control and 
starved membranes (10µg) was carried out; membranes prepared from 
parental Tango cells were included as a negative control (C). β-actin was 
also detected as a loading control. The DAGLα-V5 band intensities 
(quantified using the Odyssey software) were normalised to β-actin and are 
presented as a ratio to the normalised DAGLα-V5 band intensities measured 
in the unstarved control membranes (D) (n=2 independent experiments and 
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Figure 5.8. CaCl2 causes a reduction in DAGLα-V5 activity tested in the 
PNPB membrane assay 
Membranes prepared from V5α11 cells cultured in McCoy's media 
supplemented with 10% FCS (12.5µg/ml) were pre-incubated with different 
concentrations of CaCl2 (0.25-4mM) for 5 minutes and then incubated in the 
presence or absence of 1µM THL for a further 5 minutes. The activity was 
then measured using 250µM PNPB as previously described (mean of 3 wells 
±SEM) (A). THL sensitive activity measured in the V5α11 membranes is also 
presented (B). 
CaCl2 (mM)





































Based on the results presented in the previous chapters that identified 
regulated phospho-sites in DAGLα and DAGLβ, and the observation that 
calcium stimulated DAGL-dependent eCB signalling in Tango cells requires 
PKA and PKC activity, we postulated that direct phosphorylation of the 
DAGLs by PKA or PKC regulates their activity. We therefore next examined 
whether the DAGL activity measured in the cell membranes using the PNPB 
substrate might differ between membranes isolated from control and PKA or 
PKC stimulated cells. V5α11 cells were maintained overnight in Freestyle 
media after which they were treated with either the PKA activator forskolin 
(10µM) or the PKC activator PMA (25nM) for 1 hour. Membranes were then 
prepared from the cells and were assayed (12.5µg/ml) as described above, 
in the presence or absence of 1µM THL using 250µM PNPB. No significant 
difference in activity was observed with membranes obtained from cells 
treated with forskolin or PMA (Figure 5.9). The activity of the batches of 
forskolin and PMA was confirmed by an increase in phosphorylation of CREB 
in lysates prepared from the treated cells (by Western blotting using a 
phospho-CREB antibody, data not shown). 
 The failure of the above treatments to affect DAGL activity could be due to a 
number of possibilities, for example PKA and/or PKC sites on DAGL might be 
phosphorylated in control cells. Indeed, there is reasonable evidence to think 
that there might be basal phosphorylation of the DAGLs (Perez Roque et al., 
1998; Daub et al., 2008; Shonesy et al., 2013), and that it might be removed 
by a general phosphatase activity. For this reason we undertook a 
speculative experiment to see if phosphatase treatment could modulate 
activity. In this context direct treatment of the membranes with calf intestinal 
phosphatase (CIP) as described in the methods section had no effect on 
DAGL activity in the standard assay (Figure 5.10). This might be because the 
DAGLs are not phosphorylated, or the phosphatase might not have removed 
regulatory phosphates. These questions are explored later in the thesis. In 
summary, our experiments failed to demonstrate any changes in DAGL 






Figure 5.9. Treating V5α11 cells with PKA or PKC activators does not 
cause an increase in DAGLα-V5 activity, in vitro, in the PNPB 
membrane assay 
V5α11 cells were maintained in Freestlye media for 24 hours and then 
treated with either the PKA activator forskolin (10µM) or the PKC activator 
PMA (25nM) for 1 hour after which membranes were prepared. The 
membranes (12.5µg/ml) were incubated in the presence or absence of 1µM 
THL for 5 minutes. Activity was then measured using PNPB (250µM) as 
previously described (n=3 independent experiments and shown as the 




































Figure 5.10. Phosphatase treatment of V5α11 (or Tango membranes) did 
not affect DAGLα (-V5) activity tested in the PNPB membrane assay 
100µg V5α11 or Tango membranes were incubated with 50 units of calf 
intestinal phosphatase (37ºC for 60 minutes). The membranes (12.5µg/ml) 
were then incubated in the presence or absence of 1µM THL for 5 minutes. 
Activity was then measured using PNPB (250µM) as previously described 
(the mean of 3 wells ±SEM are presented above) (A). The THL sensitive 
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This might be because the various treatments do not impact on DAGL 
structure and function, a loss of any impact as a consequence of membrane 
preparation, or perhaps the PNPB substrate can access the catalytic domain 
of both an “open” and “closed” enzyme due to its high solubility and small 
size.   
5.1.4 Development of a DAGLα PNPB cell based assay 
In order to start to address some of the above questions it was decided to 
see if the PNPB substrate could be used to explore DAGL activity in a live 
cell assay. To this end, V5α11 or Tango cells were seeded in 96-well plates 
in Freestyle media and maintained overnight. The media was then discarded 
and the cells were washed in assay buffer (50mM HEPES pH 7.4). The 
washed cells were incubated in the presence or absence of 25µM THL for 5 
minutes and the hydrolytic activity was measured using the reaction rate 
calculated over the first 10 minutes. By varying cell number (20,000-40,000) 
and PNPB concentrations (100 to 500µM), and subtracting the background 
hydrolysis seen in the presence of 25µM THL (data not shown) conditions 
were established that showed the V5α11 cells hydrolysed the substrate at 3 
to 4-fold higher rates than the parental cells (Figure 5.11A). Importantly, the 
enhanced activity in the DAGLα transfected cells and the basal activity in the 
parental Tango cells were completely inhibited by RHC-80267 and THL 
(Figure 5.11B and C). This assay was next used to test the effects of various 
treatments on the DAGL dependent hydrolysis of PNPB. 
5.1.5 Investigating DAGLα activation using the PNPB cell based assay 
Having established a PNPB cell based assay that could detect DAGLα (V5) 
activity, various treatments were next screened for their ability to modulate 
the DAGL dependent hydrolysis of PNPB in living cells. Following up from 
previous reports, (Bisogno et al., 2003; Sugiura et al., 2006) and the results 
observed in chapter 4 (Tango assay), we first tested whether CaCl2 could 










Figure 5.11. DAGLα activity can be measured using the PNPB 
cell based assay which is inhibited by THL and RHC-80267 
40,000 V5α11 or Tango cells per well were seeded in Freestyle 
media in 96-well plates and maintained overnight. The media was 
then discarded and the cells were washed in assay buffer (50mM 
HEPES pH 7.4). The washed cells were incubated in the presence or 
absence of 25µM THL for 5 minutes. Hydrolytic activity was then 
measured using 500µM PNPB by measuring the OD400 for 60 
minutes. The reaction rate was calculated over the first 10 minutes 
and the THL sensitive activity is presented above (n=9 independent 
experiments and results show mean±SEM) (A). Additionally, cells 
that were seeded, maintained, and washed as described above were 
incubated with different concentrations of the DAGL inhibitors RHC-
80267 or THL as indicated for 5 minutes. Activity was then measured 
using 500µM PNPB and the mean of 6 replicate wells ±SEM are 



































































V5α11 or Tango cells were maintained overnight in the Freestyle media after 
which they were incubated in the absence or presence of 1 or 2mM CaCl2 
overnight as both stimulated DAGL-dependent eCB signalling under these 
conditions (see chapter 4). The cells were then washed in assay buffer and 
the activity was measured in the presence or absence of 25µM THL using 
500µM PNPB. No increase in activity was observed in the V5α11 cells, 
furthermore, an almost 50% decrease in activity was observed in the cells 
treated with 2mM CaCl2 (Figure 5.12A). This may have been caused by 
residual calcium interfering with substrate solubility or some other as of yet to 
be identified reason.  
We next tested the effects of PKA activators on the activity of DAGLα in the 
PNPB cell based assay. V5α11 and Tango cells maintained in Freestyle 
media were treated with different concentrations of forskolin for 10 minutes or 
4 hours after which the activity was measured in the presence or absence of 
THL as described above. No increase in activity was observed in the V5α11 
cells using forskolin, following 10 minute (Figure 5.12B) or 4 hour treatments 
(data not shown). Similarly, no change in activity was observed when the 
cells were treated with the stable cAMP analogue 8-MA-cAMP. In addition to 
this, treating the cells with a PKA inhibitor H89 (5µM for 1 or 4 hours) did not 
affect PNPB hydrolysis in this assay (data not shown). 
Having failed to detect a significant change in DAGL activity towards the 
PNPB substrate in the V5α11 cells following treatments with PKA activators 
or inhibitor we next tested the effects of PKC activation in the PNPB cell 
based assay. V5α11 cells were treated with the PKC activator PMA for 10 
minutes and then activity in the cells was measured using 500µM PNPB in 
the presence or absence of 25µM THL as described above. Once again, no 
major change in activity in the V5α11 cells was observed following PMA 
treatment (Figure 5.12C). We have successfully developed a cell based and 
membrane assay to monitor DAGLα activity using PNPB as a substrate. 
However we were unable to demonstrate any PKA/PKC dependent activation 









Figure 5.12. CaCl2 or PKA and PKC activators failed to stimulate 
DAGLα activity in the PNPB cell based assay 
40,000 V5α11 or Tango cells were seeded per well of 96-well plates 
in Freestyle media and then maintained overnight. The cells were 
then incubated overnight in the absence or presence of CaCl2 (1 or 
2mM). The media was then discarded and the cells were washed in 
assay buffer (50mM HEPES pH 7.4). The washed cells were 
incubated in the presence or absence of 25µM THL for 5 minutes. 
Activity was measured using 500µM PNPB as previously described. 
The THL sensitive activity (mean of 6 wells ±SEM) is presented 
above (A). For the PKA/PKC activators, V5α11 cells were seeded, 
maintained, and washed as described above (in the absence of 
CaCl2). The washed cells were then first treated with different 
concentrations of forskolin or PMA as indicated for 10 minutes and 
then incubated in the presence or absence of 25µM THL for 5 
minutes. Activity was measured using 500µM PNPB as previously 
described. The THL sensitive activities are presented above for 
Forskolin (n=2 independent experiments and results show mean±SD) 
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As discussed earlier, it is possible that PKA/PKC stimulated DAGLα activity 
cannot be detected using a relatively small substrate like PNPB (~3 times 
smaller than DAG, Figure 5.1), that is also likely to access the enzyme from 
the cytosol and not the membrane. We therefore went on to develop DAGL 
assays using the fluorogenic substrate DiFMUO which is larger (338Da) than 
PNPB (209Da), and suggested to access the enzyme from the membrane 
(Pedicord et al., 2011) to study DAGL activation. 
5.1.6 Development of a DAGLα-DiFMUO membrane and cell based 
assay 
DiFMUO is a fluorogenic substrate which can be hydrolysed to DiFMU by 
DAGLα (Pedicord et al., 2011). DAGLα activity using this substrate can be 
detected by measuring the fluorescent product DiFMU (excitation 360nm, 
emission 450nm). In order to test whether DiFMUO could be used to 
measure DAGLα activity in our set up, membranes were prepared from 
V5α11 and Tango cells (grown in McCoy's media supplemented with 10% 
FCS) as described previously for the PNPB assay. The activity of different 
concentrations of membranes (1 to 50µg/ml) was measured in the presence 
or absence of 1µM THL using 10µM DiFMUO by measuring the rate of 
product formation (excitation 360nm, emission 450nm) over 10 minutes, 
when the reaction was linear. Increasing concentrations of membranes 
resulted in increasing activity in both sets of membranes (Figure 5.13A). The 
V5α11 membranes were more active than the parental Tango membranes at 
all the concentrations tested and this was completely inhibited by 1µM THL.  
A maximum fold difference in activity between the two sets of membranes 
(1.6-fold) was achieved at a concentration of 12.5µg/ml which was then used 
to test the effects of substrate concentration in the assay (in the presence or 
absence of 1µM THL). Increasing substrate concentrations between 1-5µM 
resulted in an increase in activity, but a further increase between 5-15µM had 











Figure 5.13. Developing a DAGLα DiFMUO membrane assay 
Membranes were prepared from V5α11 or Tango cells cultured in 
McCoy's media supplemented with 10% FCS. Different 
concentrations of the membranes were incubated in the presence or 
absence of 1µM THL for 5 minutes after which activity was measured 
using DiFMUO (10µM). Activity was monitored by measuring the 
fluorescence (excitation 360nm, emission 450nm) every 30 seconds 
for 30 minutes. The reaction rates were calculated over 10 minutes 
and are presented above (mean of 3 wells ±SEM) (A). This was 
repeated using membranes at a concentration of 12.5µg/ml and 
different concentrations of DiFMUO as indicated, the THL sensitive 
activity is presented above (mean of 3 wells ±SEM) (B). The optimum 
assay conditions were achieved using membranes at a concentration 
of 12.5µg/ml and DiFMUO at 10µM. The THL (1µM) sensitive activity 
measured using these conditions are presented above (n=7 
independent experiments and results show mean±SEM) (C) *** p < 
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When using membranes at a concentration of 12.5µg/ml and DiFMUO at 
10µM (to ensure substrate was in excess) the difference in activity between 
the V5α11 and Tango membranes was much less than what was observed in 
the PNPB membrane assay (1.6-fold versus 6-fold) (Figure 5.13C). The THL 
(1µM) insensitive background was higher in this assay compared to the 
PNPB membrane assay (30% versus 10%) possibly indicating that DiFMUO 
was more unstable than PNPB, or that it was hydrolysed by other THL 
insensitive membrane associated lipases. The difference between the THL 
sensitive activity of the V5α11 and Tango membranes was also lower 
compared to the PNPB membrane assay (2-fold versus 12-fold) (Figure 
5.13C). Nevertheless we did observe a 2-fold window between the THL 
sensitive activities of the V5α11 and Tango membranes. This difference in 
activity was inhibited by two additional DAGL inhibitors RHC-80267 and 
OMDM-188 (data not shown). Furthermore, when comparing different cellular 
fractions from V5α11 and Tango cells, any enhanced activity measured in the  
V5α11 fractions compared to the Tango fractions correlated with the positive 
detection of DAGLα-V5 protein in the fraction (Western blotting) (Figure 
5.14). Collectively these results confirmed that the 2-fold difference in activity 
between the V5α11 and Tango membranes was due to the DAGLα-V5 
transgene, thereby validating the DiFMUO membrane assay as a tool to 
study DAGLα (V5) activity. The fact that 5-fold more enzyme increased 
hydrolysis by only 2-fold suggests that something other than enzyme levels 
(and possibly activation state) limits hydrolysis in this assay. 
Nonetheless, in order to assess whether phosphorylation of DAGLα-V5 might 
be influencing its activity in the DiFMUO membrane assay, V5α11 and Tango 
membranes were treated with calf intestinal phosphatase (CIP) or PKA in 
speculative experiments, however no reduction in the total or THL sensitive 
activity was observed (data not shown).  
5.1.7 Development of a DAGLα DiFMUO cell based assay 
We next determined if DiFMUO might be a suitable substrate to measure 
DAGLα activity in live cells. To this end, 40,000 V5α11 cells were seeded per 




Figure 5.14. Cellular fractionation reveals DAGLα-V5 specific activity 
can be detected in the DiFMUO membrane assay 
V5α11 and Tango cells cultured in McCoy's media supplemented with 10% 
FCS were homogenised and then subjected to centrifugation at different 
speeds (1000, 19,000 and 100,000g). Supernatants and pellets were 
collected, the pellets were resuspended in membrane buffer, and activities of 
both the supernatants and pellets (25µg/ml) were measured using DiFMUO 
(10µM) as previously described (mean of 3 wells ±SEM) (A). DAGLα-V5 was 






































































































































Prior to assaying, the media was discarded and the cells were washed with 
assay buffer (50mM MES pH 6.5).The washed cells were incubated in the 
presence or absence of THL (25µM) for 5 minutes and then activity was 
measured as the rate of DiFMUO hydrolysis over the first 10 minutes. By 
varying substrate concentration and subtracting the background hydrolysis 
seen in the presence of 25µM THL, a maximum difference in activity of 1.6-
fold was observed between V5α11 and Tango cells (Figure 5.15). This was 
lower compared to the PNPB cell based assay (3.5-fold). Nevertheless, the 
difference in activity between the V5α11 and Tango cells observed in the 
DiFMUO cell based assay (Figure 5.15) was significant and was completely 
blocked by three different DAGL inhibitors (RHC-80267, OMDM-188 and 
THL) (data not shown). Thus we can conclude that something other than 
enzyme levels is rate limiting in this assay, and can speculate that this might 
be availability of the substrate to the enzyme, or enzyme activity towards this 
substrate. 
5.1.8 Investigating DAGLα activation using the DiFMUO cell based 
assay 
We proceeded to test the effects of various stimuli on DAGLα activity using 
the DiFMUO cell based assay. Prior to the treatments, V5α11 and Tango 
cells were maintained overnight in Freestyle media. In order to test whether 
PKA activation in cells could stimulate DAGLα activity measured in the 
DiFMUO cell based assay, V5α11, or parental Tango cells were treated with 
different concentrations of the PKA activator forskolin (0 to 20µM) for 10 
minutes or 4 hours. Activity in the cells was then measured in the presence 
or absence of 25µM THL using 10µM DiFMUO. No significant increase in 
activity was observed in either the V5α11 or parental Tango cells following 
forskolin treatment (Figure 5.16A). We also tested the effects of a PKA 
inhibitor (H89 5µM) in this assay. Both cell types were treated with H89 for 1 
hour and the activity was then measured as described above. A slight 
reduction (~10%) in the THL sensitive activity was observed in the V5α11 
cells (Figure 5.16C). However, a corresponding, non-significant decrease in 




Figure 5.15.The DiFMUO cell based assay can be used to measure 
DAGLα-V5 activity in the V5α11 cells 
40,000 V5α11 or Tango cells per well were seeded in Freestyle media in 96-
well plates and cultured overnight. The media was then discarded and the 
cells were washed in assay buffer (50mM MES pH 6.5). The cells were 
incubated in the presence or absence of 25µM THL for 5 minutes and then 
the activity was measured using 10µM DiFMUO as previously described. The 
reaction rates were calculated over 10 minutes and the total activity 
(mean±SEM, V5α11 n=16, Tango n=22. In each instance, n= the number of 
independent experiments) (A) and THL sensitive activity (B) are presented 
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Figure 5.16. PKA or PKC modulators did not affect DAGLα activity in 
the DiFMUO cell based assay 
40,000 V5α11 or Tango cells were seeded in Freestyle media per well of 96-
well plates and maintained overnight. The media was discarded and the cells 
were washed in assay buffer (50mM MES pH 6.5). The washed cells were 
treated with different concentrations of forskolin or PMA as indicated for 10 
minutes after which they were incubated in the presence or absence of 25µM 
THL for 5 minutes. The activity was then measured using 10µM DiFMUO as 
previously described. The THL sensitive activity for the forskolin treatments 
(mean±SD for n=2, mean±SEM for n>2, where n=the number of independent 
experiments) (A) and PMA treatments (mean±SEM n=3 independent 
experiments) (B) are presented above. For the PKA inhibitor treatment, the 
cells were seeded and maintained as described above but then treated for 1 
hour with 5µM H89 before the activity was measured in the presence or 
absence of 25µM THL using 10µM DiFMUO. The THL sensitive activity is 
presented above. (V5α11 n=2 mean±SD, Tango n=3, mean±SEM, n=the 
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DAGLα-V5 was therefore unlikely to be responsible for this reduction in 
activity (Figure 5.16C). Finally, we tested whether PKC activation would 
stimulate DAGLα-V5 activity in the DiFMUO cell based assay. V5α11 and 
Tango cells were treated with the PKC activator PMA for 10 minutes and 
then activity was measured as described above. Once again, no significant 
change in activity was observed in either the V5α11 or the parental Tango 
cells following PMA treatment (Figure 5.16B).  
We have developed a total of 4 different DAGLα assays (membrane and cell 
based) using two different substrates (PNPB and DiFMUO). However despite 
using a range of treatments and stimuli (phosphatase, calcium, PKA 
activation, PKA inhibition, and PKC activation) we failed to detect any 
changes in DAGLα activity using either DiFMUO or PNPB. These results 
failed to support our hypothesis that PKA and PKC activate the DAGLs by 
phosphorylation which was based on our findings in chapter 4 where we 
demonstrated that calcium, PKA, and PKC stimulated DAGL dependent eCB 
signalling in the Tango cells. However, it is possible that the DAGL-
dependent eCB signalling observed in the Tango assay may have been 
mediated by DAGLβ rather than DAGLα. We therefore thought it prudent to 
conduct a similar set of experiments on DAGLβ using the V5β4 Tango cells 
described in chapter 4. This line overexpresses V5 tagged human DAGLβ to 
a similar extent that V5α11 cells over express DAGLα (Figure 4.14 and 
Figure 4.15). 
5.1.9 DAGLβ-V5 PNPB membrane and cell based assays 
All assays using the V5β4 cells were run as previously described for the 
V5α11 cells and membranes. A summary of the results are presented below.  
Activity of membranes prepared from V5β4 cells (McCoy's media 10% FCS) 
were first tested in the PNPB membrane assay. A significant difference in 
activity between the V5β4 and parental Tango membranes was observed. 
However, the window of activity between the membranes was only 2-fold 
(Figure 5.17A) which was much smaller than what was observed between 








Figure 5.17. PNPB can be used to measure DAGLβ-V5 activity 
For the membrane assay, V5β4 or Tango membranes (12.5µg/ml) 
prepared from cells cultured in McCoy's media supplemented with 
10% FCS were incubated in the presence or absence of 1µM THL for 
5 minutes. Activity was then measured using PNPB (250µM) as 
previously described and the THL sensitive activity (mean±SEM, 
V5β4 n=9, Tango n=13. where n=number of independent 
experiments) is presented above (A). For the cell based assay 
40,000 V5β4 or Tango cells were seeded per well in Freestyle media 
in 96-well plates and maintained overnight. The media was then 
discarded and the cells were washed in assay buffer (50mM HEPES 
pH 7.4). The cells were incubated in the presence or absence of 
25µM THL for 5 minutes and then the activity was measured using 
500µM PNPB as previously described. The THL sensitive activity 
(mean±SEM, V5β4 n=6, Tango n=9. where n=the number of 
independent experiments) is presented above (B) ** p < 0.01 (two 
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We also observed greater activity in the V5β4 live cell assay compared to the 
Tango cells using the PNPB cell based assay. This increase in activity was 
however relatively small (1.7-fold) (Figure 5.17B), not significant and much 
lower compared to the difference between the V5α11 and Tango cells (3.5-
fold) (Figure 5.11A). Despite the small difference in activity between the 
V5β4 and parental Tango cells we attempted to stimulate DAGLβ activity in 
the V5β4 cells working on the assumption that activation of DAGLβ might 
reveal a bigger window of activity between these cells. Activity of Vβ4 cells 
treated with the PKA activator forskolin (10 minutes and 4 hours), the PKA 
inhibitor H89 (1 hour), and the PKC activator PMA (10 minutes and 4 hours) 
were tested using the PNPB cell based assay. None of these stimuli were 
found to affect DAGLβ-V5 activity in the assay (data not shown). 
5.1.10 DAGLβ DiFMUO membrane and cell based assays 
Having failed to detect DAGLβ activation in the V5β4 cells using the small 
PNPB substrate, we next attempted to detect stimulated DAGLβ activity 
using the larger DiFMUO. Firstly, the activity of membranes prepared from 
V5β4 cells was tested in the DiFMUO membrane assay to confirm that 
DAGLβ could hydrolyse this substrate. Unlike the V5α11 membranes, no 
significant difference between V5β4 and parental Tango membranes was 
detected at membrane concentrations of 12.5 or 25µg/ml. However, a small 
but significant difference (1.4-fold) at the higher concentration of 50µg/ml was 
observed (Figure 5.18A). A significant difference between the activity (1.4-
fold) of the V5β4 and Tango cells in the DiFMUO cell based assay was also 
observed (Figure 5.18B). However, once again we generally failed to detect 
any increase in DAGLβ-V5 activity after treating the V5β4 cells with a range 
of stimuli (Forskolin, H89, PMA) when using the DiFMUO cell based assay 
(data not shown).  
As in the case of DAGLα, the DAGLβ assays using PNPB and DiFMUO did 
not (and possibly could not) detect PKA and PKC stimulated DAGL activity. 
We generally observed greater activity in the V5α11 cells and membranes 
compared to the V5β4 cells and membranes in the PNPB and DiFMUO 








Figure 5.18. DiFMUO can be used to measure DAGLβ activity 
For the membrane assay V5β4 or Tango membranes (12.5, 25 or 
50µg/ml) prepared from cells cultured in McCoy's media 
supplemented with 10% FCS were incubated in the presence or 
absence of 1µM THL for 5 minutes. Activity was then measured 
using DiFMUO (10µM) as previously described and the THL sensitive 
activity is presented above (mean±SEM. V5β4 12.5µg/ml n=4, 
25µg/ml n=4 and 50µg/ml n=3. Tango 12.5µg/ml n=8, 25µg/ml n=6 
and 50µg/ml n=4. In each instance n=the number of independent 
experiments) (A). For the cell based assay 40,000 V5β4 or Tango 
cells per well were seeded in Freestyle media in 96-well plates and 
maintained overnight. The media was then discarded and the cells 
were washed in assay buffer (50mM MES pH 6.5). The washed cells 
were incubated in the presence or absence of 25µM THL for 5 
minutes and then the activity was measured using 10µM DiFMUO as 
previously described. The THL sensitive activity (mean±SEM, V5β4 
n=6, Tango n=22. where n=number of independent experiments) is 
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V5α11 PNPB 10% 11.0 
V5β4 PNPB 31% 2.1 
Tango PNPB 55% 1.0 
V5α11 DiFMUO 31% 1.8 
V5β4 DiFMUO 32% 1.4 
Tango DiFMUO 40% 1.0 
V5α11 EnzChek 2% 1.6 
V5β4 EnzChek 3% 2.5 





































V5α11 PNPB 31% 3.4 
V5β4 PNPB 45% 1.7 
Tango PNPB 59% 1.0 
V5α11 DiFMUO 30% 1.4 
V5β4 DiFMUO 30% 1.4 
Tango DiFMUO 34% 1.0 
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5.1.11 DAGLα and DAGLβ demonstrate different activities towards the 
surrogate substrates 
In order to check whether the higher activity detected in V5α11 cells 
compared to  V5β4 cells was reflective of higher expression levels of DAGLα-
V5 compared to DAGLβ-V5, 10µg of V5α11 and V5β4 membranes were 
analysed by Western blotting using a V5 antibody. Surprisingly, the intensity 
of the DAGLβ-V5 band was found to be 5 times greater than the DAGLα-V5 
band (Figure 5.19). Admittedly, these are different proteins of different sizes 
and this can affect the efficiency of transfer and detection during the 
Westerns. However, based on these results it does seem unlikely that 
differences in expression levels could account for the 5-fold difference in the 
THL sensitive activity measured in V5α11 and V5β4 membranes using 
PNPB. The difference is even greater (9-fold) if the THL sensitive parental 
Tango activity is subtracted from the activity of both the membranes, in order 
to enable comparisons between DAGLα-V5 and DAGLβ-V5 activity.  
The DAGL enzymes may instead have different activities against these 
substrates. In order to query this, the activity of membranes (12.5µg/ml) 
prepared from V5α11, V5β4, and Tango parental cells were tested using a 
third substrate, EnzChek, which is a commercially available fluorogenic 
substrate (structure presented in Figure 5.1). Lipase activity against this 
substrate relieves internal quenching within the substrate resulting in 
increased fluorescence. Interestingly, V5β4 membranes showed the highest 
activity against this substrate followed by the V5α11 and then the Tango 
membranes (Figure 5.20). Virtually all of the activity detected in this assay 
was found to be THL sensitive (1µM)  
Based on the results in this chapter it therefore appears that PNPB is the 
best substrate for DAGLα-V5 relative to DiFMUO and EnzChek, whereas 
EnzChek is clearly the best substrate for DAGLβ-V5 (Table 5.1). These 
results indicate that the DAGLs can differentiate between different surrogate 






Figure 5.19. Western blotting analysis using the V5 antibody indicates 
that DAGLβ-V5 in the V5β4 cells are expressed at higher levels than 
DAGLα-V5 in the V5α11 cells 
Membranes were prepared from V5α11 and V5β4 cells grown in McCoy's 
media supplemented with 10% FCS. Western blotting analyses of the 
membranes (10µg) using a V5 antibody were visualised using the Odyssey 
infrared imaging system. Band intensities were quantified using the Odyssey 
software and are presented as a ratio of the DAGLα-V5 band intensities 
(mean±SEM of 5 independent experiments presented above) (A). A 











































Figure 5.20. EnzChek as a tool to measure DAGLα and DAGLβ activity 
in membranes 
Membranes were prepared from V5α11, V5β4, or Tango cells grown in 
McCoy's media supplemented with 10% FCS. Different concentrations of the 
membranes were incubated in the presence or absence of 1µM THL after 
which activity was measured using 2µM EnzChek by measuring the 
fluorescence (excitation 480nm, emission 540nm) every 48 seconds for 10 
minutes. The reaction rates were calculated over 2 minutes and are 








5.2 Discussion and conclusions 
Our results in the previous chapter showed that calcium, PKA and PKC can 
stimulate DAGL activity in a cellular context, as measured by CB1 activation 
(Tango assay). The results however did not reveal whether DAGLα, DAGLβ, 
or indeed both were responsible for the stimulated DAGL activity. In addition, 
overexpression of DAGLα (5-fold) had little if any effect on basal eCB tone in 
media containing 1% FCS and these cells showed only a modest (at best ~2-
fold) increased response to the above stimuli (data not shown). Traditionally, 
DAGL activity is measured by the quantification of its product 2-AG, however 
this requires an expensive and elaborate laboratory set up (Balgoma et al., 
2013). In this chapter, we therefore used surrogate DAGL substrates in 
conjunction with cell lines overexpressing DAGLα/β to investigate whether 
calcium, PKA or PKC could modulate the hydrolysis of these by DAGLα 
and/or DAGLβ.  
We successfully developed a range of 96-well plate assays to study both 
DAGLα and DAGLβ activity, using either membranes or cells. These assays 
exploited affordable surrogate substrates, namely DiFMUO and PNPB that 
are capable of detecting and measuring DAGL catalytic activity (Pedicord et 
al., 2011). The larger DiFMUO is fluorogenic and by virtue of that more 
sensitive compared to the smaller chromogenic PNPB.   
The cell lines overexpressing the DAGLs generally showed greater activity in 
these assays compared to the parental Tango cells (summarised in Table 5.1 
and Table 5.2) and this difference in activity was inhibited by at least 2 
different DAGL inhibitors. These assays can therefore undoubtedly measure 
DAGL catalytic activity. However, with the exception of the established 
enzyme inhibitors, our various attempts to modulate DAGL activity with the 
use of physiologically relevant stimuli using these surrogate substrates were 
unsuccessful. We included treatments that might be expected to reduce 
activity (starvation, phosphatase treatment, PKA inhibition) as well as 
treatments that might be expected to stimulate activity (CaCl2, PKA 




At first glance, these results might indicate that PKA and PKC do not activate 
the DAGLs. However, before coming to that conclusion, it is important to first 
consider the nature of these substrates. Firstly and fore-mostly, these are 
surrogate substrates and therefore might be incapable of detecting certain 
structural features and mechanisms which influence the catalytic activity of 
the DAGLs against its native substrate DAG. In support of this - 
phosphorylation of HSL by PKA has been shown to increase its activity in 
vitro when using a triglyceride substrate but not when using PNPB as the 
substrate (Tsujita et al., 1989).  
DAG is generally found integrated in the membrane (Goni and Alonso, 1999). 
The DAGLs are likely to use their transmembrane domains coupled with 
mechanisms like palmitoylation to sub localise them at the membranes, close 
to the substrate, and orient themselves in a manner facilitating DAG-catalytic 
site interaction. The regulatory loop (lid) is likely to be membrane and 
therefore substrate proximal, which would facilitate interfacial activation 
(potentially supported by phosphorylation). The surrogate substrate PNPB is 
relatively small in size (~3 times smaller than DAG) meaning that it may be 
able to access the catalytic site of the DAGLs through the aqueous phase 
(rather than membrane phase), therefore potentially by-passing any steric 
hindrance provided by the regulatory loop. This would explain why we 
observed ~10-fold difference in activity between V5α11 and Tango 
membranes in the PNPB assay but less than 2-fold difference in the DiFMUO 
assay (Table 5.1). DiFMUO is believed to access the catalytic site through 
the membrane (Pedicord et al., 2011). This could also explain why we did not 
observe any activation or inhibition of DAGL activity using the various 
treatment and stimuli in the PNPB assays.  
If DiFMUO indeed accessed the catalytic site of the DAGLs through the 
membrane then one would expect mechanisms regulating the opened and 
closed conformation of the enzyme to affect the activity seen with the 
substrate. However none of the treatments affected the activity of the DAGLs 
in the DiFMUO assays. One possible explanation is that the smaller size (~2 
times smaller than DAG) of DiFMUO coupled with other structural differences 
compared to DAG might once again enable this substrate to access the 
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catalytic site, even when the enzyme is in the 'closed' conformation. Another 
explanation is that the rate limiting step in DiFMUO hydrolysis is not the 
activity of the DAGLs but the actual rate of diffusion through the membrane 
(Pedicord et al., 2011). This is supported by the fact that the activity in our 
PNPB assays saturated at ~500µM substrate concentration and the activity 
measured using DAGL-DAG assays tend to saturate at a DAG concentration 
of 200-400µM (Pedicord et al., 2011; Shonesy et al., 2013). DiFMUO on the 
other hand showed saturation at a much lower concentration of ~10-20µM 
(differences in solubility between the substrates may also contribute to these 
differences between the substrates). Therefore, there are various reasons 
why the surrogate substrates PNPB and DiFMUO may potentially fail to 
differentiate between the 'open' and 'closed' state of the DAGLs. If this was 
the case then these substrates would also fail to detect phosphorylation 
events that would activate these enzymes by regulating the lid. 
Rather than focussing on the negative results, it is useful to consider some of 
the interesting novel findings. Foremost amongst these was the observation 
in the differences in activity of DAGLα and DAGLβ towards the various 
surrogate substrates (Table 5.1 and Table 5.2). DAGLα-V5 was far more 
active (5-fold) than DAGLβ-V5 using PNPB as the substrate in the 
membrane assay. Western blotting analysis (using the V5 tag) did not 
indicate 5-fold higher expression levels of DAGLα-V5 (V5α11 Tango cells) 
compared to DAGLβ-V5 (V5β4 Tango cells). If anything the results showed 
higher DAGLβ-V5 expression levels. This indicated that the DAGLs probably 
showed different activities against this substrate. This was supported by the 
fact that when comparing activities of V5α11 and V5β4 cells or membranes, 
the difference in activity between the DAGLs appears much less pronounced 
using DiFMUO. Thus we can conclude that despite the very high homology, 
and the fact that they catalyse the same physiological reaction, there are in 
fact clear differences between the catalytic properties of DAGLα and DAGLβ.  
In support, DAGLβ appears the more active of the two against a third 
substrate, EnzChek. These results indicated structural differences between 
the DAGLs that might indicate the possibility to develop selective inhibitors 
for each. Indeed, during the course of this work a report appeared that 
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identified a novel DAGLβ inhibitor with a 60-fold selective profile over DAGLα 
(Hsu et al., 2012). In the absence of a crystal structure for the DAGLs, 
mutagenesis studies in combination with the surrogate substrates might help 
further our understanding of both conserved and divergent features of the 
catalytic sites of these closely related enzymes. Additionally, size wise, the 
EnzChek substrate is ~5 times larger than PNPB, 3 times larger than 
DiFMUO and ~1.5 times larger than DAG. It would therefore be interesting to 
further study DAGL activity using this 'large' substrate, especially if steric 
hindrance due to the lid is a key regulatory mechanism for these enzymes. 
Unfortunately, it only became available for study towards the end of this 
thesis. 
In conclusion, the surrogate substrates used here appear to be unsuitable to 
study DAGL activation mechanisms that govern the displacement of a 
regulatory lid to allow access of the physiological substrate DAG from the cell 
membrane to the active site of the enzymes. Although data was not obtained 
to support our hypothesis that PKA/PKC directly phosphorylate the DAGLs to 
activate them, it would be premature to discard the hypothesis as there are 
clear limitations to the use of surrogate substrates. In addition, time did not 
allow for a full evaluation of EnzChek as a substrate that possibly could 
reveal differences between an open and closed state of the enzymes given 
its relatively large size. Nevertheless, the work described in this chapter 
details various assays that are valuable tools to monitor DAGL activity, and 
would be especially useful to study and screen inhibitors targeting the 
catalytic site. In particular, I have developed the first living cell based assay 
for DAGLα using the PNPB substrate, and this has the potential  to be used 
in high-throughput screens to identify DAGLα inhibitors that might be 
developed as novel pharmaceuticals. 
Key questions that remained unanswered here is how do PKA/PKC stimulate 
the DAGLs? Do these kinases induce phosphorylation (directly/indirectly) of 
DAGLα/β? And if so, how do these phosphorylation events effect DAGL 
activity? In order to begin to address these questions we purified the DAGLs 
and used them in in vitro phosphorylation studies using purified PKA and 
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PKC to determine if they are indeed substrates for these kinases. This work 





















Chapter 6 (Results 4): Generation of the purified active 
catalytic domain of the DAGLs for phosphorylation and other 
studies 
6.1 Introduction 
The structural mechanisms that govern DAGL function would be directly 
addressed by NMR and/or crystallography - this requires milligram quantities 
of highly pure catalytically active protein and although beyond the scope of 
the present study we reasoned that some headway might be made in related 
studies by embarking on this journey. For example, the phosphorylation 
status of the purified catalytic domain of these enzymes might be determined 
by mass-spec and it might be useful for direct biochemical studies with 
purified kinases to at least determine if the catalytic domain can serve as a 
kinase substrate. Identification of such sites would not only yield insights into 
the regulatory mechanism, it would also point the way to the generation of 
phospho-specific antibodies that might be able to serve as surrogate markers 
for the activation state of the DAGLs and also provide a means to identify the 
factors that function upstream of the DAGLs to regulate cell function. 
In chapter 3 we discussed how phosphorylation of the DAGLs appears to be 
a likely mechanism to regulate their activity, especially as several phospho-
sites in the DAGL sequences have been identified. In chapter 4 we 
demonstrated that PKA and PKC stimulated DAGL dependent eCB signalling 
in a cell based assay (Tango assay). We were therefore particularly 
interested in investigating whether PKA and PKC directly phosphorylated the 
DAGLs in order to activate them. We focussed on using mass spectrometry 
(MS) to try to identify phospho-sites as this is a highly sensitive method of 
choice within the field (Paradela and Albar, 2008; Macek et al., 2009; St-
Denis and Gingras, 2012) and a service was available at KCL. However, 
success is still dependant on the abundance and ionisation properties of the 
phospho-peptide(s) obtained from the protein of interest and there are also 
complexities involved in MS based quantitation (Steen et al., 2006; Alcolea et 
al., 2009; Liebler and Zimmerman, 2013).  
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In an attempt to address this question, we decided to purify the DAGLs in 
order to perform in vitro phosphorylation studies using these kinases. The E. 
coli and baculovirus expression systems have been used for years to 
generate high yields of purified proteins for a range of applications including 
highly demanding X-ray crystallography applications which require large 
amounts of protein (several mgs) of high purity. The E. coli expression 
system, is the cheaper and quicker option, and relies on a plasmid-antibiotic 
selection system to overexpress the gene. On the other hand, the 
baculovirus is more expensive (not cost prohibitive) and requires the 
generation of a recombinant baculovirus which accounts for the longer 
timelines (~1 additional month) compared to E. coli. The biggest 
disadvantage of using E. coli is that it is a prokaryotic expression system and 
therefore can sometimes fail to express correctly folded, soluble mammalian 
proteins. The baculovirus-insect cell expression system on the other hand is 
a eukaryotic expression system and is therefore more amenable towards 
expressing complex mammalian proteins. These expression systems have 
been extensively reviewed (Kost et al., 2005; Francis and Page, 2010). 
In this chapter I successfully expressed and purified the GST tagged catalytic 
domains (CD) of both DAGLs and then used a gel-shift assay to demonstrate 
that both PKA and PKC phosphorylated these proteins. No phospho-sites 
were detected within the DAGL sequence of GST-DAGLα CD and in addition 
to that this protein was inactive. On the other hand GST-DAGLβ CD was 
purified in the active form and was phosphorylated by both PKA and PKC 
within the RL. Details about the phospho-sites as well as the successful 
development of a phospho-specific antibody (pAb) against one of these sites 
are presented and discussed here.  
6.2 Results 
6.2.1 Summary of DAGL purification/phospho-mapping work 
A summary of the work carried out to purify the DAGLs is described below 
and presented in Table 6.1 (DAGLα) and Table 6.2 (DAGLβ). We initially 
focussed on purifying endogenous DAGLα by immunoprecipitation (IP) from 
the mouse cerebellum where it is highly expressed.  
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Mouse cerebellum na Immunoprecipitation Poor MS coverage
Mammalian DAGLα-V5 V5 
Immunoprecipitation
Poor yields based on 
Coomassie stained 
gels
Insect cell DAGLα-V5-6His Ni-nta (His affinity) No enrichment post 
purification 
E. coli DAGLα catalytic 
domain
(6His or MBP tagged)
na Insoluble expression,




Ni-nta (His affinity) No enrichment post 
purification  
suggesting tag not 
exposed to bind to 
resin
Insect cell GST-DAGLα catalytic 
domain 




















Mammalian DAGLβ-V5 V5 
Immunoprecipitation
Poor yields based on 
Coomassie stained 
gels
Mammalian DAGLβ-GFP GFP 
Immunoprecipitation
Poor coverage by MS
Insect cell DAGLβ-V5-6His Ni-nta (His affinity) No enrichment post 
purification 
E. coli DAGLβ catalytic 
domain
(6His or MBP tagged)
na Insoluble expression,
attempts to refold 
unsuccessful
Insect cell 6His-DAGLβ catalytic 
domain 
Ni-nta (His affinity) No enrichment post 
purification  
suggesting tag not 
exposed to bind to 
resin
Insect cell GST-DAGLβ catalytic 
domain 




Various parameters in the IP protocol were optimised including the 
concentrations of antibody and cerebellar homogenate used. The IPs were 
resolved by SDS-PAGE and the area of the gel containing DAGLα (identified 
in parallel by Western blotting) was excised and trypsinised following which 
the peptides were extracted and lyophilised. The lyophilised peptides were 
then resuspended in 50mM ammonium bicarbonate and analysed by 
LC/MS/MS. Attempts to identify phospho-sites in the IP were disappointing, 
only a 5% of total sequence coverage was obtained following the MS 
analysis. The quantity of antibody required, coupled with the cost of the MS 
analysis, was prohibitive to pursue this approach any further. In addition to 
this there were no suitable antibodies available for endogenous DAGLβ IP at 
the time. We therefore turned our efforts towards overexpression systems, 
namely the mammalian, baculovirus, and E. coli systems.  
Firstly, we focussed on DAGL (tagged) IPs from mammalian cell lines 
(untreated). If phospho-mapping from these IPs was successful then we 
intended to treat these cells with PKA/PKC activators prior to phospho-
mapping in order to identify potential PKA/PKC dependent DAGL phospho-
sites. At this stage we made a decision to only pursue MS (phospho-
mapping) analyses on purified samples that were visible on Coomassie 
stained gels as this would generally ensure decent sequence coverage. 
DAGLα-V5 IPs using the V5 tag was successful (Western blotting) but 
insufficient to visualise on Coomassie stained gels so were abandoned. 
DAGLβ-GFP IP was also successful and the yields were sufficient enough to 
visualise the sample on Coomassie stained gels. However, no DAGLβ 
peptides were identified following mass-spectrometry, indicating the band 
visualised was non-specific.  
Having failed to phospho-map the DAGLs from mammalian expression 
systems we directed our efforts towards the baculovirus-insect cell 
expression system, and the E. coli expression system. Our initial priority was 
to work with the full length proteins and so we successfully expressed both 
the full length DAGLs with a 6His tag using the baculovirus system; however 
our attempts to purify them using the 6His-tag were unsuccessful, possibly 
because the small tag (~1kDa) was not exposed.  
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We followed this up with attempts to purify the catalytic domain of the DAGLs 
using the 6His tags in both the baculovirus and E. coli expression systems. 
No soluble expression was obtained using E. coli, all the protein was found in 
inclusion bodies (aggregated, mis-folded). We successfully expressed the 
catalytic domains using the baculovirus system, but as with the full length, 
the 6His affinity purification was unsuccessful, probably because the tag was 
not exposed. We therefore expressed the catalytic domains with the larger 
(~26kDa) GST tag using the baculovirus system and using this strategy were 
able to successfully purify the catalytic domains. This will be described in 
more detail in the next section.  
6.2.2 Expression of GST tagged DAGL catalytic domains using the 
baculovirus-insect cell expression system 
Baculoviruses engineered to contain the genes expressing N-terminally GST 
tagged versions of the catalytic domains of either DAGLα or DAGLβ were 
generated as described in the methods section. The baculoviruses were then 
used to infect insect cells for expression studies.  
In order to optimise the expression of GST-DAGLβ catalytic domain (GST-
DAGLβ CD) a time course of expression was carried out. Insect cells (Sf9) 
were infected with recombinant baculoviruses containing the GST-DAGLβ 
CD gene and cell viability was monitored at different time points (0-96h). 
Recombinant baculoviruses not only infect but also amplify and propagate in 
Sf9 cells resulting in a decrease in cell viability. Cell viability is therefore a 
convenient way to monitor infection of Sf9 cells by the baculovirus. During 
the time course of this experiment a decrease in viability was observed (98% 
to 30%) indicating that the cells were successfully infected by the 
baculoviruses (data not shown). Cells were also collected at various time 
points and then lysed and analysed by Western blotting using a GST 
antibody. A band at the predicted molecular weight (~75kDa) was detected at 
all expression time points but not in the non-infected cells (0h) (Figure 6.1). 
Relative expression levels were found to be highest 48 hours post-infection 





Figure 6.1. Expression time course of GST-DAGLβ CD reveals 48 hours 
as the optimum time point 
Sf9 cells were infected with GST-DAGLβ CD baculoviruses and grown for 4 
days. Cells were collected at different time points, lysed and 20µg lysates 



















Time (h)   0      24      48     72      108     Mkr
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An additional band at ~65kDa was detected; however this was also detected 
in the non-infected cells and was therefore deemed to be non-specific.  
Another band ~60kDa was detected in all the samples except the non-
infected cells and was deemed to be a degradation product of the full size 
protein. 48 hours was deemed to be an optimal time-point based on the ratio 
of the desired protein to the degradation products and was adopted for the 
follow up studies. 
6.2.3 GST affinity purification of GST-DAGLβ CD 
Having optimised expression of GST-DAGLβ CD the next step was to purify 
the protein using the GST tag. The hydrophobic regions in lipases make 
them prone to aggregation (Salameh and Wiegel, 2010) and to mitigate this 
Triton X-100 was used in the purification process (Linke, 2009).  A high 
concentration of Triton X-100 (1%)  was used to solubilise GST-DAGLβ CD 
during lysis and then lower concentrations (0.05%) were employed to elute 
and store the protein, as described in other membrane protein purification 
protocols (Linke, 2009; Rice et al., 2009). Cells were lysed by dounce 
homogenisation in the purification buffer (50mM Tris, 150mM NaCl, 2mM 
DTT, pH 7.8) containing 1% Triton X-100 and then incubated for 2 hours 
(4ºC). The lysates were then subjected to centrifugation (75,000g for 60 
minutes). Following this the supernatant was collected and incubated with 
GST binding beads (Glutathione sepharose 4B) for 30 minutes. The beads 
were collected in a plastic drip column and washed with the purification 
buffer. Following this, 0.5ml elution fractions were collected using the elution 
buffer (purification buffer containing 0.05% Triton X-100 and 50mM 
glutathione). The GST elutions obtained were then analysed (20µl) by 
Coomassie stained SDS-PAGE. A prominent band at the predicted size of 
GST-DAGLβ CD (~75kDa) was detected in the elutions (Figure 6.2). The 
purity was adjudged to be ~50% with the major contaminants detected at 
~25kDa. Due to the significant size difference between the contaminants and 
the full size protein gel filtration chromatography was used to further purify 





Figure 6.2. GST affinity purification of GST-DAGLβ CD 
GST-DAGLβ CD (75kDa) was expressed in insect cells and then lysed 
(solubilised) in the purification buffer (50mM Tris, 150mM NaCl, 2mM DTT, 
pH 7.8) containing 1% Triton X-100. Clarified lysates obtained post 
solubilisation were incubated with glutathione sepharose 4B beads for 30 
minutes. The beads were then collected, and washed. Bound protein was 
eluted using elution buffer containing 50mM glutathione and 0.05% Triton X-
100. 20µl of the elutions were analysed by Coomassie stained SDS-PAGE 
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This step would also enable the measurement of the native molecular weight 
of the purified GST-DAGLβ CD as well as a buffer exchange of the protein to 
a suitable storage buffer (without high concentrations of glutathione). 
6.2.4 Gel filtration purification of GST-DAGLβ CD 
The GST elutions were further purified by gel filtration using a S200 column 
(HiLoad 13/300 Superdex 200). 0.5ml of the GST elution (2nd elution in 
Figure 6.2) were subjected to gel filtration chromatography in the purification 
buffer (50mM Tris, 150mM NaCl, 2mM DTT) containing 0.05% Triton X-100. 
Any fractions corresponding to peaks in the chromatogram (absorbance at 
280nm - A280) (Figure 6.3A) were analysed by Coomassie stained SDS-
PAGE (Figure 6.3B). A chromatogram (provided by the manufacturer) of 
protein standards separated using this column (not shown) was used to 
determine the approximate molecular weights of the fractions obtained 
following the gel filtration purification.  
The first peak corresponded to a molecular weight of >600kDa and consisted 
mostly of GST-DAGLβ CD (fractions 5-10ml). This was likely to be 
aggregated as indicated by the high native molecular weight of this fraction 
and the fact that the molecular weight of GST-DAGLβ CD is 75kDa. The 
second peak (estimated molecular weight ~160kDa) predominantly consisted 
of GST-DAGLβ CD (probably dimeric, especially as GST has a propensity to 
dimerise (Waugh, 2005) was collected in fractions 12-13ml. The next peak 
(~80kDa) contained much lower levels of the protein. Subsequent peaks 
corresponding to the lower molecular weight impurities were also observed. 
GST-DAGLβ CD was therefore successfully separated from the lower 
molecular weight contaminants, predominantly in 'aggregated' or 'dimeric' 
forms. 
Surprisingly the higher amounts of 'aggregated' GST-DAGLβ CD compared 
to the 'dimeric' form obtained (Figure 6.3B) following the purification did not 
correspond to a larger peak in the chromatogram (Figure 6.3A). Triton X-100 
absorbs light at 280nm which probably accounts for this. Triton X-100 micelle 









Figure 6.3. Gel filtration purification of active GST-DAGLβ CD 
(~75kDa) 
0.5mls of the elutions from the GST affinity purification (elution 2 
Figure 6.2) were loaded onto a S200 column (HiLoad 13/300 
Superdex 200 GL). The purification buffer (50mM Tris, 150mM NaCl, 
2mM DTT) contained 0.05% Triton X-100. The chromatogram 
(absorbance at 280nm) of the fractions collected and the 
corresponding Coomassie stained SDS-PAGE analysis (20µl) of the 
fractions are presented above (A and B). Estimated molecular 
weights of the peaks are annotated above, indicating whether the 
purified DAGL is likely to be in the aggregated or dimeric form. 
Activity of these fractions was tested using EnzChek. Equal volumes 
of the fractions were incubated in the presence or absence of THL 
(1µM) for 5 min after which EnzChek (2µM) was added. Activity was 
monitored by measuring the fluorescence (excitation 480nm, 
emission 540nm) every 48 seconds for 10 minutes. The reaction 
rates were calculated over 2 minutes and are presented above (C) 

















































































The peaks observed between 12-13ml could therefore correspond to either 
dimerised GST-DAGLβ CD (~150kDa) or a single GST-DAGLβ CD molecule 
associated with a Triton-X100 micelle (~165kDa) or indeed a mixture of both. 
We next compared the activities of the fractions. 
The activity of equal volumes of the fractions was tested using the 
commercially available fluorogenic lipase substrate EnzChek (2µM) in the 
presence or absence of 1µM THL (DAGL inhibitor). THL sensitive activity 
was detected in both the 'aggregated' and 'dimeric' fractions but the activity 
was notably higher in the 'dimeric' fractions despite the fact that this fraction 
had relatively low amounts of protein (Figure 6.3B and C). When normalised 
for protein concentration, the activity of the 'dimeric fraction was ~5-fold more 
active than any other fraction (data not shown). These results demonstrate 
that the GST-DAGLβ CD fraction following gel filtration, that appeared to 
have a native molecular weight greater than 600kDa, was likely to be 
aggregated and largely inactive. On the other hand the 'dimeric' fraction was 
found to be active.  
To summarise the results above GST affinity and gel filtration 
chromatography were successfully combined to purify active GST-DAGLβ 
CD at >80% purity. Additionally, including Triton X-100 in the purification was 
critical to enhancing the yield of the active protein (220µg/L insect cell 
culture) when compared to other detergents like DDM (90µg/L dimeric 
fraction but mostly inactive), Elugent (130µg/L) or LDAO (interfered with GST 
affinity purification) or to a detergent free purification (<10µg/L) (data not 
shown). We next used these conditions to purify the GST tagged catalytic 
domain of DAGLα (GST-DAGLα CD) as described in the next section. 
6.2.5 Purification of GST-DAGLα CD 
GST-DAGLα CD was expressed and purified as described for DAGLβ above. 
Following the GST affinity purification, GST-DAGLα CD was obtained at 
similar purity levels to GST-DAGLβ CD, a highly enriched band observed at 
~75kDa corresponding to GST-DAGLα CD was accompanied by prominent 








Figure 6.4. Purification of GST-DAGLα CD using GST affinity and gel 
filtration chromatography 
Lysates obtained from Sf9 cells infected with GST-DAGLα CD (75kDa) 
baculoviruses were lysed in the presence of 1% Triton X-100 after which 
GST-DAGLα CD was captured using glutathione sepharose 4B beads and 
eluted in the presence of 0.05% Triton X-100 using 50mM glutathione. Equal 
volumes of the elutions were analysed by Coomassie stained SDS-PAGE 
(A). Elutions 2-7 (3mls) were loaded onto a S200 column (HiLoad 16/600 
Superdex 200 prep grade) and 1ml fractions were collected. Fractions 
associated with the peaks observed in the A280 chromatogram (B) were 
analysed (20µl) by Coomassie stained SDS-PAGE (C). Estimated molecular 
weights of the peaks are annotated above, indicating whether the purified 
DAGL is likely to be in the aggregated (44-60ml) or dimeric (66-69ml) form. 
Activity of these fractions was tested using EnzChek. Equal volumes of the 
fractions were incubated in the presence or absence of THL (1µM) for 5 min 
after which activity was measured using EnzChek (2µM) as previously 


















































The GST elutions were further purified using gel filtration (S200 column - 
HiLoad 16/600 Superdex 200 prep grade). As with GST-DAGLβ CD, the 
lower molecular weight contaminants were effectively separated from GST-
DAGLα CD but most of the GST-DAGLα CD was collected in fractions (40-
60ml) with a native molecular weight ~440kDa and was therefore likely to be 
aggregated (Figure 6.4B and C). 
Smaller amounts of GST-DAGLα CD were collected in the fractions (66-
69ml) corresponding to a native molecular weight of ~160kDa. This fraction 
consisted of a doublet at ~75kDa when analysed by Coomassie stained 
SDS-PAGE (Figure 6.4C). Only the upper band was found to be immuno-
reactive to a GST antibody (data not shown) indicating that the lower band 
was an insect/baculovirus protein. This band was subsequently identified as 
a heat shock protein (HSP) and will be discussed further down. The GST-
DAGLα CD in this fraction is therefore likely to exist as a homodimer or as a 
heterodimer with the HSP. Additional fractions containing mainly of what 
appeared to be the HSP were also collected (70-80mls). 
The activity of the fractions obtained following the gel filtration purification 
was tested using EnzChek as the substrate. The activity detected in these 
fractions (Figure 6.4D) was extremely low compared to the GST-DAGLβ CD 
fractions (Figure 6.3C). In addition to that, no THL sensitive activity was 
detected indicating that the GST-DAGLα CD present in the fractions was 
inactive. Additionally, no THL sensitive activity was detected in the fractions 
using a different DAGL surrogate substrate PNPB (data not shown). However 
this did not necessarily preclude the use of GST-DAGLα CD as a substrate 
for PKA and PKC to identify phospho-sites which is discussed in the next 
section.  
6.2.6 In vitro phosphorylation studies of GST-DAGLα CD  
Our results in chapters 3 and 4 demonstrated that the DAGLs are 
phosphorylated and that both PKA and PKC can stimulate DAGL activity in a 
cellular context. In order to test whether PKA and PKC can directly 
phosphorylate DAGLα, the purified DAGLα catalytic domain was used as part 
of in vitro phosphorylation (IVP) studies. In order to monitor IVP, a 
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phosphate-binding molecule (Phos-tag) was used as part of a gel shift assay. 
Migration of phosphorylated proteins is retarded in SDS-PAGE gels 
containing Phos-tag as a result of which phosphorylated and non-
phosphorylated forms of a protein can be resolved to a greater extent than 
generally seen in a standard SDS-PAGE gel (Kinoshita et al., 2006).  
The ability of PKA and PKC to phosphorylate GST tagged myelin basic 
protein (GST-MBP) was first tested as a positive control (Kishimoto et al., 
1985). GST-MBP (1µM) was incubated with either PKA (0.1µM) or PKC 
(0.1µM) in IVP buffer (50mM Tris, 0.05% Triton X-100, 2mM DTT pH 7.8, 
2.4mM ATP and 240mM MgCl2) for 1 hour at 30ºC. The samples were then 
resolved by SDS-PAGE gels containing 70µM Phos-tag and detected by 
Western blotting using a GST antibody. A kinase dependent shift in GST-
MBP incubated with either PKA or PKC confirmed that Phos-tag could be 
used to detect IVP and that the PKA and PKC employed were both active 
(Figure 6.5A). GST-DAGLα CD (0.5µM) was then incubated with either PKA 
or PKC (0.1µM) in IVP buffer for 1 hour at 30ºC. The samples were resolved 
by SDS-PAGE gels containing 70µM Phos-tag and detected by Western 
blotting using a GST antibody. No shift was observed in the PKA treated 
samples (Figure 6.5A), even when incubated for longer time periods (1-3 
hours) (Figure 6.5C). On the other hand, a PKC dependent shift in the GST-
DAGLα CD samples was observed indicating that PKC could directly 
phosphorylate GST-DAGLα CD in vitro (Figure 6.5A).  
This shift was also found to be ATP dependent further validating the kinase 
dependency of this reaction (Figure 6.5B). It is worth mentioning here that 
GST-DAGLα CD was found to be unstable when stored at -80ºC, smaller 
fragments were identified on Coomassie stained SDS-PAGE when analysed 
after two months of storage (GST-DAGLβ CD was found to be stable) (Figure 
6.5D). At least one of the fragments was found to be GST immunopositive 











Figure 6.5. Detection of PKC (but not PKA) mediated 
phosphorylation of GST-DAGLα CD in vitro 
GST-MBP and GST-DAGLα CD were incubated in the presence or 
absence of PKA or PKC in IVP buffer. The samples were incubated 
for 1 hour at 30°C after which they were resolved using SDS-PAGE 
containing 70µM Phos-tag and analysed by Western blotting using a 
GST antibody (A) This was repeated using GST-DAGLα CD but with 
ATP excluded from the IVP buffer (B) or for longer incubation times 
(C). Stability of GST-DAGLα CD and GST-DAGLβ CD stored at -
80°C was analysed by Coomassie stained SDS-PAGE (D). GST-
DAGLα CD was found to be unstable, at least one of the fragments 
was GST immunopositive (Western blotting using Phos-tag 70µM) 
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For phospho-mapping studies GST-DAGLα CD was treated with PKC using 
the conditions mentioned above (0.1µM PKC, 30°C, 1 hour). The samples 
were then analysed by Coomassie stained SDS-PAGE and the bands 
corresponding to GST-DAGLα CD were excised and trypsinised. The 
peptides obtained were subjected to MS analysis as described in the 
methods section. 
Only 50% sequence coverage was achieved using mass spectrometry, the 
phospho-sites identified are shown in Table 6.3. No phospho-sites were 
identified in the DAGLα sequence, all the sites identified were located in a 
linker region between the GST tag and the DAGLα sequence in the PKC 
treated sample. Furthermore, the protein (~75kDa) found to co-purify with 
GST-DAGLα-CD following gel filtration was identified in these MS studies as 
a heat shock protein (HSP). HSPs are involved in protein folding and the 
purified GST-DAGLα CD is therefore probably an incompletely folded 
heterodimer (with the HSP), relying on the HSP to prevent it from 
aggregating. As the GST-DAGLα CD was also found to be inactive in the 
enzyme assay and unstable on storage we did not progress this work any 
further.  
6.2.7 In vitro phosphorylation studies of GST-DAGLβ CD  
In order to examine whether PKA and PKC could directly phosphorylate the 
catalytic domain of DAGLβ we employed IVP studies, similar to the DAGLα 
studies above. GST-DAGLβ CD (1µM) was incubated with either 0.1µM PKA 
or 0.1µM PKC in IVP buffer for 1 hour at 30ºC. The samples were then 
resolved by SDS-PAGE gels containing 70µM Phos-tag and detected by 
Western blotting using a GST antibody. 
A kinase dependent shift was observed in the GST-DAGLβ CD samples 
indicating that both PKA and PKC could directly phosphorylate GST-DAGLβ 
CD in vitro (Figure 6.6A). This reaction was also found to be ATP dependent 
further validating the kinase dependency of this reaction (Figure 6.6B). A 
complete shift in GST-DAGLβ CD was not observed following kinase 
treatment; further optimisation experiments were therefore carried out to 







Table 6.3. Phospho-sites identified in GST-DAGLα CD following PKC 
treatment 
 




















T228 na Linker No Yes
S229 na Linker No Yes
T241 na Linker No Yes








Figure 6.6. PKA and PKC can phosphorylate GST-DAGLβ CD in 
vitro 
GST-MBP and GST-DAGLβ CD were incubated in the presence or 
absence of PKA or PKC in IVP buffer. The samples were incubated 
for 1 hour at 30°C after which they were resolved using SDS-PAGE 
containing 70µM Phos-tag and analysed by Western blotting using a 
GST antibody (A) This was repeated using GST-DAGLβ CD but with 
ATP excluded from the IVP buffer (B) or for longer incubation times 
(C). The effects of a shorter 30 minute incubation time, temperature 
(30°C versus 37°C) and PKA/PKC concentration (0.1µM versus 1µM) 
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Firstly, longer incubation times were tested, however no major time 
dependent increase in phosphorylation was observed when comparing 1, 2 
or 3 hour incubation times (Figure 6.6C). The effects of kinase concentration 
(0.1 or 1µM) and temperature (30ºC versus 37ºC) along with two incubation 
times (30 and 60min) was also tested (Figure 6.6D). In the case of PKA, no 
difference in phosphorylation was observed between the 30 min and 60 min 
incubation times at either kinase concentrations or temperatures. Higher 
concentrations of PKA resulted in increased phosphorylation at both 
temperatures. Incubation at 37ºC resulted in phosphorylation of a greater 
proportion of GST-DAGLβ CD when compared to 30ºC, when using the 
higher concentration of PKA (1µM). In future experiments GST-DAGLβ CD 
was therefore incubated with 1µM PKA at 37ºC for 30 minutes. In the case of 
PKC, the higher concentrations of the kinase impeded the visualisation of 
GST-DAGLβ CD causing wavy bands. The lower concentration (0.1µM) 
shifted a large proportion of the GST-DAGLβ CD when incubated for 60 min 
at 37ºC and so these conditions were used in further experiments.  
Phosphatase treatment of the GST-DAGLβ CD did not cause a shift in the 
Phos-tag assay indicating no background phosphorylation (data not shown). 
For phospho-mapping studies GST-DAGLβ CD was treated with PKA and 
PKC using the optimised conditions mentioned above. The samples were 
then analysed by Coomassie stained SDS-PAGE and the bands 
corresponding to GST-DAGLβ CD were excised and trypsinised. The 
peptides obtained were subjected to MS analysis as described in the 
methods section. 70% sequence coverage was achieved using mass 
spectrometry which also identified several phospho-sites (Table 6.4).  
Surprisingly, 6 phospho-sites were identified in the control (no kinase) 
sample, 4 of which were within the DAGLβ CD sequence and 2 of which 
were within the regulatory loop. Both of the regulatory loop sites pS574 and 





Table 6.4. Phospho-sites identified in GST-DAGLβ CD following PKA 
and PKC treatment 
 
*S570 identified in 3 published and 0 CST reports 
*S574 identified in 1 published and 17 CST reports 
*S584 identified in 5 published and 0 CST reports 
 (see Table 3.2 for references) 
 




















T228 na Linker Yes Yes
S229 na Linker Yes Yes
Y327 Y318 CD Yes
S377 S368 CD Yes
S510 S501 CD Yes
S579 S570* RL Yes
S583 S574* RL Yes Yes
S593 S584* RL Yes Yes
S614 S605 RL Yes
S626 S617 CD Yes
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The relative amounts of phosphorylated GST-DAGLβ CD in the control 
sample could not be determined using the mass spectrometry data; however 
the fact that no shift in the GST-DAGLβ CD band was observed following 
phosphatase treatment probably indicates that only a small proportion of the 
sample was phosphorylated. Only 3 of the 6 sites identified in the control 
were also identified in the PKC treated samples (2 in the linker region and 1 
in the regulatory loop). This discrepancy between the control and kinase 
treated sample was unexpected. Contaminating phosphatases in the purified 
PKC (commercial source) could provide a possible explanation for this. 3 
additional sites were also identified in the PKC treated sample, one of which 
is a tyrosine. This was again surprising as PKC is a Serine/Threonine kinase. 
Once again, a contaminating kinase in the purified PKC (commercial source) 
could provide a possible explanation for this. Both the other phospho-sites 
were located with the catalytic domain (pS605, pS617), one of which was 
within the regulatory loop (pS605). Neither of these sites has been previously 
reported.  
In the case of the PKA treated sample, only 1 of the 6 phospho-sites 
identified in the control was detected (S584). Contaminating phosphatases in 
the purified PKA (commercial source) could once again provide a possible 
explanation for this. Furthermore, the site (S584) that was identified in the 
control and PKA treated sample lies within a PKA consensus sequence. IVP 
by PKA may have out-competed the action of the contaminating 
phosphatases. As mentioned above, this phospho-site is located in the 
regulatory loop and has been identified in the literature (Table 3.2, chapter 3). 
The other phospho-site (S570) identified in the PKA treated sample was not 
identified in the control, was located within the regulatory loop, lies within a 
PKA consensus sequence and has been previously reported in the literature 
(Table 3.2 and Table 3.4, chapter 3). 
 The fact that both these phospho-sites have been previously reported, on 
more than one occasion, indicated that phosphorylation at these sites may be 
physiologically relevant. As the final part of this project we had pAbs against 
these two (S570 and S584) sites generated (Eurogentec) in order to study 
these phosphorylation events within cells. To date, we have been unable to 
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get the pS584 pAb to work in Western blotting, immunohisto/cytochemical 
studies or by ELISA. Work is ongoing to optimise the conditions using this 
pAb in those experimental formats. The last section of this thesis will focus 
on recent results obtained using the pS570 pAb. 
6.2.8 Studying phosphorylation of DAGLβ at S570 in a cellular context 
In order to establish whether the S570 pAb could be used as an analytical 
tool, the pAb was tested by Western blotting using membranes prepared 
from the V5β4 cells (cultured in McCoy's media 10% FCS). The V5β4 cells 
are Tango cells that stably overexpress human DAGLβ-V5 by 5-fold 
compared to the endogenous gene (Figure 4.15, chapter 4). Tango 
membranes were also included in the experiment as a negative control.  
The pAb was tested at different dilutions (1/100 to 1/1000) using different 
blocking agents (milk versus BSA). All dilutions of antibodies and blocking 
agents were carried out in PBS 0.01% Tween (PBST). When both the S570 
pAb and the corresponding secondary antibody (rabbit HRP conjugate) were 
diluted in blocking buffer containing 2% BSA, several bands were detected 
(Figure 6.7A). No difference was observed between the V5β4 and Tango 
membranes at any of the antibody dilutions. This indicated that the pAb was 
either extremely non-specific or that the blocking conditions were inadequate. 
2% milk PBST was next used to dilute both the antibodies. This reduced the 
overall intensity of the bands detected (compared to BSA) although several 
bands were still detected in both samples (Figure 6.7B). Notably, a band was 
detected at ~75kDa, in the V5β4 samples when using lower dilutions of the 
pAb (1/100, 1/200), and this is the predicted and observed molecular weight 
for human DAGLβ-V5. This band was absent/less prominent in the Tango 
samples indicating that the pAb could recognise human DAGLβ-V5. 
Furthermore, when the pAb was diluted using 2% BSA but the secondary 
was diluted using 2% milk, several of the non-specific bands detected using 
the other blocking conditions were not visualised and a prominent band at 
~75kDa was detected in the V5β4 samples at all 3 dilutions using these 
blocking conditions (Figure 6.7C). These results demonstrated that the pAb 









Figure 6.7. Optimisation of Western blotting conditions for the 
DAGLβ pS570 antibody 
V5β4 and Tango membranes (10µg) were analysed by Western 
blotting using different dilutions of the DAGLβ pS570 antibody as 
indicated. Different blocking conditions were tested for the primary 
and corresponding secondary (rabbit HRP conjugate) antibody as 
follows. Primary and secondary diluted in 2% BSA PBST (A), primary 
and secondary diluted in 2% Milk PBST (B), primary diluted in 2% 
BSA PBST and secondary diluted in 2% Milk PBST (C). Longer 






































































Additionally, at lower dilutions of the antibody or using longer exposure times, 
a fainter band at a slightly lower molecular weight compared to the V5β4 
75kDa band was detected (Figure 6.7C and D) which may correspond to 
endogenous DAGLβ.  
Having confirmed that the S570 pAb can detect human DAGLβ-V5 by 
Western blotting, we also confirmed that this binding did not occur via the V5 
epitope using membranes containing DAGLα-V5 (from V5α11 cells) as a 
negative control (data not shown). In order to confirm the phospho-specific 
nature of the antibody, V5β4 membranes were treated with phosphatase and 
then analysed by Western blotting using the S570 pAb. The phosphatase 
treatment abolished the binding of the pAb to DAGLβ-V5 confirming that the 
pAb was indeed recognising a phosphorylated epitope within DAGLβ-V5 
(Figure 6.8). In addition to this, the site specificity of the pAb has very 
recently been confirmed as the antibody failed to detect the corresponding 
non-phosphorylatable mutant (S570A) of DAGLβ by Western blotting 
(recently completed experiment, data not shown). Collectively these results 
confirm the phospho-site specificity of the human DAGLβ S570 pAb when 
using Western blotting.  
The final set of experiments focussed on determining whether 
phosphorylation at this phospho-site could be modulated in cells. In order to 
address this V5β4 cells were first cultured in McCoy's media supplemented 
with 10% FCS and then maintained in Freestyle media, in the absence of 
serum (starvation) for 24 or 48 hours. Membranes from the cells were then 
prepared and analysed by Western blotting using the S570 pAb. A highly 
significant decrease in phosphorylation at S570 was detected following 24 
hours starvation (Figure 6.9). No further decrease was detected after 48 








Figure 6.8.The DAGLβ S570 pAb is phospho-specific 
V5β4 membranes (10µg) prepared from cells cultured in McCoy's media 10% 
FCS were treated in the presence or absence of calf intestinal phosphatase 
(50 units) for 30 minutes at 37°C. The membranes were then analysed by 
Western blotting and DAGLβ was detected using the S570 pAb as well as a 



















Figure 6.9. Reduction in phosphorylation at DAGLβ-V5 S570 in V5β4 
cells following 24 hours starvation 
V5β4 cells were maintained overnight in Freestyle media (starved) or 
cultured in McCoy's media 10% FCS for 24 hours. Membranes were then 
prepared and analysed (10µg) by Western blotting. DAGLβ was detected 
using the S570 pAb as well as a V5 antibody (A). The intensity of the 
phospho S570 band was quantified using ImageJ and the V5 band using the 
Odyssey software. The reduction in phosphorylation was then quantified by 
first normalising the DAGLβ phospho S570 band intensities to the 
corresponding V5 bands and then presenting them as a ratio of the control 
(McCoy's 10% FCS) (mean±SEM of 5 independent experiments are 
presented) (B).  



































Having established that serum deprivation can reduce DAGLβ 
phosphorylation at S570, we next tested whether serum treatment could 
increase phosphorylation at S570 following 24 hours starvation. V5β4 cells 
grown in Freestyle media for 24 hours were treated with different 
concentrations of serum (1% to 10%) for either 4 hours or 24 hours. 
Membranes were then prepared and analysed by Western blotting using the 
S570 pAb which revealed that serum treatment did indeed enhance DAGLβ 
phosphorylation at S570 in the starved cells (Figure 6.10). As this site lies 
within a PKA and PKC consensus phosphorylation motif, we finally tested the 
effects of PKA and PKC activators on phosphorylation at this site. V5β4 cells 
were maintained in Freestyle media for 24 hours and then treated with the 
PKA activator Forskolin (10 and 20µM) or the PKC activator PMA (25 or 
50nM) for 24 hours. Membranes were then prepared from the cells which 
were analysed by Western blotting using the S570 pAb which indeed 
revealed that both PKA and PKC activators caused an increase in 
phosphorylation at this site (Figure 6.11). 
We have therefore shown that the pAb can be used to study DAGLβ (S570) 
phosphorylation by Western blotting and using this tool we have detected 
both the up and down regulation of phosphorylation at S570 within cells.  
6.3 Discussion 
Results presented in the previous chapters identified regulated phospho-sites 
in DAGLα and DAGLβ and demonstrated that calcium stimulated DAGL-
dependent eCB signalling in Tango cells requires PKA and PKC activity. We 
have therefore postulated that direct phosphorylation of the DAGLα/β by PKA 
or PKC regulates their activity. In order to investigate this further, in this 
chapter, we set out to test whether purified PKA and PKC could indeed 
phosphorylate DAGLα/β in vitro.  
Several unsuccessful attempts to purify the full length DAGLs (at the required 
yields) have been made in our lab (Table 6.1 and Table 6.2). Working with 
full length proteins is generally more desirable, however, the N-terminus 










Figure 6.10. Serum treatment causes an increase in DAGLβ 
phosphorylation at S570 following 24 hours starvation 
V5β4 cells were maintained overnight in Freestyle media (starved) 
after which they were treated with different concentrations of serum 
as indicated for either 4 or 24 hours. Membranes were then prepared 
and analysed (10µg) by Western blotting. DAGLβ was then detected 
using the S570 pAb as well as a V5 antibody (A). The intensity of the 
phospho S570 bands were quantified using ImageJ and the V5 
bands using the Odyssey software. Changes in phosphorylation 
levels was then quantified by first normalising the DAGLβ phospho 
S570 band intensities to the corresponding V5 bands and then 
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Figure 6.11. PKA and PKC activators cause an increase in 
DAGLβ phosphorylation at S570  
V5β4 cells were maintained overnight in Freestyle media (starved) 
after which they were treated with 10/20µM forskolin or 25/50nM 
PMA for 24 hours. Membranes were then prepared and analysed 
(10µg) by Western blotting. DAGLβ was detected using the S570 
pAb as well as a V5 antibody and a representative blot for the 10µM 
forskolin and 25nM PMA treatments is presented (A). Similar results 
were obtained using the higher concentrations of forskolin/PMA and 
were also included in the quantification. The intensity of the phospho 
S570 bands were quantified using ImageJ and the V5 bands using 
the Odyssey software. Changes in phosphorylation levels was then 
quantified by first normalising the DAGLβ phospho S570 band 
intensities to the corresponding V5 bands and then presenting them 
as a ratio of the control (untreated) (mean±SEM of 5 independent 



























































Furthermore, we were particularly interested in mechanisms that regulate the 
'open' and 'closed' conformation of the DAGLs and based on other lipase 
models (HSL) we predicted that phosphorylation within the regulatory loop 
(RL) is a likely mechanism to regulate this (Holm, 2003; Krintel et al., 2009; 
Lampidonis et al., 2011). As the active site and regulatory loop of the DAGLs 
is located within a well defined catalytic domain (Chapter 3) we focussed our 
efforts on purifying this for IVP studies. 
Attempts to express the catalytic domains in the E. coli prokaryotic 
expression system were unsuccessful. We therefore employed the 
baculovirus expression system which is a eukaryotic expression system. The 
principle behind this expression system is as follows - baculoviruses 
engineered to contain the gene of interest are used to infect insect (Sf9) cell 
cultures. The baculoviruses then not only infect but also multiply within these 
cells as a consequence of which high levels of expression of the gene of 
interest are obtained (Jarvis, 2009). This expression system has been used 
to express and purify mammalian proteins from a wide range of target 
classes including kinases (McCoy et al., 2005), topoisomerases (Singh et al., 
2011) and lipases (Krintel et al., 2009).  
We made unsuccessful attempts to purify the catalytic domains with a small 
6His tag (~1kDa), possibly due to the tag not being exposed, and therefore 
focussed our efforts on employing the commonly used larger GST tag 
(27kDa) (Waugh, 2005). We successfully purified the catalytic domains of the 
DAGLs using the GST tag to ~50% purity, with reasonable yields (~1 to 
2mg/L) using GST affinity purification. However, further analysis using gel 
filtration chromatography revealed that a majority of the purified protein was 
aggregated and inactive. The hydrophobic regions in lipases make them 
prone to aggregation (Salameh and Wiegel, 2010). We therefore included 
detergents that are commonly used to purify membrane proteins in the 
purification process (Linke, 2009; Rice et al., 2009) which enabled us to 




GST-DAGLα CD on the other hand was found to co-purify with a HSP 
indicating that it was incompletely or incorrectly folded. This would explain 
why it was inactive and unstable. We nevertheless attempted to use this as a 
substrate for IVP studies. PKA did not phosphorylate this protein whereas 
PKC was only found to phosphorylate the protein within a linker region 
(incorporated as part of the molecular biology strategy) between the GST tag 
and the CD. Due to the misfolded/aggregated nature of the purified DAGLα 
CD we were unable to obtain any evidence to support the hypothesis that 
PKA/PKC directly phosphorylates DAGLα within the CD and RL. Previous 
reports have demonstrated that the DAGLα tail and transmembrane domain 
is dispensable for activity (Won et al., 2009; Pedicord et al., 2011). We were 
therefore surprised to find GST-DAGLα CD to be completely aggregated and 
inactive. One may attribute this to the GST tag but 6His-DAGLα CD was also 
found to be inactive (comparing overexpressing and control lysates using the 
surrogate substrates, data not shown). However, full length DAGLα 
expressed using the baculovirus system is active (data not shown) confirming 
that this expression system can be used to express active DAGLα - however 
attempts to purify it were unsuccessful. It was for this reason we pursued the 
catalytic domain strategy. The domain boundaries selected for the DAGLα 
CD were similar to DAGLβ which was successfully purified; therefore one 
would also assume these boundaries were suitable choices for DAGLα too. 
As this does not appear to be the case, one would need to probably screen a 
few different constructs to identify the most appropriate boundaries to 
express and purify the catalytic domain (Dyson, 2010). Our collaborator who 
performed the mass spectrometry studies for us has recently acquired a 
mass spec with greater sensitivity compared to what was used at the start of 
the project, thereby reducing the amount of material required for phospho-
mapping analysis (Steve Lynham, personal communication). Therefore IPs 
from mammalian cell lines would probably be a more attractive, feasible, and 
rewarding approach to further investigate DAGLα phosphorylation. Unlike the 
GST-DAGLα CD, we were successfully able to purify active GST-DAGLβ CD. 
Furthermore PKA and PKC were found to phosphorylate the protein in vitro 




Firstly, we were surprised to find 6 phospho-sites in the control sample, not 
due to the fact that insect cell kinases could have phosphorylated the DAGL, 
but because we had not detected any phosphorylation in the Phos-tag gel 
shift assay. It is worth mentioning here that the abundance of the phospho-
sites could not be estimated. This was a revelation to us as we expected this 
to be easily acquired from the MS analysis. However, despite our 
collaborators best efforts this was not possible. This meant that the 
phosphorylation levels at the individual sites in the control could range from 
very low to very high percentages, however based on our gel-shift assay the 
former seems more likely. For future studies, it will be worthwhile to either 
phosphatase treat the GST-DAGLβ CD prior to the kinase treatment in order 
to eliminate background phosphorylation or to include internal peptide 
standards (of the GST-DAGLβ CD sequence) during the MS run to enable 
quantitation of the post-translational modifications (Liebler and Zimmerman, 
2013). Additionally, certain discrepancies were observed when comparing 
the control and kinase treated samples, i.e. some sites were identified in the 
control samples but not in the kinase treated samples. This may have 
occurred due to contaminating phosphatases, including phosphatase 
inhibitors in the future may help avoid such discrepancies. However, without 
an idea of the abundance of these phospho-sites it is difficult to assess what 
factors are truly behind this discrepancy. For example, these phospho-sites 
may be present at levels testing the lower limits of sensitivity of the MS and 
therefore discrepancies in samples would not be surprising. In the absence of 
the desired quantitative data we were still able to draw some clear and 
important conclusions from the phospho-mapping of the GST-DAGLβ 
samples as discussed below.  
In the control, amongst the 6 sites identified, 2 were non DAGL; they were 
located in a linker region between the GST tag and the CD. 2 sites (S368 and 
S501) were located within the CD, these phospho-sites have not been 
reported previously, and any functional significance of these phospho-sites is 
unclear. Based on our catalytic model presented earlier, only one of these 
sites (S501) is membrane proximal, but both are predicted to be phospho-
sites by NetPhos 2.0 (but not DISPHOS). Both these sites are conserved in 
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mouse but neither is conserved in DAGLα. Whether these phosphorylation 
events are simply the consequence of an irrelevant event involving a human 
protein and insect cell kinase or bear more significance remains to be seen.  
This brings us to the last two samples identified in the control, S574 and 
S584. Both these samples are located in the regulatory loop. Phosphorylation 
at S574 has only been previously reported once in the literature, in the 
phosphoproteome of Jurkat cell line (T lymphocyte) (Mayya et al., 2009). 
However this has also been detected 17 times in the unpublished CST 
studies in different cancer cells/tissues (Table 3.2). Here, we have reported 
an additional instance of this site being phosphorylated. This site does not lie 
within a PKA or PKC consensus sequence; however it lies in close proximity 
to a PKA phospho-site (S570, discussed below). It is tempting to speculate 
that phosphorylation at S574 site plays a role in relation to the S570 site, i.e. 
phosphorylation at S574 could prevent phosphorylation at S570 (e.g. S563 
and S565 in HSL (Garton et al., 1989)) or indeed enhance the effect of 
phosphorylation at S570, potentially towards the displacement of the lid 
(Salazar and Hofer, 2009). Although this site is not conserved in DAGLα, or 
even in mouse DAGLβ, the numerous reports of this phospho-site combined 
with its localisation to the regulatory loop means that this site would be an 
interesting candidate for mutagenesis and activity studies. The other 
phospho-site identified in the control sample was S584 and is discussed 
further down.  
6 sites were identified in the PKC treated samples, once again like the 
control, 2 were located in the linker region between the tag and the DAGL 
sequence. Phosphorylation at the 574 site, located in the RL, which was 
identified in the control, was also detected. On the other hand 3 of the sites 
identified in the control were not identified in the PKC sample. One possible 
explanation is that contaminating phosphatases (in the purified PKC) specific 
for these sites but not for others may have caused this. Additionally 
phosphorylation at a tyrosine residue (Y318) was detected in the PKC 
sample but not in the control, as PKC is a serine/threonine kinase it is likely 
that a contaminating kinase in the purified PKC probably accounted for this. 
As mentioned above, we could not determine the abundance of these 
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phosphorylations, in theory this tyrosine phospho-site could have been 
present at extremely low levels (theoretically could be <<<1%), maybe at the 
lower detection limits of the MS in which case variation between the samples 
would be understandable.  
This takes us to the two serine phospho-sites identified in the PKC treated 
sample but not in the control - S605 (RL) and S617 (6 amino acids after the 
RL). Both sites are located within PKC (and PKA) consensus sequences and 
are predicted to be phospho-sites by NetPhos 2.0 (but not DISPHOS). S605 
is predicted to be membrane proximal and is conserved in mouse but not in 
DAGLα. On the other hand S617 is not conserved at all and is not predicted 
to be membrane proximal. Neither site has been reported before, whether 
phosphorylation at these sites is physiologically relevant remains to be seen. 
The fact that S605 is located within the RL and is conserved in mouse does 
make it an attractive candidate to regulate DAGL activity. 
In the PKA treated sample, 5 of the 6 sites from the control were not detected 
in this sample. This was surprising and the likely explanation is that, once 
again a contaminating phosphatase in the purified kinase may have been 
responsible for this. Interestingly, the only 2 phospho-sites detected in this 
sample are PKA consensus sites, S570 and S584. S584 was also detected 
in the control. We were unable to determine the relative abundance of this 
phospho-site in both the samples, however the fact that this was the only site 
in the control sample to be detected in the PKA sample may indicate that 
PKA activity outweighed the activity of contaminating phosphatases to 
preserve or increase phosphorylation levels at this site.  
The alignment of this site is ambiguous with the mouse sequence, mouse 
S582 could align with either S583 or S584 in the human sequence. Human 
S584 lies within a PKA/PKC consensus sequence whereas mouse S582 
does not, but this site in both species does share other consensus motifs for 
kinases, e.g. CDK5. There have been 4 published reports that have identified 
phosphorylation at S582 (mouse) in the brain (Tweedie-Cullen et al., 2009; 
Huttlin et al., 2010; Wisniewski et al., 2010; Trinidad et al., 2012). In human 
samples, there have been no reports of phosphorylation at S583 but one for 
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S584 (plus this report), in HeLa cells (Dephoure et al., 2008). The fact that 
the S584 phospho-site lies within a PKA/PKC consensus motif does make it 
an interesting site to pursue, however the fact that the motif is not conserved 
within mouse does raise doubts as to whether this site would be a major 
determinant of PKA/PKC stimulated DAGLβ activity. A pAb against this site 
has been generated and is currently being evaluated in our lab. 
This takes us to possibly, the most exciting finding of the thesis. Firstly, 
phosphorylation at S570 was not detected in the control but was detected in 
the PKA treated sample. This site is conserved in mouse (but not DAGLα) 
and lies within a PKA (and PKC) consensus sequence in the RL of both 
human and mouse DAGLβ. S570 is predicted to be a phospho-site by 
DISPHOS (but not NetPhos 2.0) and is also membrane proximal. This site 
has been reported by three published studies using HeLa (Daub et al., 2008; 
Olsen et al., 2010) and Jurkat cells (Mayya et al., 2009). Collectively, these 
data suggest that this site is a prime candidate to be phosphorylated by PKA 
and PKC, in order to most probably regulate DAGLβ activity.  
We have successfully developed an antibody that can specifically recognise 
phospho S570 by Western blotting as demonstrated here using phosphatase 
and mutagenesis studies. This antibody was used to demonstrate that 
phosphorylation at this site is regulated within cells. Firstly, maintaining 
(starving) cells in Freestyle media (serum free) resulted in a significant 
decrease in phosphorylation at this site when compared to cells grown in 
McCoy's media supplemented with 10% serum. Furthermore, 
phosphorylation was then upregulated by feeding the starved cells with 
serum or by treating them with PKA and PKC activators, the latter two having 
previously been shown to stimulate DAGL-dependent eCB signalling in the 
CB1-Tango assay (chapter 4), thus confirming that phosphorylation at this 
site is regulated.  
To summarise, our attempts to study in vitro phosphorylation of DAGLα by 
PKA and PKC were unsuccessful due to the misfolded/aggregated nature of 
the purified DAGL. On the other hand we successfully purified the catalytic 
domain of DAGLβ, in the active state and also identified phospho-sites in the 
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control as well as PKA and PKC treated samples. We successfully developed 
a phospho-specific antibody against the PKA phospho-site S570 and 
demonstrated that phosphorylation at this site is regulated in cells. As this is 
the only PKA or PKC consensus site in the RL that is conserved in mouse, 
we postulate that this site is a key mediator in the regulation of DAGLβ 
activity by playing a role in the displacement of the lid. As far as we are 
aware, this is the first report of the successful purification of active DAGLα/β 
as well as of a DAGL pAb tool. Both these tools will undoubtedly prove to be 



















Chapter 7 : General Discussion 
7.1 Why study DAGL regulation - the physiological, pathological and 
therapeutic significance of these enzymes 
In the last decade - the cloning (Bisogno et al., 2003) and genetic deletion 
(Gao et al., 2010; Tanimura et al., 2010) of the major 2-AG synthesising 
enzymes, DAGLα and DAGLβ, has helped establish the importance of these 
enzymes in various physiological processes mediated by eCB signalling. 
These enzymes impact developmental processes to ensure that axons are 
extended in the correct manner and are directed towards their targets 
(Mulder et al., 2008; Keimpema et al., 2010; Wu et al., 2010). They promote 
the formation of new neurons in the adult brain (Goncalves et al., 2008; Gao 
et al., 2010) where these enzymes are also relied on to ensure synaptic 
signalling is appropriately regulated (Gao et al., 2010; Tanimura et al., 2010; 
Hashimotodani et al., 2013).  
The DAGL cloning and knockout studies were also important in establishing 
2-AG as the major eCB. These enzymes, individually, are responsible for 
virtually all the 2-AG in the brain (DAGLα) and liver (DAGLβ) (Gao et al., 
2010). It was surprising that these enzymes can exert such control over this 
important signalling molecule, especially as knockout studies have failed to 
identify major synthesising pathways for the other widely studied (putative) 
eCB AEA (Leung et al., 2006; Simon and Cravatt, 2010). What was even 
more surprising was the parallel reduction of AA levels with 2-AG levels in 
the brain and liver in the DAGL KO mice. This coupled with dramatic 
increases in 2-AG and complementary decreases in AA and eicosanoids 
following deletion or inhibition of the major 2-AG hydrolysing enzyme MAGL, 
has established non-eCB roles for the DAGLs in the context of eicosanoid 
signalling (Schlosburg et al., 2010; Nomura et al., 2011; Piro et al., 2012).  
Several studies have therefore demonstrated that the DAGLs, by virtue of 
their DAG hydrolysis activity, regulate 2-AG (eCB) and AA (eicosanoid) 
signalling pathways, but despite these important roles, very little is known 
about how these enzymes are regulated. Studying the regulation of these 
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enzymes will improve our understanding of both their physiological and 
pathological roles which in turn will help assess and exploit any therapeutic 
potential they may hold. Indeed, as key eCB signalling mediators as well as 
potential inflammatory mediators, they are implicated in various diseases. 
For example, aberrant DAGLα localisation coupled to disrupted mGluR5 
synaptic signalling in mouse Fragile X mental retardation protein (FMRP) KO 
models has recently been implicated in Fragile X syndrome. Fragile X 
syndrome is caused by the failure to express FMRP which plays an important 
role in the transport of various mRNA to the synapses and this has recently 
been extended to DAGLα (Jung et al., 2012; Sidorov et al., 2013). Blocking 
2-AG hydrolysis helped overcome the dysregulated mGluR5 signalling as 
well as corresponding behavioural deficits in FMRP KO mice thereby 
indicating a potential therapeutic role for DAGLα activators towards treating 
certain aspects of Fragile X syndrome (Jung et al., 2012). Furthermore, such 
activators could potentially be exploited to enhance the stress induced 
antinociceptive properties of DAGLα in the context of synaptic signalling in 
the dlPAG (Gregg et al., 2012). Additionally, as the DAGLs play a role in 
adult neurogenesis (Goncalves et al., 2008; Gao et al., 2010), such activators 
may also hold therapeutic potential in counteracting the effects of neuronal 
loss in brain injury and neurodegenerative diseases.  
The role of the DAGL-MAGL pathway in AA and thereby eicosanoid 
production in the brain has also implicated them in neurodegenerative 
diseases. For example, elevated brain levels of AA and eicosanoids are 
observed in an Alzheimer's disease mouse model. These are reduced 5 to 
10-fold (coupled with an increase in 2-AG levels) following the genetic 
deletion of MAGL in this model which also causes a reduction in microglia 
and astrocyte activation, inflammatory cytokine levels, and amyloid plaques 
(Piro et al., 2012). Similarly, in a Parkinson's disease model, MAGL deletion 
or inhibition prevents MPTP induced increases in AA and eicosanoids as well 
as neuronal loss in the brain (Nomura et al., 2011). These studies have 
focussed on the disruption of MAGL activity to prevent neuroinflammation. As 
the DAGLs are responsible for most of the AA in the brain, DAGLα/β 
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inhibition is likely to have similar effects making them attractive targets to 
treat neuroinflammation (Gao et al., 2010).  
Beyond the nervous system, in the liver of mice, increased CB1 expression, 
DAGLβ expression and 2-AG levels are observed following ethanol feeding 
which has been linked to alcohol induced hepatic steatosis (Jeong et al., 
2008). In addition to this, a reduction in ethanol induced hepatic steatosis and 
inflammation is observed in CB1 KO mice or in wild type mice treated with a 
CB1 antagonist (Jeong et al., 2008; Trebicka et al., 2011). CB1 has also 
been linked to the pathogenesis of high fat diet induced hepatic steatosis 
(Osei-Hyiaman et al., 2008). Inhibiting DAGLβ in this context may prevent 
CB1 activation and thereby hepatic steatosis, especially as DAGLβ accounts 
for ~90% of 2-AG in the liver.  
In general, DAGLα and DAGLβ demonstrate different tissue specific 
contributions towards 2-AG (and AA) levels and hence targeting them 
individually could prove to be therapeutically attractive and achievable (Gao 
et al., 2010). A DAGLβ selective inhibitor (50 times more potent against 
DAGLβ than DAGLα) has recently been developed (Hsu et al., 2012), this 
provides encouraging signs that differences in these enzymes can be 
exploited by medicinal chemistry.  
Furthering our understanding about how DAGLα and DAGLβ are regulated, 
which may include both overlapping and distinct mechanisms, will help 
further our understanding of these enzymes and eCB signalling and support 
longer term studies to evaluate their therapeutic potential as drug targets. But 
firstly, are the DAGLs regulated? 
7.2 Stimulus dependent increases in 2-AG levels indicate mechanisms 
regulating the DAGLs exist 
Over the last 30 years, there have been numerous reports of increased 2-AG 
levels in response to various stimuli in a range of cells/tissues (reviewed in 
(Sugiura et al., 2006). Some examples of the stimuli that enhance 2-AG 
levels include Endothelin 1, ionomycin (5-fold) and ATP (60-fold) in 
astrocytes (Walter and Stella, 2003; Walter et al., 2004), ethanol (~1.7-fold), 
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ionomycin (~2-fold) and glutamate (~1.6-fold) in cerebellar granular neurons 
(CGNs) (Basavarajappa et al., 2000), ionomycin (~1.6-fold), glutamate and 
NMDA (~3-fold) in cortical neurons (Stella et al., 1997; Stella and Piomelli, 
2001), ionomycin in neuroblastoma cells (Bisogno et al., 1997; Bisogno et al., 
1999a) and Pictrotoxinin (~5-fold) and CaCl2 (6-fold) in rat brains  (Kondo et 
al., 1998; Sugiura et al., 2000a). As the major 2-AG synthesising enzymes, 
the DAGLs are likely candidates to mediate these increases in 2-AG levels 
and in some cases this has been demonstrated using a DAGL inhibitor 
(Stella et al., 1997; Bisogno et al., 1999a; Walter et al., 2004). These several 
fold increases in 2-AG in response to a range of stimuli strongly indicate that 
mechanisms regulating the DAGLs do exist.  
7.3 DAGL post-translational modifications indicate that these enzymes 
are tightly regulated 
As presented in this thesis, several reports of DAGL phosphorylation (30 
DAGLα and 12 DAGLβ phospho-sites) have been published (see Table 3.1 
and Table 3.2 for references). Phosphorylation can regulate an enzyme in 
multiple ways, including its activity, localisation and stability by impacting on 
inter and intra-molecular interactions (Johnson and Lewis, 2001; Salazar and 
Hofer, 2009). Furthermore, the regulatory potential of phosphorylation on a 
protein is increased exponentially when multiple phospho-sites exist. In other 
words, an enzyme that is phosphorylated at n number of sites can potentially 
exist in 2n phosphorylation states, each potentially exhibiting different 
properties (Cohen, 2000; Salazar and Hofer, 2009). Therefore the reported 
DAGL phospho-sites, coupled with other reported post translational 
modifications of these enzymes, including palmitoylation (Kang et al., 2008; 
Martin and Cravatt, 2009; Yang et al., 2010) and ubiquitination (Wagner et 
al., 2011; Wagner et al., 2012) provide evidence that these enzymes are 
tightly regulated. 
7.4 Mechanisms defining DAGL localisation  
As a general concept, mechanisms determining the localisation and activity 
of an enzyme play a crucial role in their regulation. In this context, detailed 
anatomical studies of DAGLα have demonstrated that this enzyme is often 
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localised in close proximity to the CB1 receptor, thus enabling 2-AG 
mediated activation of the receptor in either an autocrine or paracrine 
manner. For example, several studies have shown that DAGLα, along with 
the CB1 receptor are both present in axons during development, thereby 
enabling eCB signalling to regulate axonal growth and guidance (Bisogno et 
al., 2003; Berghuis et al., 2007; Mulder et al., 2008; Watson et al., 2008; 
Keimpema et al., 2010). On the other hand, restricted expression of the 
DAGLα to dendritic spines and the CB1 receptor to pre-synaptic terminals in 
the adult brain plays an important role in retrograde synaptic signalling. In 
this case, 2-AG produced in the post synaptic cell, in response to 
depolarisation or receptor activation (e.g. mGluR5), activates pre-synaptic 
CB1 receptors to suppress synaptic signalling (Bisogno et al., 2003; Yoshida 
et al., 2006; Uchigashima et al., 2007; Nyilas et al., 2009).  
The mechanisms determining the localisation of the DAGLs are poorly 
understood. A recent report has demonstrated a role for FMRP in the 
transport and precise localisation of DAGLα mRNA and protein at the 
synapse (Jung et al., 2012), thereby demonstrating localised translation as a 
mechanism regulating its localisation.  
Reversible post-translational modifications are also likely to play a role in 
DAGL localisation. As discussed in this report, both the DAGLs have been 
shown to be palmitoylated (Kang et al., 2008; Martin and Cravatt, 2009; Yang 
et al., 2010),  most likely in a cysteine rich insert within the catalytic domain 
identified here. This insert probably plays a role in targeting these enzymes 
to lipid rafts, in close proximity to their substrate DAG and the CB1 receptor 
(Canobbio et al., 2008; Rimmerman et al., 2008; Oddi et al., 2012). 
Furthermore, palmitoylated DAGLα has been specifically identified in rat 
brain synaptosomes (Kang et al., 2008) where this enzyme is specifically 
localised to regulate synaptic signalling.  
Likewise, several DAGLα derived phospho-peptides have been identified in 
the brain and more specifically in synaptosomes (Table 3.1). Two 
independent knockout studies of the DAGLs have implicated DAGLα and not 
DAGLβ in eCB driven retrograde synaptic signalling (Gao et al., 2010; 
249 
 
Tanimura et al., 2010), despite the fact that both these enzymes are 
expressed in the adult brain, and more specifically in neurons (Bisogno et al., 
2003; Yoshida et al., 2006; Jain et al., 2013). The most obvious structural 
difference between the DAGLs is the presence of a C-terminal tail region in 
DAGLα that is completely absent in DAGLβ (Reisenberg et al., 2012). It is 
therefore highly probable that this tail region (primarily but not necessarily 
exclusively) plays a role in regulating DAGLα in a synapse specific context.  
As shown in the DAGLα phospho-map compiled in this report, a total of 20 
phospho-sites have been identified in the tail region reflecting its regulatory 
potential (see Table 3.1 for references) and as mentioned above a large 
number of these phospho-sites were identified in the brain and more 
specifically in synaptosomes/synaptic membranes (Trinidad et al., 2006; 
Munton et al., 2007; Trinidad et al., 2008; Trinidad et al., 2012). These 
phospho-sites may therefore play a role in localising DAGLα towards the 
synapse, possibly by modulating protein-protein interactions. Indeed, this tail 
region contains a PPxxF consensus motif for binding Homer proteins (Jung 
et al., 2007), a family of adaptor proteins for many post-synaptic proteins, 
including mGluR5 (Shiraishi-Yamaguchi and Furuichi, 2007). This motif has 
been shown to be important for DAGLα interaction with homer proteins 
(Homer-1b, Homer-2) and its localisation to the plasma membrane as 
determined by overexpression studies in Neuro-2A cells (Jung et al., 2007).  
Regulated degradation of the DAGLs is also likely to play a role in 
determining the localisation of these enzymes. This would facilitate the shift 
observed in the role of DAGLα, from autocrine CB1 activation in the axons 
during development, towards paracrine retrograde CB1 activation at the 
synapse (mediated by its dendritic localisation). In support of this, 
ubiquitination at three DAGLα and three DAGLβ sites have been reported in 
unbiased proteomic studies (Wagner et al., 2011; Wagner et al., 2012) and a 
putative D-box motif has also been identified within the DAGLα tail (Gareth 
Williams, unpublished data). The D-box (destruction box) is a consensus 
binding sequence for the anaphase promoting complex ubiquitin ligase which 




7.5 Regulating DAG levels will regulate the DAGLs 
Localisation of the DAGLs close to DAG and the cannabinoid receptors is 
potentially a dynamic process thereby regulating eCB signalling. When in 
proximity of DAG and the cannabinoid receptors, further mechanisms have 
been implicated in regulating the activity of these enzymes. One of these is 
substrate availability. Detailed pharmacological studies using cerebellar 
neuron cultures have implicated a PLCγ-DAGL-CB1 pathway in FGFR 
receptor driven neurite outgrowth mechanisms (Williams et al., 1994b; 
Williams et al., 1994a; Saffell et al., 1997; Bisogno et al., 2003; Williams et 
al., 2003). In this pathway, increased PLCγ activity is likely to increase DAG 
levels by the hydrolysis of phospholipids and thereby increase DAGL activity, 
2-AG levels, and ultimately CB1 activation. Similarly, detailed studies have 
also linked increased PLCβ activity to increased DAGL dependent 2-AG 
signalling at the synapse (Hashimotodani et al., 2007b, a; Tanimura et al., 
2010). In this context, activation of certain post synaptic receptors like 
mGluR5 coupled with increased post synaptic calcium levels collectively 
activate PLCβ, which will thereby increase DAG levels and consequently 
DAGL activity and 2-AG levels (termed as Ca-RER - calcium assisted 
receptor-driven endocannabinoid release).  
Therefore, palmitoylation and phosphorylation of DAGLα, coupled with its 
interaction with adaptor proteins like Homer, probably work cooperatively to 
ensure that the DAGLs are at the right place at the right time to take 
advantage of increased substrate levels (via FGFR/mGluR5 activation), 
thereby driving eCB signalling.  
7.6 Phosphorylation as a mechanism to regulate DAGL catalytic activity 
The processes described above (DAGL localisation and increased DAG 
levels) may indeed contribute towards the elevated 2-AG levels observed in 
various cells/tissues in response to a range of stimuli as mentioned earlier. In 
addition to this, further evidence also points towards intra-molecular 
mechanisms regulating the catalytic activity of the DAGLs. For example, 
glutamate elevates DAGL activity in primary mouse neuronal cultures when 
measured in vitro (Farooqui et al., 1993). Synaptosomes treated with an 
251 
 
mGluR5 agonist demonstrate increased DAGL activity using a synthetic 
substrate (Jung et al., 2012). Additionally, two CamKIIa phospho-sites (S782 
and S808) in the tail region of DAGLα have been shown to exert an inhibitory 
effect on its catalytic activity in vitro (Shonesy et al., 2013).  
In this context, phosphorylation is a widely used mechanism to regulate the 
activity of enzymes, including lipases like TGL4, PLCγ, and HSL (Kurat et al., 
2009; Gresset et al., 2010; Lampidonis et al., 2011). In light of the numerous 
reports identifying DAGL phospho-peptides (see Table 2 and 3), 
phosphorylation appears to be a likely mechanism to regulate DAGL activity 
as well. Furthermore, some of the stimuli that drive an increase in 2-AG 
levels in cells/tissues also activate various kinases.  
7.7 PKA and PKC dependent stimulation of DAGL activity 
Two kinases implicated in stimulating 2-AG synthesis in cells are PKA and 
PKC. Approximately 3-fold increases in 2-AG levels were observed when 
treating HEK293 cells with the PKC activator PMA (blocked by a PKC 
inhibitor) or the PKA activator forskolin (blocked by a PKA inhibitor) (Vellani 
et al., 2008). Similarly, increases in 2-AG in glucocorticoid stimulated 
hypothalamic slices was shown to be PKA dependent (Malcher-Lopes et al., 
2006). Furthermore these kinases are stimulated by calcium (Steinberg, 
2008; Dunn et al., 2009) and as mentioned earlier, calcium and ionomycin 
(calcium ionophore) stimulated 2-AG synthesis has been widely reported 
using cell lines (Bisogno et al., 1999a; Bisogno et al., 2003), primary cell 
cultures (Stella et al., 1997; Aguado et al., 2005) and tissues (Kondo et al., 
1998). In a physiological context, increased calcium levels in the post-
synaptic cell drive the production of 2-AG during synaptic signalling and 
although in some instances (Ca-RER) this has been linked to PLCβ 
activation, in other instances (DSI/DSE) the mechanisms behind this are still 
unknown (for reviews see (Hashimotodani et al., 2007a; Castillo et al., 2012). 
Based on the discussion above, it is tempting to speculate that these 
unknown mechanisms involve phosphorylation of DAGLα, by calcium 
dependent kinases like PKA or PKC, thereby increasing its activity. We 
exploited a cell based CB1 activation assay, namely the Tango assay to test 
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this hypothesis, crucial to this was the fact that the Tango cells express 
DAGLα/β. Indeed we found that calcium stimulated DAGL dependent eCB 
signalling in this assay was blocked by both PKA and PKC inhibitors. Equally 
encouraging was the fact that PKA and PKC activators themselves 
stimulated DAGL dependent eCB signalling in the assay. In addition to this, 
an earlier report has shown that PKA treated bovine rod membranes 
demonstrate ~70% increase in DAGL activity in vitro (Perez Roque et al., 
1998) and that a DAGL activity purified from bovine brain (albeit much 
smaller protein than DAGLα/β) is stimulated by PKA in vitro. These results 
coupled with the DAGL phospho-site analysis summarised below indicate 
that PKA and PKC activate the DAGLs by phosphorylating them. 
7.8 Potential PKA and PKC phospho-sites within the DAGLs 
As discussed in this report, several DAGL phospho-peptides have been 
identified by mass spectrometry analysis of a range of cell/tissue extracts. 
Amongst the 42 potential DAGL phospho-sites collated in this report, 11 lie 
within PKA and PKC consensus motifs (Amanchy et al., 2007).  
Phosphoproteomic analysis of complex samples can often result in the 
detection of false positives (and negatives) (Alcolea et al., 2009), however, a 
detailed probation of these sites using structure/sequence based predictions 
carried out as part of this project strongly indicates that several of these are 
genuine phospho-sites, especially as they have been reported in multiple 
studies. In this regard, at least 9 of the phospho-sites are likely to be 
genuine, 4 of which are candidate PKA/PKC phospho-sites.  
2 of these sites are located within the DAGLβ RL. Indeed, using purified 
kinases and the purified catalytic domain of DAGLβ, we have shown that 
PKA can phosphorylate one of these sites (S570). We were unable to 
determine whether PKA phosphorylates the other site due to background 
phosphorylation in the control sample. Phosphatase treatment of the control 
sample prior to PKA treatment will help address this. The other 2 PKA/PKC 
'genuine' phospho-sites are located within the tail region of DAGLα, the work 
in this report focussed on in vitro phosphorylation studies using the DAGLα 
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CD, it therefore remains to be seen if PKA/PKC can indeed phosphorylate 
these sites. 
In general, the increases in 2-AG levels observed in cells/tissues in response 
to various stimuli (e.g. ionomycin) are likely to be mediated by DAGL activity; 
however the individual contribution of DAGLα and DAGLβ towards this is 
unclear. In this context the Tango cells express both DAGLα and DAGLβ. 
Therefore any of the 4 phospho-sites highlighted above may indeed be 
responsible for the calcium/PKA/PKC stimulated DAGL dependent eCB 
signalling observed in the Tango assay here, and also for the calcium 
stimulated 2-AG synthesis widely reported in other cells and tissues. But how 
would these phospho-sites affect DAGL activity? 
7.9 Potential mechanisms dictating intra-molecular activation of the 
DAGLs 
Several clues with regards to intra-molecular activation mechanisms can be 
gained from the architecture of the DAGLs. There is no reported crystal 
structure for the mammalian DAGLs. However, using homology modelling, 
we have identified a regulatory loop (RL) consisting of 50-60 amino acids and 
located as an insert  within the catalytic domain of the DAGLs. The RL is 
likely to function as a lid, thereby restricting substrate access to the catalytic 
site. Related lid like structures have been reported for several lipases 
(Holmquist, 2000).  
The lid is responsible for the 'interfacial activation' phenomenon, commonly 
observed with these enzymes. Interfacial activation refers to the lid 
displacement and increased activity of a lipase when it comes in contact with 
a lipid phase (Nardini and Dijkstra, 1999; Holmquist, 2000). Once membrane 
and substrate proximal, the displacement of the DAGL regulatory loop is 
likely to be triggered, thereby activating the enzymes. 
In the case of hormone sensitive lipase (HSL), the lid is represented by an 
~150 amino acid regulatory module and contains several PKA phospho-sites 
(Lampidonis et al., 2011). Furthermore, phosphorylation by PKA increases 
the activity and hydrophobic surface area of HSL in vitro (Tsujita et al., 1989; 
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Holm et al., 1994; Anthonsen et al., 1998; Krintel et al., 2009). This has led to 
a model whereby PKA dependent phosphorylation of HSL results in the 
displacement of the lid which exposes the hydrophobic catalytic core of the 
enzyme, thereby enabling substrate access to the catalytic site, resulting in 
increased activity. Several phospho-sites have been identified in the RL of 
the DAGLs. Particularly striking, is a short 15 amino acid hyper-
phosphorylated region within the RL of DAGLβ containing 8 reported 
phospho-sites. There is only one conserved PKA/PKC consensus sequence 
within the RL of DAGLβ, S570. This site has been reported to be 
phosphorylated in cells by 3 different reports (Daub et al., 2008; Mayya et al., 
2009; Olsen et al., 2010), is membrane proximal (and therefore substrate 
facing) and is also predicted to be a phospho-site (DISPHOS). This site is 
therefore a prime candidate to mediate PKA/PKC stimulatory effects within 
the enzyme, potentially by regulating the 'open' and closed conformation of 
the enzyme. Furthermore, as mentioned earlier we have used the purified 
catalytic domain of DAGLβ and purified PKA to demonstrate that this kinase 
can indeed directly phosphorylate this site in vitro. We have also 
demonstrated using a pAb, that treating cells with PKA and PKC activators 
upregulates phosphorylation at this site. Work is ongoing to determine the 
effect of phosphorylation at this site on the activity of DAGLβ.  
There have been 2 reported phospho-sites located within the RL of DAGLα, 
however neither have been reported in published studies. It remains to be 
seen whether these are genuine phospho-sites and/or whether additional 
phospho-sites within the DAGLα RL do exist. However, the tail region of 
DAGLα contains numerous phospho-sites (20), 5 of which have been 
reported in at least 3 published studies. 2 of these phospho-sites - S743 
which has been reported in 8 independent published studies and S806 which 
has been reported in 5 independent published studies, are located within 
PKA/PKC consensus sequences (see Table 3.1 and Table 3.3 for details and 
references). The tail region of DAGLα has been shown to be dispensable for 
catalytic activity (Pedicord et al., 2011). However, the recent study 
demonstrating the inhibitory effect of two CamKIIa phospho-sites located 
within the DAGLα tail, on its catalytic activity in vitro (Shonesy et al., 2013), 
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indicates that this region may interact with other regions of the protein (like 
the RL) to modulate DAGLα activity. Therefore the two PKA/PKC consensus 
sites within the tail region, that have been widely reported, may indeed be 
responsible for calcium/PKA/PKC stimulated DAGLα activity discussed 
earlier.   
7.10  Phosphorylation and activity of the DAGLs 
Our results in this study showed that both PKA and PKC inhibitors blocked 
calcium stimulated DAGL dependent activity in the Tango (cell based CB1 
activation) assay. Additionally, PKA and PKC activators stimulated DAGL 
dependent eCB signalling in this assay. These results coupled with the fact 
that some of the 'genuine' DAGL phospho-sites lie within PKA/PKC 
consensus sequences led us to postulate that PKA and PKC directly 
phosphorylate and thereby activate the DAGLs.  
In order to test this hypothesis we used two different DAGL surrogate 
substrates (PNPB and DiFMUO) (Pedicord et al., 2011) to develop 
membrane and live cell assays which were capable of detecting increased 
DAGL activity in cells overexpressing DAGLα/β. However, despite using a 
range of treatments (phosphatase, calcium, PKA activators, PKA inhibitors, 
PKC activators, starvation), some of which stimulated DAGL in the Tango 
assay, no change in DAGL activity was detected using these substrates. This 
indicated that either the treatments did not affect (phosphorylate) the DAGLs 
or that these substrates were incapable of detecting changes in the DAGLs 
induced by these treatments that may otherwise be detected using the native 
substrate DAG. The latter could be due to size and/or structural differences 
between the surrogate substrates and the native substrate DAG. In support 
of this - phosphorylation of HSL by PKA has been shown to increase its 
activity in vitro when using a triglyceride substrate but not when using PNPB 
as the substrate (Tsujita et al., 1989). In future studies, if changes in DAGL 
activity are indeed detected using DAG, following the treatments mentioned 
above, then the negative results with the surrogate substrates become all the 
more interesting as they might help understand specific aspects of DAGL-
DAG interactions that are responsible for the treatment dependent changes 
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in activity. Furthermore, if these treatments do result in DAGL 
phosphorylation then pAbs would be particularly useful tools in these studies 
as they would enable one to optimise the concentration and treatment times 
of the stimulus to maximise its effect on the DAGLs. 
7.11  DAGL phospho-antibodies as tools to investigate and monitor 
eCB signalling 
Site specific pAbs are valuable biological tools, especially as they can be 
used to identify and study pathways that modulate the phosphorylation status 
of the site. Indeed site specific pAbs have been useful in studying down-
stream signalling pathways of CB1 e.g. in granule cell precursors (phospho-
AKT and phospho-GSK-3β) (Trazzi et al., 2010) and in the hippocampus 
(phospho-ERK) (Derkinderen et al., 2003).  
Developing site specific pAbs of biological value however is no trivial task. A 
phospho-site first needs to be identified. If one is relying on global 
phosphoproteomics data then 'false positives' can prove a hindrance (Alcolea 
et al., 2009). If one is relying on overexpressing systems (coupled with in 
vitro phosphorylation studies) then its physiological occurrence needs to be 
established. Following that, the pAb itself has to be generated which can be 
technically challenging (Brumbaugh et al., 2011). Immunogenicity/specificity 
of the antigen, purification of the pAb and ultimately specificity of the pAb are 
issues commonly faced. If a site specific pAb is successfully generated, it 
also needs to be functional in the desired format(s) (e.g. Western blotting, 
immunohisto/cytochemistry, immunoprecipitation, ELISAs, or other antibody 
dependent assays). Coupled with all of this, a physiological function needs to 
be assigned to the phospho-site, which in itself can take years; this can 
actually be greatly aided by site-specific pAbs.  
In this study we have successfully developed what we believe to be is the 
first site specific DAGL pAb (DAGLβ S570). This pAb has successfully been 
used in Western blotting and its phospho-site specificity has been validated 
by mutagenesis and phosphatase studies. Using this validated tool we found 
that phosphorylation at DAGLβ S570 is regulated within cells. More 
specifically, treating cells with PKA and PKC activators causes an 
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upregulation of phosphorylation at this site. This phospho-site is a prime 
candidate to be responsible for potential PKA/PKC dependent DAGLβ 
activation as it is the only conserved PKA/PKC (predicted) phospho-site 
located within its RL loop and as reported here, this site can be directly 
phosphorylated by PKA. As of yet, a function has not been assigned to this 
site, studies are currently ongoing to determine the effect of this phospho-site 
on DAGLβ activity. 
Understanding the impact of the various DAGL phospho-sites on their activity 
coupled with the generation of other DAGL pAbs may indeed prove to be 
crucial in understanding how these enzymes are regulated. Furthermore, 
once a phospho-site has a function assigned to it, then a pAb against that 
site will prove to be a valuable tool to understand pathways regulating DAGL 
and thereby eCB signalling. A better understanding of how the DAGLs are 
regulated will be fundamental towards assessing and unlocking their 
therapeutic potential, whether it is to exploit their antinociceptive or 
neurogenic properties by activating them or to inhibit them in order to 
suppress neuroinflammation and hepatic steatosis.  
7.12  Future directions 
The phospho-maps of the DAGLs contain 42 phospho-sites, indicating that 
these enzymes are tightly regulated. However, to date, only two of these 
phospho-sites have a function attributed to them.  
In order to assess the impact they have on the DAGLs we are currently 
adapting the Tango cells to use them as a platform for detailed DAGL 
structure/function studies. The parental Tango cells are engineered to 
measure CB1 activation and in this study we have adapted them to detect 
calcium stimulated DAGL (endogenous) dependent eCB signalling. We are 
currently knocking out the endogenous DAGL genes in these cells to provide 
us with a platform to screen various mutated version of the DAGLs. This will 
allow us to test the impact of the DAGL phospho-sites on their activity in a 
cellular context. Screening these mutants in biochemical assays using the 
native DAG substrate will also be imperative in establishing the effect of the 
various phospho-sites on DAGL activity. Of particular interest is the impact 
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phosphorylation at S570 has on DAGLβ activity, as we have demonstrated 
that PKA directly phosphorylates this site. We have also demonstrated that 
phosphorylation at this site is regulated in a cellular context using a pAb. 
Furthermore, this phospho-site, located within the RL, is well placed to 
regulate the 'open' and 'closed' conformation of the enzyme. Additional 
studies using hydrophobic probes will help test this hypothesis. We have 
recently also designed, generated, and successfully expressed a DAGLβ 
construct with the RL (lid) deleted; enzymology studies are currently 
underway to establish the impact this will have on the enzymes activity. 
In addition to screening mutated versions of the DAGLs in the 
aforementioned Tango assay, we will also determine the impact of these 
mutations on DAGL localisation using high resolution microscopy. This work 
will be further supported by a panel of pAbs we have generated against some 
of the reported DAGL phospho-sites.  
It is not feasible to generate and thoroughly test pAbs against all 42 reported 
DAGL phospho-sites due to which we have focussed on the catalytic domain 
of the DAGLs. Generating pAbs against relatively uncharacterised phospho-
sites is a high risk approach because if a pAb does not work, it is difficult to 
assess whether that is due to issues with the pAb, issues with the detection 
of the pAb or due to the fact that conditions stimulating the phosphorylation 
event have not been determined. Furthermore, we cannot completely rule out 
that some of the phospho-sites these antibodies are designed against are not 
genuine phospho-sites. However, with high risk comes high reward. If any of 
these antibodies can successfully detect the DAGLs then it is relatively 
straight forward to validate the phospho-site specific nature of the pAb, and 
as discussed earlier, a validated pAb can be a powerful biological tool to 
study the impact of the phospho-site, not only on the enzyme but also on its 
related pathways.  
The approaches described above will begin to validate and assign functions 
to the 42 DAGL phospho-sites and as a consequence of which further our 
understanding on the mechanisms and pathways driving DAGL dependent 
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